

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
28 June 2007 (28.06.2007)

PCT

(10) International Publication Number
WO 2007/073303 A2

(51) International Patent Classification:

C07D 235/08 (2006.01) **A61P 19/02** (2006.01)
A61K 31/4184 (2006.01) **A61P 29/00** (2006.01)
A61K 31/4439 (2006.01) **A61P 35/00** (2006.01)
A61P 1/04 (2006.01) **C07D 401/12** (2006.01)
A61P 11/06 (2006.01) **C07D 405/12** (2006.01)
A61P 17/06 (2006.01) **C07D 409/12** (2006.01)

D Montreal, 7171 Frederick-banting, Ville St. Laurent, Montreal, Québec H4S 1Z9 (CA). **KERS, Inger** [SE/SE]; AstraZeneca R & D Södertälje, S-151 85 Södertälje (SE). **NYLÖF, Martin** [SE/SE]; AstraZeneca R & D Södertälje, S-151 85 Södertälje (SE). **SKOGHOLM, Karin** [SE/SE]; AstraZeneca R & D Södertälje, S-151 85 Södertälje (SE).

(21) International Application Number:

PCT/SE2006/001467

(22) International Filing Date:

21 December 2006 (21.12.2006)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/753,604 23 December 2005 (23.12.2005) US

(71) Applicant (for all designated States except US): **ASTRAZENECA AB** [SE/SE]; S-151 85 Södertälje (SE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BESIDSKI, Yevgeni** [SE/SE]; AstraZeneca R & D Södertälje, S-151 85 Södertälje (SE). **GRIFFIN, Andrew** [GB/CA]; AstraZeneca R & D Montreal, 7171 Frederick-banting, Ville St. Laurent, Montreal, Québec H4S 1Z9 (CA). **LABRECQUE, Denis** [CA/CA]; AstraZeneca R & D Montreal, 7171 Frederick-banting, Ville St. Laurent, Montreal, Québec H4S 1Z9 (CA). **JOHNSTONE, Shawn** [CA/CA]; AstraZeneca R & D Montreal, 7171 Frederick-banting, Ville St. Laurent, Montreal, Québec H4S 1Z9 (CA). **JONES, Paul** [CA/CA]; AstraZeneca R &

(74) Agent: **ASTRAZENECA AB**; Global Intellectual Property, S-151 85 Södertälje (SE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: NEW COMPOUNDS III



(57) Abstract: The present invention relates to new compounds [Chemical formula should be inserted here. Please see paper copy] (I) or salts, solvates or solvated salts thereof, processes for their preparation and to new intermediates used in the preparation thereof, pharmaceutical compositions containing said compounds and to the use of said compounds in therapy.

WO 2007/073303 A2

NEW COMPOUNDS III

FIELD OF THE INVENTION

The present invention relates to new compounds, to pharmaceutical compositions containing said compounds and to the use of said compounds in therapy. The present invention
5 further relates to processes for the preparation of said compounds and to new intermediates used in the preparation thereof.

BACKGROUND OF THE INVENTION

Pain sensation in mammals is due to the activation of the peripheral terminals of a specialized population of sensory neurons known as nociceptors. Capsaicin, the active ingredient
10 in hot peppers, produces sustained activation of nociceptors and also produces a dose-dependent pain sensation in humans. Cloning of the vanilloid receptor 1 (VR1 or TRPV1) demonstrated that VR1 is the molecular target for capsaicin and its analogues (Caterina, M.J., Schumacher, M.A., et.al. Nature (1997) v.389 p 816-824). Functional studies using
15 VR1 indicate that it is also activated by noxious heat, tissue acidification and other inflammatory mediators (Tominaga, M., Caterina, M.J. et.al. Neuron (1998) v.21, p.531-543). Expression of VR1 is also regulated after peripheral nerve damage of the type that leads to neuropathic pain. These properties of VR1 make it a highly relevant target for pain and for diseases involving inflammation. While agonists of the VR1 receptor can act as
20 analgesics through nociceptor destruction, the use of agonists, such as capsaicin and its analogues, is limited due to their pungency, neurotoxicity and induction of hypothermia. Instead, agents that block the activity of VR1 should prove more useful. Antagonists would maintain the analgesic properties, but avoid pungency and neurotoxicity side effects.

Compounds with VR1 inhibitor activity are believed to be of potential use for the treatment
25 and/or prophylaxis of disorders such as pain, especially that of inflammatory or traumatic origin such as arthritis, ischaemia, cancer, fibromyalgia, low back pain and post-operative pain (Walker et al J Pharmacol Exp Ther. (2003) Jan;304(1):56-62). In addition to this visceral pains such as chronic pelvic pain, cystitis, irritable bowel syndrome (IBS), pancreatitis and the like, as well as neuropathic pain such as sciatica, diabetic neuropathy, HIV neuropathy, multiple sclerosis, and the like (Walker et al *ibid*, Rashid et al J Pharmacol Exp
30 Ther. (2003) Mar;304(3):940-8), are potential pain states that could be treated with VR1 inhibition. These compounds are also believed to be potentially useful for inflammatory

disorders like asthma, cough, inflammatory bowel disease (IBD) (Hwang and Oh Curr Opin Pharmacol (2002) Jun;2(3):235-42). Compounds with VR1 blocker activity are also useful for itch and skin diseases like psoriasis and for gastro-esophageal reflux disease (GERD), emesis, cancer, urinary incontinence and hyperactive bladder (Yiangou et al BJU Int (2001) Jun;87(9):774-9, Szallasi Am J Clin Pathol (2002) 118: 110-21). VR1 inhibitors are also of potential use for the treatment and/or prophylaxis of the effects of exposure to VR1 activators like capsaicin or tear gas, acids or heat (Szallasi *ibid*).

A further portential use relates to the treatment of tolerance to VR1 activators.

VR1 inhibitors may also be useful in the treatment of interstitial cystitis and pain related to interstitial cystitis.


VR1 inhibitors may also be useful in the treatment of obesity and migraine; WO2006/007851 discloses the use of VR1 antagonists for the treatment of obesity.

WO2004/100865 discloses compounds exhibiting inhibitory activity at the vanilloid receptor 1 (VR1).

DETAILED DESCRIPTION OF THE INVENTION

The object of the present invention is to provide compounds of said kind of compounds exhibiting inhibitory activity at the vanilloid receptor 1 (VR1), which compounds exhibit not only improved potency but optimized combinations of potency and other desirable properties, in particular solubility, along with good Drug Metabolism and Pharmacokinetics (DMPK) properties.

The present invention provides compounds of formula I



wherein:

R^1 is selected from nitro, cyano, halo, and acetyl; R^2 is selected from phenyl, heteroaryl, phenylmethyl, and phenyloxymethyl;

where R² is optionally substituted with one or more substituents Q selected from C₁₋₆alkyl, C₁₋₆alkoxy, C₁₋₆haloalkyl, halo, C₁₋₆haloalkoxy, C₃₋₇cycloalkoxy, C₃₋₇cycloalkyl, C₁₋₆alkynyl, C₃₋₇cycloalkylalkoxy, C₃₋₇heterocycloalkyloxy, and C₁₋₃alkoxyC₁₋₆alkoxy, said substituent(s) Q being attached to the aromatic and/or heteroaromatic ring(s) of R²;

5 R³ is H or F;

R⁴ is methyl, methoxycarbonyl or ethyl; or R² and R⁴ may together form a monocyclic or bicyclic ring system;

and salts, solvates or solvated salts thereof.

10 One embodiment of the invention relates to compounds of formula I wherein R¹ is selected from nitro, cyano, fluoro, chloro, and acetyl.

Another embodiment of the invention relates to compounds of formula I wherein R¹ is nitro.

15

A further embodiment of the invention relates to compounds of formula I wherein R¹ is cyano or halo.

20

One embodiment of the invention relates to compounds of formula I wherein R¹ is cyano, chloro, or fluoro.

Another embodiment of the invention relates to compounds of formula I wherein R² is selected from phenyl, pyridinyl, thienyl, phenylmethyl, and phenyloxymethyl.

25

A further embodiment of the invention relates to compounds of formula I wherein R² is phenyl substituted with one or more substituent(s) Q with one substituent Q in para-position relative to the point of attachment.

30

One embodiment of the invention relates to compounds of formula I wherein R² is pyridin-3-yl substituted with one or more substituent(s) Q, wherein one substituent Q is a substituent at position 6 of the pyridine ring.

Another embodiment of the invention relates to compounds of formula I wherein R² is pyridin-2-yl substituted with one or more substituent(s) Q, wherein one substituent Q is a substituent at position 5 of the pyridine ring.

- 5 A further embodiment of the invention relates to compounds of formula I wherein R² is thien-2-yl substituted with one or more substituent(s) Q, wherein one substituent Q is a substituent at position 5 of the thiophene ring.

One embodiment of the invention relates to compounds of formula I wherein R² is phenylmethyl.

10

Another embodiment of the invention relates to compounds of formula I wherein R² is phenoxymethyl.

- 15 A further embodiment of the invention relates to compounds of formula I wherein Q is selected from (1-methylprop-2-yn-1-yl)oxy, 1-methylpropyloxy, 2,2,2-trifluoro-ethoxy, 2,2,3,3-tetrafluoro-propoxy, 2,2-difluoro-ethoxy, 2-fluoro-1-fluoromethyl-ethoxy, 2-fluoroethoxy, 2-methoxy-1-methyl-ethoxy, 2-methoxy-propoxy, chloro, chloro(difluoro)methyl, cyclopentyloxy, cyclopropyl, cyclopropylmethoxy, ethoxy, ethynylphenyl, fluoro, isopropoxy, isopropyl, methoxy, methylpiperidinylox, propoxy, tert-butyl, trifluoromethoxy, and trifluoromethyl.
- 20

One embodiment of the invention relates to compounds of formula I wherein R² is substituted with two substituents Q, one of which is selected from 2-fluoro-1-fluoromethyl-ethoxy, 2-fluoroethoxy, cyclopentyloxy, methoxy, 2-fluoro-1-fluoromethyl-ethoxy, 2-methoxypropyloxy, and methylpiperidinyloxy; and the other one of which is selected from chloro, fluoro, and trifluoromethyl.

25

Another embodiment of the invention relates to compounds of formula I wherein R⁴ is methyl.

30

A further embodiment of the invention relates to compounds of formula I wherein R^2 and R^4 together form a monocyclic or bicyclic ring system.

One embodiment of the invention relates to compounds of formula I wherein R^2 and R^4
5 together form a bicyclic ring system.

Another embodiment of the invention relates to compounds of formula I wherein R^2 and R^4 together form a chromanyl group.

10 A further embodiment of the invention relates to compounds of formula I wherein R^1 is selected from nitro, cyano, chloro, fluoro, and acetyl; and R^2 is phenyl substituted with one or more substituent(s) Q selected from (1-methylprop-2-yn-1-yl)oxy, 1-methylpropyloxy, 2,2,2-trifluoro-ethoxy, 2,2,3,3-tetrafluoro-propoxy, 2,2-difluoroethoxy, 2-fluoro-1-fluoromethyl-ethoxy, 2-fluoroethoxy, 2-methoxy-1-methyl-ethoxy, 2-methoxy-propoxy, chloro, chloro(difluoro)methyl, cyclopentyloxy, cyclopropyl,
15 ethoxy, ethynylphenyl, fluoro, isopropyl, methylpiperidinyloxy, propoxy, tert-butyl, trifluoromethoxy, and trifluoromethyl, with one substituent Q in para-position relative to the point of attachment. Specifically, R^1 may be selected from nitro, cyano, and fluoro; and R^2 phenyl may be substituted with one or more substituent(s) Q selected from (1-methyl-prop-2-yn-1-yl)oxy, 1-methylpropyloxy, 2,2,2-trifluoro-ethoxy, 2,2,3,3-tetrafluoro-propoxy, 2-fluoroethoxy, 2-methoxy-1-methyl-ethoxy, chloro, cyclopentyloxy, cyclopropyl,
20 ethoxy, ethynylphenyl, fluoro, isopropyl, methylpiperidinyloxy, propoxy, tert-butyl, trifluoromethoxy, and trifluoromethyl, with one substituent Q in para-position relative to the point of attachment.

25

One embodiment of the invention relates to compounds of formula I wherein R^1 is selected from nitro, cyano, chloro, and fluoro; and R^2 is pyridinyl or thienyl substituted with one or more substituent(s) Q selected from 2,2,2-trifluoro-ethoxy, 2,2,3,3-tetrafluoro-propoxy, 2,2-difluoro-ethoxy, 2-fluoro-1-fluoro-methyl-ethoxy, 2-fluoroethoxy, 2-isopropoxy, chloro, cyclopentyloxy, cyclopropylmethoxy, isopropoxy, tert-butyl, and trifluoromethyl. Specifically, R^2 may be pyridinyl or
30 thienyl substituted with one or more substituent(s) Q selected from 2,2,2-trifluoro-ethoxy,

2,2,3,3-tetrafluoro-propoxy, 2,2-difluoro-ethoxy, 2-isopropoxy, chloro, cyclopentyloxy, cyclopropylmethoxy, isopropoxy, tert-butyl, and trifluoromethyl.

A further embodiment of the invention relates to compounds selected from the group consisting of

2-(6,7-difluoro-1H-benzimidazol-1-yl)-N-{1-[4-(trifluoromethyl)phenyl]ethyl}acetamide,

2-(7-acetyl-1H-benzimidazol-1-yl)-N-(1-{4-[2-fluoro-1-(fluoromethyl)ethoxy]phenyl}ethyl)acetamide,

2-(7-chloro-1H-benzimidazol-1-yl)-N-(1-{4-[2-fluoro-1-(fluoromethyl)ethoxy]phenyl}ethyl)acetamide,

2-(7-chloro-1H-benzimidazol-1-yl)-N-(1-{4-[chloro(difluoro)methyl]phenyl}ethyl)acetamide,

2-(7-chloro-1H-benzimidazol-1-yl)-N-[1-(4-ethynylphenyl)ethyl]acetamide,

2-(7-chloro-1H-benzimidazol-1-yl)-N-{1-[3-chloro-5-(trifluoromethyl)pyridin-2-yl]ethyl}acetamide,

2-(7-chloro-1H-benzimidazol-1-yl)-N-{1-[4-(1,1,2,2-tetrafluoroethoxy)phenyl]ethyl}acetamide,

2-(7-chloro-1H-benzimidazol-1-yl)-N-{1-[4-(2,2-difluoroethoxy)phenyl]ethyl}acetamide,

2-(7-chloro-1H-benzimidazol-1-yl)-N-{1-[4-(trifluoromethyl)phenyl]ethyl}acetamide,

2-(7-chloro-1H-benzimidazol-1-yl)-N-{1-[6-(2,2,2-trifluoroethoxy)pyridin-3-yl]ethyl}acetamide,

2-(7-chloro-1H-benzimidazol-1-yl)-N-{1-[6-(2,2,3,3-tetrafluoropropoxy)pyridin-3-yl]ethyl}acetamide,

2-(7-Chloro-benzoimidazol-1-yl)-N-[1-(6-isopropoxy-pyridin-3-yl)-ethyl]-acetamide,

2-(7-cyano-1H-benzimidazol-1-yl)-N-(1-{4-[2-fluoro-1-(fluoromethyl)ethoxy]phenyl}ethyl)acetamide,

2-(7-cyano-1H-benzimidazol-1-yl)-N-[1-(4-isopropylphenyl)ethyl]acetamide,

2-(7-cyano-1H-benzimidazol-1-yl)-N-{1-[3-fluoro-4-(trifluoromethyl)phenyl]ethyl}acetamide,

2-(7-cyano-1H-benzimidazol-1-yl)-N-{1-[4-(2,2,2-trifluoroethoxy)phenyl]ethyl}acetamide,

2-(7-cyano-1H-benzimidazol-1-yl)-N-{1-[4-(trifluoromethoxy)phenyl]ethyl}acetamide,

- 2-(7-cyano-1H-benzimidazol-1-yl)-N-{1-[4-(trifluoromethyl)phenyl]ethyl}acetamide,
2-(7-cyano-1H-benzimidazol-1-yl)-N-{(1S)-1-[4-(trifluoromethyl)phenyl]ethyl}acetamide,
2-(7-cyano-1H-benzimidazol-1-yl)-N-{1-[4-[2-fluoro-1-(fluoromethyl)ethoxy]-2-(trifluoromethyl)phenyl]ethyl}acetamide,
5 2-(7-fluoro-1H-benzimidazol-1-yl)-N-[1-(4-isopropylphenyl)ethyl]acetamide,
2-(7-fluoro-1H-benzimidazol-1-yl)-N-{1-[4-(trifluoromethyl)phenyl]ethyl}acetamide,
2-(7-nitro-1H-benzimidazol-1-yl)-N-{1-[4-(1,1,2,2-tetrafluoroethoxy)phenyl]ethyl}acetamide,
2-(7-nitro-1H-benzimidazol-1-yl)-N-{1-[4-(2,2,2-trifluoroethoxy)phenyl]ethyl}acetamide,
10 2-(7-nitro-1H-benzimidazol-1-yl)-N-{1-[4-(trifluoromethoxy)phenyl]ethyl}acetamide,
2-(7-nitro-1H-benzimidazol-1-yl)-N-{1-[4-(trifluoromethyl)phenyl]ethyl}acetamide,
2-(7-nitro-1H-benzimidazol-1-yl)-N-{1-[5-(trifluoromethyl)pyridin-2-yl]propyl}acetamide,
2-(7-nitro-1H-benzimidazol-1-yl)-N-{1-[5-(trifluoromethyl)pyridin-2-yl]ethyl}acetamide,
15 2-(7-nitro-1H-benzimidazol-1-yl)-N-{1-[6-(2,2,2-trifluoroethoxy)pyridin-3-yl]ethyl}acetamide,
2-(7-nitro-1H-benzimidazol-1-yl)-N-{1-[6-(2,2,3,3-tetrafluoropropoxy)pyridin-3-yl]ethyl}acetamide,
methyl (4-tert-butylphenyl){[(6,7-difluoro-1H-benzimidazol-1-yl)acetyl]amino}acetate,
20 N-((1S)-1-[4-[(1-methylprop-2-yn-1-yl)oxy]phenyl]ethyl)-2-(7-nitro-1H-benzimidazol-1-yl)acetamide,
N-((1S)-1-[4-[2-fluoro-1-(fluoromethyl)ethoxy]phenyl]ethyl)-2-(7-nitro-1H-benzimidazol-1-yl)acetamide,
N-(1-{2-chloro-4-[2-fluoro-1-(fluoromethyl)ethoxy]phenyl}ethyl)-2-(7-cyano-1H-benzimidazol-1-yl)acetamide,
25 N-(1-{4-[chloro(difluoro)methyl]phenyl}ethyl)-2-(7-nitro-1H-benzimidazol-1-yl)acetamide,
N-(1-{5-chloro-6-[2-fluoro-1-(fluoromethyl)ethoxy]pyridin-3-yl}ethyl)-2-(7-nitro-1H-benzimidazol-1-yl)acetamide,
30 N-(1-{6-[2-fluoro-1-(fluoromethyl)ethoxy]pyridin-3-yl}ethyl)-2-(7-nitro-1H-benzimidazol-1-yl)acetamide,

N-[(1S)-1-(4-{[(1S)-1-methylpropyl]oxy}phenyl)ethyl]-2-(7-nitro-1H-benzimidazol-1-yl)acetamide,
N-[(1S)-1-(4-ethoxyphenyl)ethyl]-2-(7-nitro-1H-benzimidazol-1-yl)acetamide,
N-[(1S)-1-(4-isopropoxyphenyl)ethyl]-2-(7-nitro-1H-benzimidazol-1-yl)acetamide,
5 N-[(3R)-5-Methoxy-3,4-dihydro-2H-chromen-3-yl]-2-(7-nitro-1H-benzimidazol-1-yl)acetamide,
N-[(3R)-8-Fluoro-5-methoxy-3,4-dihydro-2H-chromen-3-yl]-2-(7-nitro-1H-benzimidazol-1-yl)acetamide,
N-[1-(4-{[(2S)-2-methoxypropyl]oxy}phenyl)ethyl]-2-(7-nitro-1H-benzimidazol-1-yl)acetamide,
10 N-[1-(4-cyclopropylphenyl)ethyl]-2-(7-nitro-1H-benzimidazol-1-yl)acetamide,
N-[1-(4-ethynylphenyl)ethyl]-2-(7-nitro-1H-benzimidazol-1-yl)acetamide,
N-[1-(4-tert-butylphenyl)ethyl]-2-(6,7-difluoro-1H-benzimidazol-1-yl)acetamide,
N-[(1S)-1-(4-tert-butylphenyl)ethyl]-2-(6,7-difluoro-1H-benzimidazol-1-yl)acetamide, N-
15 [1-(4-tert-butylphenyl)ethyl]-2-(7-cyano-1H-benzimidazol-1-yl)acetamide,
N-[1-(5-isopropoxypyridin-2-yl)ethyl]-2-(7-nitro-1H-benzimidazol-1-yl)acetamide,
N-[1-(5-tert-butyl-2-thienyl)ethyl]-2-(6,7-difluoro-1H-benzimidazol-1-yl)acetamide,
N-[1-(5-tert-butyl-2-thienyl)ethyl]-2-(7-cyano-1H-benzimidazol-1-yl)acetamide,
N-[1-(5-tert-butyl-2-thienyl)ethyl]-2-(7-fluoro-1H-benzimidazol-1-yl)acetamide,
20 N-[1-(5-tert-butylpyridin-2-yl)ethyl]-2-(7-fluoro-1H-benzimidazol-1-yl)acetamide,
N-[1-(6-isopropoxypyridin-3-yl)ethyl]-2-(7-nitro-1H-benzimidazol-1-yl)acetamide,
N-[2-(4-chlorophenyl)-1-methylethyl]-2-(7-nitro-1H-benzimidazol-1-yl)acetamide,
N-{(1S)-1-[4-(2-fluoroethoxy)phenyl]ethyl}-2-(7-nitro-1H-benzimidazol-1-yl)acetamide,
N-{(1S)-1-[4-(2-methoxy-1-methylethoxy)phenyl]ethyl}-2-(7-nitro-1H-benzimidazol-1-yl)acetamide,
25 N-{1-[3-chloro-5-(trifluoromethyl)pyridin-2-yl]ethyl}-2-(7-nitro-1H-benzimidazol-1-yl)acetamide,
N-{1-[4-(2,2-difluoroethoxy)phenyl]ethyl}-2-(7-nitro-1H-benzimidazol-1-yl)acetamide,
N-{1-[4-(cyclopentyloxy)-3-fluorophenyl]ethyl}-2-(7-nitro-1H-benzimidazol-1-yl)acetamide,
30 N-{1-[4-[(1-Methylpiperidin-4-yl)oxy]-3-(trifluoromethyl)phenyl]ethyl}-2-(7-nitro-1H-benzimidazol-1-yl)acetamide,

N-{1-[4-{{(2S)-2-Methoxypropyl}oxy}-3-(trifluoromethyl)phenyl]ethyl}-2-(7-nitro-1H-benzimidazol-1-yl)acetamide,

N-{1-[5-(cyclopropylmethoxy)pyridin-2-yl]ethyl}-2-(7-nitro-1H-benzimidazol-1-yl)acetamide,

5 N-{1-[5-chloro-6-(2-fluoroethoxy)pyridin-3-yl]ethyl}-2-(7-nitro-1H-benzimidazol-1-yl)acetamide,

N-{1-[6-(2,2-difluoroethoxy)pyridin-3-yl]ethyl}-2-(7-nitro-1H-benzimidazol-1-yl)acetamide,

N-{1-[6-(2-fluoroethoxy)pyridin-3-yl]ethyl}-2-(7-nitro-1H-benzimidazol-1-yl)acetamide,

10 N-{1-[6-(cyclopentylloxy)pyridine-3-yl]ethyl}-2-(7-nitro-1H-benzimidazol-1-yl)acetamide,
and

N-{1-methyl-2-[3-(trifluoromethyl)phenoxy]ethyl}-2-(7-nitro-1H-benzimidazol-1-yl)acetamide.

15 Another embodiment of the invention relates to compounds selected from the group consisting of

N-((1S)-1-{4-[2-fluoro-1-(fluoromethyl)ethoxy]phenyl}ethyl)-2-(7-nitro-1H-benzimidazol-1-yl)acetamide,

20 2-(7-nitro-1H-benzimidazol-1-yl)-N-{1-[6-(2,2,3,3-tetrafluoropropoxy)pyridin-3-yl]ethyl}acetamide,

N-[1-(4-tert-butylphenyl)ethyl]-2-(6,7-difluoro-1H-benzimidazol-1-yl)acetamide, and

N-[(1S)-1-(4-tert-butylphenyl)ethyl]-2-(6,7-difluoro-1H-benzimidazol-1-yl)acetamide

25 Yet another embodiment of the invention relates to compounds selected from the group consisting of

2-(6,7-difluoro-1H-benzimidazol-1-yl)-N-{1-[4-(trifluoromethyl)phenyl]ethyl}acetamide,

2-(7-acetyl-1H-benzimidazol-1-yl)-N-(1-{4-[2-fluoro-1-(fluoromethyl)ethoxy]phenyl}ethyl)acetamide,

30 2-(7-chloro-1H-benzimidazol-1-yl)-N-(1-{4-[2-fluoro-1-(fluoromethyl)ethoxy]phenyl}ethyl)acetamide,

2-(7-chloro-1H-benzimidazol-1-yl)-N-(1-{4-

[chloro(difluoro)methyl]phenyl}ethyl)acetamide,

- 2-(7-chloro-1H-benzimidazol-1-yl)-N-[1-(4-ethynylphenyl)ethyl]acetamide,
2-(7-chloro-1H-benzimidazol-1-yl)-N-{1-[4-(1,1,2,2-tetrafluoroethoxy)phenyl]ethyl}acetamide,
2-(7-chloro-1H-benzimidazol-1-yl)-N-{1-[4-(2,2-difluoroethoxy)phenyl]ethyl}acetamide,
5 2-(7-chloro-1H-benzimidazol-1-yl)-N-{1-[4-(trifluoromethyl)phenyl]ethyl}acetamide,
2-(7-cyano-1H-benzimidazol-1-yl)-N-(1-{4-[2-fluoro-1-(fluoromethyl)ethoxy]phenyl}ethyl)acetamide,
2-(7-cyano-1H-benzimidazol-1-yl)-N-[1-(4-isopropylphenyl)ethyl]acetamide,
2-(7-cyano-1H-benzimidazol-1-yl)-N-{1-[3-fluoro-4-(trifluoromethyl)phenyl]ethyl}acetamide,
10 2-(7-cyano-1H-benzimidazol-1-yl)-N-{1-[4-(2,2,2-trifluoroethoxy)phenyl]ethyl}acetamide,
2-(7-cyano-1H-benzimidazol-1-yl)-N-{1-[4-(trifluoromethoxy)phenyl]ethyl}acetamide,
2-(7-cyano-1H-benzimidazol-1-yl)-N-{1-[4-(trifluoromethyl)phenyl]ethyl}acetamide,
15 2-(7-cyano-1H-benzimidazol-1-yl)-N-((1S)-1-[4-(trifluoromethyl)phenyl]ethyl)acetamide,
2-(7-cyano-1H-benzimidazol-1-yl)-N-{1-[4-[2-fluoro-1-(fluoromethyl)ethoxy]-2-(trifluoromethyl)phenyl]ethyl}acetamide,
2-(7-fluoro-1H-benzimidazol-1-yl)-N-[1-(4-isopropylphenyl)ethyl]acetamide,
2-(7-fluoro-1H-benzimidazol-1-yl)-N-{1-[4-(trifluoromethyl)phenyl]ethyl}acetamide,
20 2-(7-nitro-1H-benzimidazol-1-yl)-N-{1-[4-(1,1,2,2-tetrafluoroethoxy)phenyl]ethyl}acetamide,
2-(7-nitro-1H-benzimidazol-1-yl)-N-{1-[4-(2,2,2-trifluoroethoxy)phenyl]ethyl}acetamide,
2-(7-nitro-1H-benzimidazol-1-yl)-N-{1-[4-(trifluoromethoxy)phenyl]ethyl}acetamide,
2-(7-nitro-1H-benzimidazol-1-yl)-N-{1-[4-(trifluoromethyl)phenyl]ethyl}acetamide,
25 methyl (4-tert-butylphenyl){[(6,7-difluoro-1H-benzimidazol-1-yl)acetyl]amino}acetate,
N-((1S)-1-{4-[(1-methylprop-2-yn-1-yl)oxy]phenyl}ethyl)-2-(7-nitro-1H-benzimidazol-1-yl)acetamide,
N-((1S)-1-{4-[2-fluoro-1-(fluoromethyl)ethoxy]phenyl}ethyl)-2-(7-nitro-1H-benzimidazol-1-yl)acetamide,
30 N-(1-{2-chloro-4-[2-fluoro-1-(fluoromethyl)ethoxy]phenyl}ethyl)-2-(7-cyano-1H-benzimidazol-1-yl)acetamide,

N-(1-{4-[chloro(difluoro)methyl]phenyl}ethyl)-2-(7-nitro-1H-benzimidazol-1-yl)acetamide,

N-[(1S)-1-(4-{[(1S)-1-methylpropyl]oxy}phenyl)ethyl]-2-(7-nitro-1H-benzimidazol-1-yl)acetamide,

5 N-[(1S)-1-(4-ethoxyphenyl)ethyl]-2-(7-nitro-1H-benzimidazol-1-yl)acetamide,

N-[(1S)-1-(4-isopropoxyphenyl)ethyl]-2-(7-nitro-1H-benzimidazol-1-yl)acetamide,

N-[1-(4-{[(2S)-2-methoxypropyl]oxy}phenyl)ethyl]-2-(7-nitro-1H-benzimidazol-1-yl)acetamide,

N-[1-(4-cyclopropylphenyl)ethyl]-2-(7-nitro-1H-benzimidazol-1-yl)acetamide,

10 N-[1-(4-ethynylphenyl)ethyl]-2-(7-nitro-1H-benzimidazol-1-yl)acetamide,

N-[1-(4-tert-butylphenyl)ethyl]-2-(6,7-difluoro-1H-benzimidazol-1-yl)acetamide,

N-[(1S)-1-(4-tert-butylphenyl)ethyl]-2-(6,7-difluoro-1H-benzimidazol-1-yl)acetamide,

N-[1-(4-tert-butylphenyl)ethyl]-2-(7-cyano-1H-benzimidazol-1-yl)acetamide,

N-{(1S)-1-[4-(2-fluoroethoxy)phenyl]ethyl}-2-(7-nitro-1H-benzimidazol-1-yl)acetamide,

15 N-{(1S)-1-[4-(2-methoxy-1-methylethoxy)phenyl]ethyl}-2-(7-nitro-1H-benzimidazol-1-yl)acetamide,

N-{1-[4-(2,2-difluoroethoxy)phenyl]ethyl}-2-(7-nitro-1H-benzimidazol-1-yl)acetamide,

N-{1-[4-(cyclopentyloxy)-3-fluorophenyl]ethyl}-2-(7-nitro-1H-benzimidazol-1-yl)acetamide,

20 N-{1-[4-[(1-Methylpiperidin-4-yl)oxy]-3-(trifluoromethyl)phenyl]ethyl}-2-(7-nitro-1H-benzimidazol-1-yl)acetamide, and

N-{1-[4-{[(2S)-2-Methoxypropyl]oxy}-3-(trifluoromethyl)phenyl]ethyl}-2-(7-nitro-1H-benzimidazol-1-yl)acetamide.

25 One embodiment of the invention relates to compounds selected from the group consisting of

N-{1-[6-(2-fluoroethoxy)pyridin-3-yl]ethyl}-2-(7-nitro-1H-benzimidazol-1-yl)acetamide,

N-(1-{6-[2-fluoro-1-(fluoromethyl)ethoxy]pyridin-3-yl}ethyl)-2-(7-nitro-1H-benzimidazol-1-yl)acetamide,

30 N-{1-[6-(cyclopentyloxy)pyridine-3-yl]ethyl}-2-(7-nitro-1H-benzimidazol-1-yl)acetamide,
N-(1-{5-chloro-6-[2-fluoro-1-(fluoromethyl)ethoxy]pyridin-3-yl}ethyl)-2-(7-nitro-1H-benzimidazol-1-yl)acetamide,

2-(7-nitro-1H-benzimidazol-1-yl)-N-{1-[5-(trifluoromethyl)pyridin-2-yl]propyl}acetamide,
2-(7-nitro-1H-benzimidazol-1-yl)-N-{1-[5-(trifluoromethyl)pyridin-2-yl]ethyl}acetamide,
2-(7-chloro-1H-benzimidazol-1-yl)-N-{1-[3-chloro-5-(trifluoromethyl)pyridin-2-yl]ethyl}acetamide,
5 N-{1-[3-chloro-5-(trifluoromethyl)pyridin-2-yl]ethyl}-2-(7-nitro-1H-benzimidazol-1-yl)acetamide,
N-{1-[5-chloro-6-(2-fluoroethoxy)pyridin-3-yl]ethyl}-2-(7-nitro-1H-benzimidazol-1-yl)acetamide,
10 2-(7-Chloro-benzoimidazol-1-yl)-N-[1-(6-isopropoxy-pyridin-3-yl)-ethyl]-acetamide,
N-[1-(6-isopropoxypyridin-3-yl)ethyl]-2-(7-nitro-1H-benzimidazol-1-yl)acetamide,
N-{1-[5-(cyclopropylmethoxy)pyridin-2-yl]ethyl}-2-(7-nitro-1H-benzimidazol-1-yl)acetamide,
N-[1-(5-isopropoxypyridin-2-yl)ethyl]-2-(7-nitro-1H-benzimidazol-1-yl)acetamide,
15 N-[1-(5-tert-butylpyridin-2-yl)ethyl]-2-(7-fluoro-1H-benzimidazol-1-yl)acetamide,
N-[1-(5-tert-butyl-2-thienyl)ethyl]-2-(7-fluoro-1H-benzimidazol-1-yl)acetamide,
N-[1-(5-tert-butyl-2-thienyl)ethyl]-2-(7-cyano-1H-benzimidazol-1-yl)acetamide,
2-(7-nitro-1H-benzimidazol-1-yl)-N-{1-[6-(2,2,2-trifluoroethoxy)pyridin-3-yl]ethyl}acetamide,
20 2-(7-chloro-1H-benzimidazol-1-yl)-N-{1-[6-(2,2,2-trifluoroethoxy)pyridin-3-yl]ethyl}acetamide,
2-(7-nitro-1H-benzimidazol-1-yl)-N-{1-[6-(2,2,3,3-tetrafluoropropoxy)pyridin-3-yl]ethyl}acetamide,
2-(7-chloro-1H-benzimidazol-1-yl)-N-{1-[6-(2,2,3,3-tetrafluoropropoxy)pyridin-3-yl]ethyl}acetamide,
25 N-{1-[6-(2,2-difluoroethoxy)pyridin-3-yl]ethyl}-2-(7-nitro-1H-benzimidazol-1-yl)acetamide, and
N-[1-(5-tert-butyl-2-thienyl)ethyl]-2-(6,7-difluoro-1H-benzimidazol-1-yl)acetamide.

30 A yet further embodiment of the invention relates to compounds selected from the group consisting of

N-[1-(6-tert-butyl-2-methoxypyridin-3-yl)ethyl]-2-(7-cyano-1H-benzimidazol-1-yl)acetamide,

N-[1-(6-tert-butyl-2-methylpyridin-3-yl)ethyl]-2-(6,7-difluoro-1H-benzimidazol-1-yl)acetamide,

5 N-[1-(6-tert-butyl-4-methylpyridin-3-yl)ethyl]-2-(7-cyano-1H-benzimidazol-1-yl)acetamide,

N-[1-(6-tert-butyl-2-chloropyridin-3-yl)ethyl]-2-(7-cyano-1H-benzimidazol-1-yl)acetamide,

N-[1-(6-tert-butylpyridin-3-yl)ethyl]-2-(7-cyano-1H-benzimidazol-1-yl)acetamide,

10 N-[1-(4-tert-butylphenyl)ethyl]-2-(7-cyano-1H-benzimidazol-1-yl)acetamide, and
2-(7-acetyl-1H-benzimidazol-1-yl)-N-[(1S)-1-(4-tert-butylphenyl)ethyl]acetamide

Listed below are definitions of various terms used in the specification and claims to de-
15 scribe the present invention.

For the avoidance of doubt it is to be understood that where in this specification a group is qualified by 'hereinbefore defined', 'defined hereinbefore' or 'defined above' the said group encompasses the first occurring and broadest definition as well as each and all of the
20 other definitions for that group.

For the avoidance of doubt it is to be understood that in this specification 'C₁₋₃' means a carbon group having 1, 2 or 3 carbon atoms, 'C₁₋₆' means a carbon group having 1, 2, 3, 4, 5 or 6 carbon atoms, and 'C₃₋₇' means a carbon group having 3, 4, 5, 6 or 7 carbon atoms,

25

In this specification, unless stated otherwise, the term "alkyl" includes both straight and branched chain alkyl groups and may be, but are not limited to methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl, t-butyl, n-pentyl, i-pentyl, t-pentyl, neo-pentyl, n-hexyl or i-hexyl, t-hexyl.

30

The term "amine" or "amino" refers to radicals of the general formula -NRR', wherein R and R' are independently selected from hydrogen or a hydrocarbyl radical.

The term "aromatic" refers to hydrocarbonyl radicals having one or more polyunsaturated carbon rings having aromatic character, (*e.g.*, $4n + 2$ delocalized electrons) and comprising 6 up to about 14 carbon atoms.

5

The term "aryl" used alone or as suffix or prefix, refers to a hydrocarbon radical having one or more polyunsaturated carbon rings having aromatic character, (*e.g.*, $4n + 2$ delocalized electrons) and comprising 5 up to about 14 carbon atoms, wherein the radical is located on a carbon of the aromatic ring.

10

In this specification, unless stated otherwise, the term "cycloalkyl" refers to an optionally substituted, saturated cyclic hydrocarbon ring system. The term "C₃₋₇cycloalkyl" may be cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl.

15 The term "heterocycle" or "heterocyclic" or "heterocyclic moiety" refers to ring-containing monovalent and divalent radicals having one or more heteroatoms, independently selected from N, O, P and S, as part of the ring structure and comprising at least 3 and up to about 20 atoms in the rings preferably 5 and 6 membered rings. Heterocyclic moieties may be saturated or unsaturated, containing one or more double bonds, and heterocyclic moieties
20 may contain more than one ring.

The term "heterocycloalkyloxy" denotes a 3- to 7-membered, non-aromatic, partially or completely saturated hydrocarbon group, which contains one ring and at least one heteroatom. Examples of said heterocycle include, but are not limited to pyrrolidinyloxy, pyrrolidonyloxy, piperidinyloxy, piperazinyloxy, morpholinyloxy, oxazolyloxy, 2-oxazolidonyloxy or tetrahydrofuranyloxy.

In this specification, unless stated otherwise, the term "heteroaryl" refers to an optionally substituted monocyclic or bicyclic unsaturated aromatic ring system containing at least one
30 heteroatom selected independently from N, O or S. Examples of "heteroaryl" may be, but are not limited to pyridyl, pyrrolyl, furyl, thienyl, imidazolyl, oxazolyl, isoxazolyl, thia-

zoyl, pyrazoyl, benzofuryl, indoyl, isoindoyl, benzimidazolyl, pyridazinyl, pyrimidinyl, pyrazinyl, tetrazoyl, triazolyl or oxazolyl.

In this specification, unless stated otherwise, the terms “arylalkyl” and “heteroarylalkyl”
5 refer to a substituent that is attached via the alkyl group to an aryl or heteroaryl group.

In this specification, unless stated otherwise, the terms “halo” and “halogen” may be fluoro, iodo, chloro or bromo.

10 In this specification, unless stated otherwise, the term “haloalkyl” means an alkyl group as defined above, which is substituted with halo as defined above. The term “C₁₋₆haloalkyl” may include, but is not limited to fluoromethyl, difluoromethyl, trifluoromethyl, fluoroethyl, difluoroethyl or bromopropyl.

15 The present invention relates to the compounds of the invention as hereinbefore defined as well as to the salts, solvates or solvated salts thereof. Salts for use in pharmaceutical compositions will be pharmaceutically acceptable salts, but other salts may be useful in the production of the compounds of the invention.

A suitable pharmaceutically acceptable salt of the compounds of the invention is, for example,
20 an acid-addition salt, for example an inorganic or organic acid. In addition, a suitable pharmaceutically acceptable salt of the compounds of the invention is an alkali metal salt, an alkaline earth metal salt or a salt with an organic base.

Other pharmaceutically acceptable salts and methods of preparing these salts may be found in, for example, Remington's Pharmaceutical Sciences (18th Edition, Mack Publishing
25 Co.).

Some compounds of the invention may have chiral centres and/or geometric isomeric centres (E- and Z- isomers), and it is to be understood that the invention encompasses all such optical, diastereoisomeric and geometric isomers.

30

The invention also relates to any and all tautomeric forms of the compounds of the invention.

Methods of Preparation

Some compounds of the present invention may be prepared according to the methods described in PCT/SE2004/000738.

5

Another aspect of the present invention provides processes for preparing compounds of formula I, or salts, solvates or solvated salts thereof.

Throughout the following description of such processes it is to be understood that, where appropriate, suitable protecting groups will be added to, and subsequently removed from, the various reactants and intermediates in a manner that will be readily understood by one skilled in the art of organic synthesis. Conventional procedures for using such protecting groups as well as examples of suitable protecting groups are described, for example, in “Protective Groups in Organic Synthesis”, T.W. Green, P.G.M. Wuts, Wiley-Interscience, New York, (1999). References and descriptions of other suitable reactions are described in textbooks of organic chemistry, for example, “Advanced Organic Chemistry”, March, 4th ed. McGraw Hill (1992) or, “Organic Synthesis”, Smith, McGraw Hill, (1994). For representative examples of heterocyclic chemistry see for example “Heterocyclic Chemistry”, J. A. Joule, K. Mills, G. F. Smith, 3rd ed. Chapman and Hall (1995), p. 189-224 and “Heterocyclic Chemistry”, T. L. Gilchrist, 2nd ed. Longman Scientific and Technical (1992), p. 248-282.

15
20


The term “room temperature” and “ambient temperature” shall mean, unless otherwise specified, a temperature between 16 and 25 °C.

Methods of Preparation

One embodiment of the invention relates to processes for the preparation of the compound of formula I according to the General Method A or Method B, wherein R¹ through R⁴, are defined as in formula I, comprising;


25

Method A



- whereby the target compound of formula I is obtained from the benzimidazolylacetic acid of formula II or its deprotonated form, *via* its conversion into an activated form, i.e. either the acyl chloride by treatment with oxalyl chloride or the mixed anhydride by treatment with *O*-(7-azabenzotriazol-1-yl)-*N,N,N',N'*-tetramethyluronium hexafluorophosphate and further treatment with an appropriate amine $\text{NH}_2\text{CHR}^2\text{R}^4$. This reaction may be performed in any manner known to the skilled man in the art. The activation may be performed using any other similar activating reagent like 1,3-dicyclohexylcarbodiimide, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride or 1,1'-carbonyldiimidazole. Suitable solvents to be used for this reaction may be halogenated hydrocarbons such as chloroform, dichloromethane and dichloroethane or aromatic and heteroaromatic compounds such as benzene, toluene, xylene, pyridine and lutidine or ethers such as ethyl ether, tetrahydrofuran and dioxan or aprotic polar solvents like acetonitrile and dimethylformamide, or any mixtures thereof. Catalysts such as heteroaromatic bases like pyridine and lutidine or tertiary amines like triethylamine, *N*-methylmorpholine and ethyl diisopropylamine may be used as well. The temperature may be between -30 and 50°C and the reaction time between 1 and 30 h.
- Starting materials, the acids of formula II, may be obtained using multistep procedures described in detail in the following examples of synthesis, starting from commercially available appropriately 1,2,3-trisubstituted benzenes and 1,2,3,4-tetrasubstituted benzenes.

Method B



whereby the target compound of formula Ia is obtained by two-step procedure from the benzimidazolylacetic acid of formula II or its deprotonated form. The first step includes conversion of acid II into intermediate III according to the procedure of Method A, while at the second step the intermediate is converted into the final product in Mitsunobu conditions using an appropriate alcohol R^5OH .

Intermediates

A further embodiment of the invention relates to compounds selected from the group consisting of

N-[(1S)-1-(4-hydroxyphenyl)ethyl]-2-(7-nitro-1H-benzimidazol-1-yl)acetamide,

1-[6-(2-fluoroethoxy)pyridin-3-yl]ethanamine,

1-[6-(2,2,2-trifluoroethoxy)pyridin-3-yl]ethanamine,

1-[6-(2,2-difluoroethoxy)pyridin-3-yl]ethanamine,

1-[6-(2,2,3,3-tetrafluoropropoxy)pyridin-3-yl]ethanamine,

1-[6-(cyclopentyloxy)pyridin-3-yl]ethanamine,

1-(4-{[(2S)-2-methoxypropyl]oxy}phenyl)ethanamine,

1-[4-(2,2,2-trifluoroethoxy)phenyl]ethanamine,

1-[4-[(1-Methylpiperidin-4-yl)oxy]-3-(trifluoromethyl)phenyl]ethanamine,

1-[4-{[(2S)-2-Methoxypropyl]oxy}-3-(trifluoromethyl)phenyl]ethanamine,
(6,7-difluoro-1*H*-benzimidazol-1-yl)acetic acid,
[(5-*tert*-butyl-2-thienyl)methyl]amine,
[1-(5-*tert*-butylpyridin-2-yl)ethyl]amine,
5 6-*tert*-butyl-4-methylnicotinonitrile,
[1-(6-*tert*-butylpyridin-3-yl)ethyl]amine,
[1-(6-*tert*-butyl-2-chloropyridin-3-yl)ethyl]amine,
[1-(6-*tert*-butyl-2-methoxypyridin-3-yl)ethyl]amine,
[1-(6-*tert*-butyl-4-methylpyridin-3-yl)ethyl]amine,
10 6-*tert*-butyl-2-methylnicotinonitrile, and
[1-(6-*tert*-butyl-2-methylpyridin-3-yl)ethyl]amine.

Another embodiment relates to the use of these compounds as intermediates in the preparation of compounds of the invention.

Pharmaceutical composition

According to one embodiment of the present invention there is provided a pharmaceutical composition comprising as active ingredient a therapeutically effective amount of the compound of the invention, or salts, solvates or solvated salts thereof, in association with
20 one or more pharmaceutically acceptable diluents, excipients and/or inert carriers.

The composition may be in a form suitable for oral administration, for example as a tablet, pill, syrup, powder, granule or capsule, for parenteral injection (including intravenous, subcutaneous, intramuscular, intravascular or infusion) as a sterile solution, suspension or
25 emulsion, for topical administration e.g. as an ointment, patch or cream or for rectal administration e.g. as a suppository.

In general the above compositions may be prepared in a conventional manner using one or more conventional excipients, pharmaceutical acceptable diluents and/or inert carriers.

Suitable daily doses of the compounds of the invention in the treatment of a mammal, including man, are approximately 0.01 to 250 mg/kg bodyweight at peroral administration
30 and about 0.001 to 250 mg/kg bodyweight at parenteral administration.

The typical daily dose of the active ingredient varies within a wide range and will depend

on various factors such as the relevant indication, severity of the illness being treated, the route of administration, the age, weight and sex of the patient and the particular compound being used, and may be determined by a physician.

5 Examples of pharmaceutical composition

The following illustrate representative pharmaceutical dosage forms containing a compound of the invention, or salts, solvates or solvated salts thereof, (hereafter compound X), for preventive or therapeutic use in mammals:

(a): Tablet	mg/tablet
Compound X	100
Lactose	182.75
Croscarmellose sodium	12.0
Maize starch paste (5% w/v paste)	2.25
Magnesium stearate	3.0

10

(b): Capsule	mg/capsule
Compound X	10
Lactose	488.5
Magnesium stearate	1.5

(c): Injection	(50 mg/ml)
Compound X	5.0% w/v
1M Sodium hydroxide solution	15.0% v/v
0.1M Hydrochloric acid	(to adjust pH to 7.6)
Polyethylene glycol 400	4.5% w/v
Water for injection	up to 100%

The above compositions may be obtained by conventional procedures well known in the pharmaceutical art.

Medical use

Surprisingly, it has been found that the compounds according to the present invention are useful in therapy. The compounds of the invention, or salts, solvates or solvated salts thereof, as well as their corresponding active metabolites, exhibit a high degree of potency
5 and selectivity for individual vanilloid receptor 1 (VR1) groups. Accordingly, the compounds of the present invention are expected to be useful in the treatment of conditions associated with excitatory activation of vanilloid receptor 1 (VR1).

The compounds may be used to produce an inhibitory effect of VR1 in mammals, including man.

10 VR1 are highly expressed in the peripheral nervous system and in other tissues. Thus, it is expected that the compounds of the invention are well suited for the treatment of VR1 mediated disorders.

The compounds of the invention are expected to be suitable for the treatment of acute
15 and chronic pain, acute and chronic neuropathic pain and acute and chronic inflammatory pain.

Examples of such disorder may be selected from the group comprising low back pain, post-operative pain, visceral pains like chronic pelvic pain and the like.

The compounds of the invention are also expected to be suitable for the treatment of
20 acute and chronic nociceptive pain.

Further relevant disorders may be selected from the group comprising cystitis, including interstitial cystitis and pain related thereto, ischemic, sciatica, diabetic neuropathy, multiple sclerosis, arthritis, osteoarthritis, rheumatoid arthritis, fibromyalgia, pain and other signs and symptoms associated with psoriasis, pain and other signs and symptoms associated
25 with cancer, emesis, urinary incontinence, hyperactive bladder and HIV neuropathy.

Additional relevant disorders may be selected from the group comprising gastro-esophageal reflux disease (GERD), irritable bowel syndrome (IBS), inflammatory bowel disease (IBD) and pancreatitis.

Other relevant disorders are related to respiratory diseases and may be selected from the
30 group comprising asthma, cough, chronic obstructive lung disease, specifically chronic obstructive pulmonary disease (COPD) and emphysema, lung fibrosis and interstitial lung disease.

Yet other relevant disorders are obesity and obesity-related diseases or disorders, or migraine.

In one embodiment the obesity or obesity-related diseases or disorders is selected from the following: type 1 diabetes, type 2 diabetes, impaired glucose tolerance, cardiovascular disease, hypertension, insulin resistance, cancer and reproductive disorders.

The VR1 inhibitor(s) may be administrated by either an oral or inhaled route. The respiratory disease may be an acute and chronic illness and may be related to infection(s) and/or exposure to environmental pollution and/or irritants.

The compounds of the invention may also be used as antitoxin to treat (over-) exposure to VR1 activators like capsaicin, tear gas, acids or heat. Regarding heat, there is a potential use for VR1 antagonists in (sun-) burn induced pain, or inflammatory pain resulting from burn injuries.

The compounds may further be used for treatment of tolerance to VR1 activators.

One embodiment of the invention relates to the compounds of the invention as hereinbefore defined, for use as a medicament.

Another embodiment of the invention relates to the compounds of the invention as hereinbefore defined, for use as a medicament for treatment of VR1 mediated disorders.

A further embodiment of the invention relates to the compounds of the invention as hereinbefore defined, for use as a medicament for treatment of acute and chronic pain disorders.

Another embodiment of the invention relates to the compounds of the invention as hereinbefore defined for use as a medicament for treatment of acute and chronic nociceptive pain.

Yet another embodiment of the invention relates to the compounds of the invention as hereinbefore defined, for use as a medicament for treatment of acute and chronic neuropathic pain.

Yet a further embodiment of the invention relates to the compounds of the invention as hereinbefore defined, for use as a medicament for treatment of acute and chronic inflammatory pain.

5

One embodiment of the invention relates to the compounds of the invention as hereinbefore defined, for use as a medicament for treatment of low back pain, post-operative pain and visceral pains like chronic pelvic pain.

10 Another embodiment of the invention relates to the compounds of the invention as hereinbefore defined, for use as a medicament for treatment of cystitis, including interstitial cystitis and pain related thereto, ischeamic, sciatica, diabetic neuropathy, multiple sclerosis, arthritis, osteoarthritis, rheumatoid arthritis, fibromyalgia, pain and other signs and symptoms associated with psoriasis, pain and other signs and symptoms associated with cancer,
15 emesis, urinary incontinence, hyperactive bladder and HIV neuropathy.

A further embodiment of the invention relates to the compounds of the invention as hereinbefore defined, for use as a medicament for treatment of gastro-esophageal reflux disease (GERD), irritable bowel syndrome (IBS), inflammatory bowel disease (IBD) and pan-
20 creatitis.

Yet a further embodiment of the invention relates to the compounds of the invention as hereinbefore defined, for use as a medicament for treatment of respiratory diseases selected from the group comprising asthma, cough, chronic obstructive pulmonary disease (COPD),
25 chronic obstructive lung disease and emphysema, lung fibrosis and interstitial lung disease.

One embodiment of the invention relates to the use of the compound of the invention as hereinbefore defined, in the manufacture of a medicament for treatment of VR1 mediated disorders and for treatment of acute and chronic pain disorders, acute and chronic
30 neuropathic pain and acute and chronic inflammatory pain, and respiratory diseases and any other disorder mentioned above.

Another embodiment of the invention relates to a method of treatment of VR1 mediated disorders and acute and chronic pain disorders, acute and chronic neuropathic pain and acute and chronic inflammatory pain, and respiratory diseases, and any other disorder mentioned above, comprising administering to a mammal, including man in need of such treatment, a therapeutically effective amount of the compounds of the invention, as herein-
5 before defined.

A further embodiment of the invention relates to a pharmaceutical composition comprising a compound of the invention as hereinbefore defined, for use in treatment of VR1 mediated disorders and for treatment of acute and chronic pain disorders, acute and chronic
10 neuropathic pain and acute and chronic inflammatory pain, and respiratory diseases, and any other disorder mentioned above.

In the context of the present specification, the term "therapy" and "treatment" includes prevention and prophylaxis, unless there are specific indications to the contrary. The terms
15 "treat", "therapeutic" and "therapeutically" should be construed accordingly.

In this specification, unless stated otherwise, the term "inhibitor" and "antagonist" mean a compound that by any means, partly or completely, blocks the transduction pathway lead-
20 ing to the production of a response by the ligand.

The term "disorder", unless stated otherwise, means any condition and disease associated with vanilloid receptor activity.

25 **Non- Medical use**

In addition to their use in therapeutic medicine, the compounds of the invention, or salts, solvates or solvated salts thereof, are also useful as pharmacological tools in the development and standardisation of *in vitro* and *in vivo* test systems for the evaluation of the effects of inhibitors of VR1 related activity in laboratory animals such as cats, dogs, rabbits,
30 monkeys, rats and mice, as part of the search for new therapeutics agents.

Examples

The invention will now be illustrated by the following non-limiting examples.

Abbreviations

5	DCE	dichloroethane
	DCM	dichloromethane
	DMAP	dimethylaminopyridine
	EDC	1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride
10	HATU	O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate
	HPLC	high performance liquid chromatography
	LC	liquid chromatography
	MS	mass spectrometry
15	ret. time	retention time
	TFA	trifluoroacetic acid
	THF	tetrahydrofuran
	DMF	dimethylformamide
	TMEDA	tetramethylethylenediamine
20	EtOAc	ethyl acetate

General methods


All starting materials are commercially available or described in the literature. The ¹H NMR spectra were recorded on Bruker at 400 MHz. The mass spectra were recorded
25 utilising electrospray (LC-MS; LC:Waters 2790, column XTerra MS C₈ 2.5 μm 2.1X30 mm, buffer gradient H₂O+0.1%TFA:CH₃CN+0.04%TFA, MS: micromass ZMD// ammonium acetate buffer) ionisation techniques.

Synthesis of the intermediates: 7-substituted 1H-benzimidazol-1-yl-acetic acids, 1) - 5)

30 **1) (7-Nitro-1H-benzimidazol-1-yl)acetic acid** - this synthesis is described in WO2004/100865.

2) (7-chloro-1*H*-benzimidazol-1-yl)acetic acid - this synthesis is described in WO2004/100865.

3) (6,7-difluoro-1*H*-benzimidazol-1-yl)acetic acid



5

a) Ethanol, aminoethanol, b) Pd/C 10%, ethanol, ethyl acetate c) 1- formic acid, 2- 2N NH₃ ethanol
d) TEMPO, NaClO₂, NaClO, MeCN, 6.8 Phosphate buffer

A 2-[(2,3-difluoro-6-nitrophenyl)amino]ethanol: A solution of 1,2,3-trifluoro-4-nitrobenzene (5.0 g, 28.2 mmol) and ethanolamine (1.72 g, 28.2 mmol) in 100 ml of ethanol is stirred over night at room temperature then at 70 °C for 5 hours. The reaction is concentrated to dryness and purified by silica gel flash chromatography using a gradient of 80/20 to 20/80 heptane/ethyl acetate providing an orange solid. Yield (3.8 g, 62 %). ¹H NMR (400 MHz, CDCl₃) δ ppm 1.67 (t, *J*=5.08 Hz, 1 H) 3.77 - 3.83 (m, 2 H) 3.88 - 3.94 (m, 2 H) 6.51 (ddd, *J*=9.77, 8.59, 7.03 Hz, 1 H) 8.02 (ddd, *J*=9.77, 5.66, 2.34 Hz, 1 H) 8.21 (s, 1 H)

B 2-[(6-amino-2,3-difluorophenyl)amino]ethanol: To a solution of 2-[(2,3-difluoro-6-nitrophenyl)amino]ethanol (3.8 g, 17.4 mmol) in 70 ml of ethyl acetate and 30 ml of ethanol is added 10 % Pd/C (380 mg). The reaction is shaken under 50 PSI of hydrogen for 3 hours. The pressure is periodically adjusted to 50 PSI. The reaction is filtered through celite, rinsed with ethanol and concentrated. The resulting material is used without further purification in the next step. ¹H NMR (400 MHz, CDCl₃) δ ppm 3.17 - 3.27 (m, 2 H) 3.68 - 3.78 (m, 2 H) 6.38 (ddd, *J*=8.89, 4.69, 2.05 Hz, 1 H) 6.61 - 6.70 (m, 1 H)

25

C 2-(6,7-difluoro-1*H*-benzimidazol-1-yl)ethanol: A solution of 2-[(6-amino-2,3-difluorophenyl)amino]ethanol in 100 ml of formic acid is heated at 100 °C for 2 hours. The reaction is concentrated to dryness, taken into 100 ml of 2 N NH₃ in ethanol and stirred for 2.5 hrs. The reaction is concentrated and taken into ethyl acetate. The resulting precipitate is collected by filtration and rinsed with cold ethyl acetate. The mother liquor is concentrated and purified by silica gel flash chromatography using ethyl acetate/heptane. The combined yield is 3.2 g or 93 % for two steps based on 3.8 g of 2-[(2,3-difluoro-6-nitrophenyl)amino]ethanol. ¹H NMR (400 MHz, CDCl₃) δ ppm 4.06 (dt, *J*=4.78, 0.98 Hz, 2 H), 4.39 (t, *J*=4.78 Hz, 2 H), 6.92 (ddd, *J*=11.03, 8.89, 7.42 Hz, 1 H), 7.12 (ddd, *J*=8.89, 3.71, 1.27 Hz, 1 H), 7.76 (s, 1 H)

D (6,7-difluoro-1*H*-benzimidazol-1-yl)acetic acid.

2-(6,7-difluoro-1*H*-benzimidazol-1-yl)ethanol (2.96 g, 15 mmol) is taken into 75 ml of MeCN and sodium phosphate buffer (56 ml, 0.67 M, pH 6.8) and the mixture is heated to 42 °C. Tempo (165 mg, 1.05 mol) is added followed by the simultaneous dropwise addition of a solution of NaClO₂ (3.38 g, 80 % pure, 30 mmol in 15 ml water) and a solution of bleach (350 μL of 6 % NaOCl in 7.5 mL water) over 1.5 hours. After 48 hrs, the same quantities of NaClO₂ and bleach are added. After a further 24 hours, Tempo (165 mg, 1.05 mol) is added and the reaction is stirred for 72 hrs. The darkened reaction is allowed to cool to room temperature followed by the dropwise addition of 30 ml of a saturated solution of Na₂SO₃ (exothermic). The reaction becomes almost colourless. Using 2 N NaOH, the pH is raised to 9.2 and the reaction is extracted 4 times with ethyl acetate. The pH is then lowered to 3.8 with 2 N HCl and the solution allowed to stand for 48 hours. 1.98 grams of white crystalline material is recovered. The mother liquor is reduced to half the volume and allowed to stand. A further 260 mg is collected. (Combined yield 2.23 g, 70 %)

¹H NMR (400 MHz, DMSO-D₆) δ ppm 5.19 (s, 2 H) 7.25 (ddd, *J*=11.62, 8.89, 7.62 Hz, 1 H) 7.49 (ddd, *J*=8.94, 3.86, 1.07 Hz, 1 H) 8.13 - 8.28 (m, 1 H) 13.38 (s, 1 H)

4) (7-Cyano-1*H*-benzimidazol-1-yl)acetic acid - this synthesis is described in WO2004/100865, Example 12.

5) (7-Acetyl-1H-benzimidazol-1-yl)acetic acid

A. 1-[1-(2-Hydroxyethyl)-1H-benzimidazol-7-yl]ethanone.

A solution of 1-(2-hydroxyethyl)-1H-benzimidazole-7-carbonitrile (0.29 g, 1.5 mmol) in dry THF (6.2 ml) was cooled to -78°C and MeLi (5.8 mL, 9.3 mmol) was added slowly.

5 After the addition the reaction mixture was allowed to warm up to ambient temperature and kept such for 30 min. Then the temperature was brought down to -78°C again and water (4 ml) was added slowly. After warming up the reaction mixture was acidified to pH 4 and heated at 50°C for 30 min. Solvents were removed under reduced pressure and the residue was partitioned between ethyl acetate and aq. NaHCO_3 . The organic extract was
10 further washed with water and brine, dried over Na_2SO_4 and concentrated. Purification was performed on flash silica column using ethyl acetate – methanol as the eluent.

Yield 0.25 g (80%). Calculated for $\text{C}_{11}\text{H}_{12}\text{N}_2\text{O}_3$ m/z : 204.23, found 205.23 $[\text{M}+\text{H}]^+$.

^1H NMR (400 MHz, DMSO- D_6) δ ppm 2.67 (s, 3 H) 3.51 (q, $J=5.1$ Hz, 2 H) 4.41 (t, $J=5.3$ Hz, 2 H) 4.77 (t, $J=5.1$ Hz, 1 H) 7.29 (t, $J=7.8$ Hz, 1 H) 7.78 (dd, $J=7.6$, 1.0 Hz, 1 H) 7.88
15 (dd, $J=8.1$, 1.0 Hz, 1 H) 8.20 (s, 1 H).

B. The title compound: (7-acetyl-1H-benzimidazol-1-yl)acetic acid, was prepared and isolated as a triethylammonium salt according to the procedure described for the synthesis of (7-Cyano-1H-benzimidazol-1-yl)acetic acid (part D). Yield 116 mg (30%). Calculated for
20 $\text{C}_{11}\text{H}_{10}\text{N}_2\text{O}_3$ m/z : 218.21, found 219.16 $[\text{M}+\text{H}]^+$. ^1H NMR (400 MHz, DMSO- D_6) δ ppm 1.02 (t, $J=7.1$ Hz, 9 H) 2.56 (s, 3 H) 2.68 - 2.77 (m, 6 H) 4.91 (s, 2 H) 7.24 (t, $J=7.8$ Hz, 1 H) 7.70 (d, $J=7.6$ Hz, 1 H) 7.81 - 7.85 (m, 1 H) 8.16 (s, 1 H).

Syntheses of the intermediates: amines, 6) – 16)**25 6) N-[(1S)-1-(4-hydroxyphenyl)ethyl]-2-(7-nitro-1H-benzimidazol-1-yl)acetamide**

The title compound was synthesised according to the general method of synthesis of target compounds (see below) from (7-nitro-1H-benzimidazol-1-yl)acetic acid and 4-[(1S)-1-aminoethyl]phenol. ^1H NMR (400 MHz, DMSO- d_6) δ ppm 9.26 (s, 1 H) 8.55 (d, $J=8.03$ Hz, 1 H) 8.40 (s, 1 H) 8.10 (d, $J=8.03$ Hz, 1 H) 7.98 (d, $J=7.53$ Hz, 1 H) 7.39 (t, $J=8.03$ Hz, 1 H) 7.05 - 7.15 (m, 2 H) 6.64 - 6.75 (m, 2 H) 5.19 (s, 2 H) 4.71 - 4.83 (m, 1 H) 1.32
30 (d, $J=6.78$ Hz, 3 H). MS (ESI) m/z : 341 $[\text{M}+\text{H}]$

7) 1-[6-(2,2,2-trifluoroethoxy)pyridin-3-yl]ethanamine**A. 6-(2,2,2-trifluoroethoxy)nicotinonitrile**

To 6-chloronicotinonitrile (0.30 g, 2.2 mmol) was a mixture of 2,2,2-trifluoroethanol (0.19 mL, 2.6 mmol) and potassium *tert*-butoxide (1M solution in THF, 2.5 mL, 2.5 mmol) added at 0-5°C. The resulting mixture was stirred at ambient temperature for 1 hour. Water was added (20 mL) followed by extraction with ethyl acetate (2 x 20 mL). The organic layer was dried over sodium sulphate and concentrated in vacuum affording 6-(2,2,2-trifluoroethoxy)nicotinonitrile, 0.42 g (96%). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 8.76 (d, *J*=2.26 Hz, 1 H) 8.28 (dd, *J*=8.53, 2.26 Hz, 1 H) 7.21 (d, *J*=8.78 Hz, 1 H) 5.09 (q, *J*=8.95 Hz, 2 H).

B. To 6-(2,2,2-trifluoroethoxy)nicotinonitrile (0.42 g, 2.1 mmol) in THF (4 mL) methyl magnesium bromide (3M in diethyl ether, 1.4 mL, 4.2 mmol) was added dropwise at -78°C. The reaction mixture was stirred at ambient temperature for 3-5 hours then cooled to -78°C. Methanol (10 mL) was added followed by addition of sodium borohydride (0.24 g, 6.3 mmol) and the reaction mixture was stirred at ambient temperature overnight. The mixture was diluted with water (20 mL), concentrated and extracted with chloroform (40 mL). The mixture was filtered to facilitate separation of the layers. The organic phase was separated and extracted with hydrochloric acid (5%, 20 mL). The aqueous phase was concentrated to dryness in vacuum and coevaporated twice with acetonitrile to yield the title product as a salt with hydrochloric acid (0.4 g, 75%). It was converted into the neutral form of 1-[6-(2,2,2-trifluoroethoxy)pyridin-3-yl]ethanamine by extraction with chloroform from a basicified (pH 8-9) water solution. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 8.13 (d, *J*=2.26 Hz, 1 H) 7.81 (dd, *J*=8.53, 2.51 Hz, 1 H) 6.91 (d, *J*=8.28 Hz, 1 H) 4.96 (q, *J*=9.29 Hz, 2 H) 4.00 (q, *J*=6.53 Hz, 1 H) 1.24 (d, *J*=6.53 Hz, 3 H). MS (ESI) *m/z*: 221 [M+H]

8) 1-[6-(2-fluoroethoxy)pyridin-3-yl]ethanamine

The title compound was synthesised according to the 2-step procedure described for the synthesis of 1-[6-(2,2,2-trifluoroethoxy)pyridin-3-yl]ethanamine starting from 6-chloronicotinonitrile and 2-fluoroethanol.

6-(2-fluoroethoxy)nicotinonitrile ^1H NMR (400 MHz, $\text{DMSO-}d_6$) δ ppm 8.70 (d, $J=2.51$ Hz, 1 H) 8.18 (dd, $J=8.66$, 2.38 Hz, 1 H) 7.07 (d, $J=8.78$ Hz, 1 H) 4.49 - 4.88 (m, 4 H). MS (ESI) m/z : 167 $[\text{M}+\text{H}]$

1-[6-(2-fluoroethoxy)pyridin-3-yl]ethanamine ^1H NMR (400 MHz, $\text{DMSO-}d_6$) δ ppm 8.08 (d, $J=2.26$ Hz, 1 H) 7.74 (dd, $J=8.53$, 2.51 Hz, 1 H) 6.80 (d, $J=8.53$ Hz, 1 H) 4.37 - 4.81 (m, 4 H) 3.97 (q, $J=6.53$ Hz, 1 H) 1.24 (d, $J=6.53$ Hz, 3 H). MS (ESI) m/z : 185 $[\text{M}+\text{H}]$

9) 1-[6-(2,2-difluoroethoxy)pyridin-3-yl]ethanamine

The title compound was synthesised according to the 2-step procedure described for the synthesis of 1-[6-(2,2,2-trifluoroethoxy)pyridin-3-yl]ethanamine starting from 6-chloronicotinonitrile and 2,2-difluoroethanol.

6-(2,2-difluoroethoxy)nicotinonitrile: ^1H NMR (400 MHz, $\text{DMSO-}d_6$) δ ppm 8.73 (d, $J=2.51$ Hz, 1 H) 8.23 (dd, $J=8.78$, 2.51 Hz, 1 H) 7.14 (dd, $J=8.66$, 0.63 Hz, 1 H) 6.23 - 6.62 (m, 1 H) 4.58 - 4.74 (m, 2 H)

1-[6-(2,2-difluoroethoxy)pyridin-3-yl]ethanamine: ^1H NMR (400 MHz, $\text{DMSO-}d_6$) δ ppm 8.11 (d, $J=2.51$ Hz, 1 H) 7.77 (dd, $J=8.53$, 2.51 Hz, 1 H) 6.85 (d, $J=8.53$ Hz, 1 H) 6.19 - 6.54 (m, 1 H) 4.46 - 4.60 (m, 2 H) 3.99 (q, $J=6.53$ Hz, 1 H) 1.24 (d, $J=6.53$ Hz, 3 H) MS (ESI) m/z : 203 $[\text{M}+\text{H}]$

10) 1-[6-(2,2,3,3-tetrafluoropropoxy)pyridin-3-yl]ethanamine

The title compound was synthesised according to the 2-step procedure described for the synthesis of 1-[6-(2,2,2-trifluoroethoxy)pyridin-3-yl]ethanamine starting from 6-chloronicotinonitrile and 2,2,3,3-tetrafluoropropan-1-ol.

6-(2,2,3,3-tetrafluoropropoxy)nicotinonitrile: ^1H NMR (400 MHz, $\text{DMSO-}d_6$) δ ppm 8.75 (d, $J=2.26$ Hz, 1 H) 8.26 (dd, $J=8.53$, 2.26 Hz, 1 H) 7.17 (d, $J=8.78$ Hz, 1 H) 6.51 - 6.84 (m, 1 H) 4.96 (t, $J=14.18$ Hz, 2 H)

1-[6-(2,2,3,3-tetrafluoropropoxy)pyridin-3-yl]ethanamine: ^1H NMR (400 MHz, $\text{DMSO-}d_6$) δ ppm 8.12 (d, $J=2.51$ Hz, 1 H) 7.80 (dd, $J=8.53$, 2.51 Hz, 1 H) 6.88 (d, $J=8.53$ Hz, 1 H) 6.48 - 6.82 (m, 1 H) 4.82 (t, $J=14.30$ Hz, 2 H) 3.99 (q, $J=6.61$ Hz, 1 H) 1.24 (d, $J=6.78$ Hz, 3 H). MS (ESI) m/z : 253 $[\text{M}+\text{H}]$

11) 1-[6-(cyclopentyloxy)pyridin-3-yl]ethanamine

The title compound was synthesised according to the 2-step procedure described for the synthesis of 1-[6-(2,2,2-trifluoroethoxy)pyridin-3-yl]ethanamine starting from 6-chloronicotinonitrile and cyclopentanol.

5 6-(cyclopentyloxy)nicotinonitrile: ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 8.67 (d, *J*=1.76 Hz, 1 H) 8.11 (dd, *J*=8.78, 2.26 Hz, 1 H) 6.93 (d, *J*=9.29 Hz, 1 H) 5.37 - 5.48 (m, 1 H) 1.84 - 2.05 (m, 2 H) 1.51 - 1.81 (m, 6 H). MS (ESI) *m/z*: 189 [M+H]

1-[6-(cyclopentyloxy)pyridin-3-yl]ethanamine: ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 8.06 (d, *J*=2.51 Hz, 1 H) 7.67 (dd, *J*=8.53, 2.51 Hz, 1 H) 6.67 (d, *J*=8.53 Hz, 1 H) 5.27 -
10 5.36 (m, 1 H) 3.95 (q, *J*=6.53 Hz, 1 H) 1.85 - 2.00 (m, 2 H) 1.53 - 1.77 (m, 6 H) 1.23 (d, *J*=6.78 Hz, 3 H). MS (ESI) *m/z*: 207 [M+H]

12) 1-[4-(2,2,2-trifluoroethoxy)phenyl]ethanamine

The title compound was synthesised according to the procedure described for the synthesis
15 of 1-[6-(2,2,2-trifluoroethoxy)pyridin-3-yl]ethanamine, step B, starting from 4-(2,2,2-trifluoroethoxy)benzonitrile. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 7.28 - 7.34 (m, 2 H) 6.94 - 7.00 (m, 2 H) 4.70 (q, *J*=8.78 Hz, 2 H) 3.95 (q, *J*=6.53 Hz, 1 H) 1.21 (d, *J*=6.78 Hz, 3 H). MS (ESI) *m/z*: 220 [M+H]

20 14) 1-[4-[(1-Methylpiperidin-4-yl)oxy]-3-(trifluoromethyl)phenyl]ethanamine**A. 4-[(1-Methylpiperidin-4-yl)oxy]-3-(trifluoromethyl)benzonitrile**

A mixture of 4-hydroxy-*N*-methylpiperidine (133 mg, 1.15 mmol) and potassium *tert*-butoxide (150 mg, 1.27 mmol) in tetrahydrofuran (2.5 mL) was stirred under nitrogen for 10 min. 4-Fluoro-3-(trifluoromethyl)benzonitrile (218 mg, 1.15 mmol) was added, and the
25 reaction mixture was stirred at ambient temperature for 1 h. The solvent was removed *in vacuo*, and the residue was partitioned between a 1 M NaOH solution and ethyl acetate. The organic layer was dried (Na₂SO₄) and evaporated. The residue was purified by column chromatography on silica gel (eluent: CHCl₃/MeOH/conc. NH₃, 95:5:0.5) affording 0.18 g (54% yield) of the pure product as a colourless solid. MS (APCI) *m/z* 285 [M+H]. ¹H NMR
30 (400 MHz, DMSO-*D*₆) δ ppm 1.67-1.74 (m, 2 H), 1.89-1.95 (m, 2 H), 2.16 (s, 3 H), 2.26-2.31 (m, 2 H), 2.44-2.48 (m, 2 H), 4.78-4.82 (m, 1 H), 7.51 (d, *J* = 8.8 Hz, 1 H), 8.08 (dd, *J* = 8.8, 2.0 Hz, 1 H), 8.14 (d, *J* = 2.0 Hz, 1 H).

B. The title compound was synthesized according to the procedure described for the synthesis of 1-[6-(2,2,2-trifluoroethoxy)pyridin-3-yl]ethanamine, step B, starting from 4-[(1-methylpiperidin-4-yl)oxy]-3-(trifluoromethyl)benzonitrile. Yield 49 mg, 62% (oil) after column chromatography on silica gel (eluent: CHCl₃/MeOH/conc.NH₃, 80:20:1). MS (APCI) *m/z* 303 [M+H]. ¹H NMR (400 MHz, DMSO-D₆) δ ppm 1.23 (d, *J* = 6.5 Hz, 3 H), 1.64-1.72 (m, 2 H), 1.86-1.92 (m, 2 H), 2.17 (s, 3 H), 2.21-2.27 (m, 2 H), 2.47-2.55 (m, partly overlapped with DMSO peaks, 2 H), 3.97-4.02 (m, 1 H), 4.55-4.60 (m, 1 H), 7.21 (d, *J* = 8.9 Hz, 1 H), 7.55 (dd, *J* = 8.7, 1.9 Hz, 1 H), 7.60 (d, *J* = 2.0 Hz, 1 H).

15) 1-[4-{{(2S)-2-Methoxypropyl}oxy}-3-(trifluoromethyl)phenyl]ethanamine

The title compound was synthesized according to the procedure described for the synthesis of 1-[4-[(1-methylpiperidin-4-yl)oxy]-3-(trifluoromethyl)phenyl]ethanamine, part A and B, starting from 4-fluoro-3-(trifluoromethyl)benzonitrile and (S)-(+)-2-methoxypropanol.

Yield 39 mg, 30% (oil) after column chromatography on silica gel (eluent: CHCl₃/MeOH/conc.NH₃, 92:8:0.5). MS (APCI) *m/z* 278 [M+H]. ¹H NMR (400 MHz, DMSO-D₆) δ ppm 1.18 (d, *J* = 6.5 Hz, 3 H), 1.22 (d, *J* = 6.5 Hz, 3 H), 3.32 (s, overlapped with water peak, 3 H), 3.62-3.68 (m, 1 H), 3.98-4.08 (m, 3 H), 7.18 (d, *J* = 8.5 Hz, 1 H), 7.55-7.58 (m, 1 H), 7.60-7.61 (m, 1 H).

16) 1-(4-{{(2S)-2-methoxypropyl}oxy}phenyl)ethanamine

A. *tert*-butyl [1-(4-hydroxyphenyl)ethyl]carbamate

To 1-(4-hydroxyphenyl)ethanamine (0.96 g, 7.0 mmol) in THF (20 mL) triethylamine (2.9 mL, 21 mmol) was added followed by the addition of di-*tert*-butyl dicarbonate (1.8 g, 8.4 mmol) in THF (20 mL) during 5 minutes. The resulting mixture was stirred for 15 hours, the volatiles removed under reduced pressure and the residue purified by silica gel column chromatography using a gradient of heptanes : ethyl acetate 9:1 to 1:1 affording 1.1 g of the *tert*-butyl [1-(4-hydroxyphenyl)ethyl]carbamate (64 %). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 9.18 (s, 1 H) 7.18 (d, *J*=7.78 Hz, 1 H) 7.03 - 7.11 (m, *J*=8.41 Hz, 2 H) 6.63 - 6.72 (m, 2 H) 4.45 - 4.56 (m, 1 H) 1.35 (s, 9 H) 1.25 (d, *J*=7.03 Hz, 3 H)


MS (ESI) *m/z*: 238 [M+H]

B. *tert*-butyl [1-(4-{[(2*S*)-2-methoxypropyl]oxy}phenyl)ethyl]carbamate

To *tert*-butyl [1-(4-hydroxyphenyl)ethyl]carbamate (0.31 g, 1.3 mmol) in THF (10 mL) (s)-(+)-2-methoxypropanol (0.14 g, 1.5 mmol), triphenylphosphine (0.36 g, 1.4 mmol) and diisopropyl azodicarboxylate (0.27 mL, 1.4 mmol) were added; the resulting reaction
 5 mixture stirred at ambient temperature for 21 hours. The volatiles were removed under reduced pressure and the residue purified on silica gel column chromatography using heptanes : ethyl acetate 4:1 affording 0.29 g of *tert*-butyl [1-(4-{[(2*S*)-2-methoxypropyl]oxy}phenyl)ethyl]carbamate (74 %). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 7.29 (d, *J*=8.28 Hz, 1 H) 7.15 - 7.21 (m, *J*=8.78 Hz, 2 H) 6.84 - 6.89 (m, *J*=8.53 Hz, 2 H) 4.50 -
 10 4.60 (m, 1 H) 3.84 - 3.93 (m, 2 H) 3.59 - 3.68 (m, 1 H) 3.30 (s, 3 H) 1.35 (s, 9 H) 1.26 (d, *J*=7.03 Hz, 3 H) 1.15 (d, *J*=6.53 Hz, 3 H). MS (ESI) *m/z*: 310 [M+H]

C. 1-(4-{[(2*S*)-2-methoxypropyl]oxy}phenyl)ethanamine

tert-Butyl [1-(4-{[(2*S*)-2-methoxypropyl]oxy}phenyl)ethyl]carbamate (0.29 g, 0.94 mmol)
 15 was treated with trifluoroacetic acid (2 mL) in dichloromethane (18 mL) for 25 minutes, the volatiles removed under reduced pressure and the residue purified by silica gel column chromatography using dichloromethane : methanol : triethylamine 98:1:1 giving the title compound in 0.12 g (59 %) yield. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 8.14 (s, 2 H) 7.34 - 7.41 (m, *J*=8.78 Hz, 2 H) 6.97 - 7.03 (m, 2 H) 4.35 (q, *J*=6.78 Hz, 1 H) 3.93 (d, *J*=5.02 Hz, 2 H) 3.60 - 3.70 (m, 1 H) 3.30 (s, 3 H) 2.96 (q, *J*=7.11 Hz, 1 H) 1.45 (d, *J*=6.78 Hz, 3 H) 1.16 (d, *J*=6.27 Hz, 3 H)


Syntheses of the intermediates: amines, 19) – 20)**19) [(5-*tert*-butyl-2-thienyl)ethyl]amine.**

1-(5-*tert*-butyl-2-thienyl)ethanone (410 mg, 2.2 mmol) and Ti(OiPr)₄ (128 mg, 4.5 mmol) are stirred overnight in 2 N NH₃ in ethanol (5.5 mL, 11 mmol). To this paste is added
 30 NaBH₄ (124 mg, 3.3 mmol) and stirring is continued for a further 24 hrs. The reaction is


then diluted with NH_4OH and stirred for 1 hour. The mixture is filtered through celite and rinsed with ethyl acetate. Water and ethyl acetate are added and the organic layer is separated. The aqueous layer is extracted three times with ethyl acetate and the combined organics are washed with 1 N HCl. The aqueous phase is separated and washed with ethyl acetate, made basic with 1 N NaOH then extracted three times with ethyl acetate. The combined organic layers are then dried with over MgSO_4 , filtered and concentrated. Yielded 171 mg, 42 %.

^1H NMR (400 MHz, CDCl_3) δ ppm 1.37 (s, 9 H), 1.47 (d, $J=6.64$ Hz, 3 H), 4.29 (q, $J=6.64$, 1 H), 6.64 (d, $J=3.52$ Hz, 1 H), 6.69 (dd, $J=3.52$, 0.59 Hz, 1 H).

20 [1-(5-*tert*-butylpyridin-2-yl)ethyl]amine



1-(5-*tert*-butylpyridin-2-yl)ethanone (2.2 mmol) and $\text{Ti}(\text{O}i\text{Pr})_4$ (128 mg, 4.5 mmol) are stirred overnight in 2 N NH_3 in ethanol (5.5 ml, 11 mmol). To this paste is added NaBH_4 (124 mg, 3.3 mmol) and stirring is continued for a further 24 hrs. The reaction is then diluted with NH_4OH and stirred for 1 hour. The mixture is filtered through celite and rinsed with ethyl acetate. Water and ethyl acetate are added and the organic layer is separated. The aqueous layer is extracted three times with ethyl acetate and the combined organics are washed with 1 N HCl. The aqueous phase is separated and washed with ethyl acetate, made basic with 1 N NaOH then extracted three times with ethyl acetate. The combined organic layers are then dried with over MgSO_4 , filtered and concentrated.

Syntheses of the intermediates: nicotinonitriles, 21) – 24)**Intermediate 21:** R=H, R'=H**Intermediate 22:** R=H, R'=Cl**Intermediate 23:** R=H, R'=OCH₃**Intermediate 24:** R=CH₃, R'=Ha) (CH₃)₃CO₃H, AgNO₃, H₂SO₄ (NH₄)₂S₂O₈**5 21) 6-*tert*-butylnicotinonitrile**

Pivalic acid (144 mol, 5 eq) and AgNO₃ (3.76 mmol, 0.13 eq) are added to a suspension of the 3-cyanopyridine (29 mmol, 1 eq) in 40 ml H₂O. The mixture is stirred for 20 min after which is added 60 ml of a 10 % H₂SO₄ solution. The reaction is stirred for a further 20 min then heated to 70°C. An aqueous solution of (NH₄)₂S₂O₈ (8.6 mmol, 1.3 eq) is added dropwise over 30 minutes and the heating is continued for 2 hours or until completion by TLC. After cooling the in ice, 2 N NaOH is added and the reaction is extracted 3 times with ethyl acetate, dried over Na₂SO₄, filtered and concentration. Purification is performed on silica gel with ethyl acetate/hexanes.

15 22) 6-*tert*-butyl-2-chloronicotinonitrile

The title compound was synthesized according to the procedure described for the synthesis of 6-*tert*-butylnicotinonitrile starting from 2-chloronicotinonitrile (3.91 g, 28 mmol), pivalic acid (14.4 g, 141 mmol), AgNO₃ (0.622 g, 3.66 mmol), (NH₄)₂S₂O₈ (8.36 g, 36.6 mmol) and 50 ml 10 % H₂SO₄. Purified by normal phase chromatography using 100 heptane to 95/5 heptane/ethyl acetate. (Yield: 42 %, 2.3 g). ¹H NMR (400 MHz, CDCl₃) δ ppm 1.34 (s, 9 H), 7.36 (d, *J*=8.20 Hz, 1 H), 7.88 (d, *J*=8.20 Hz, 1 H).

23) 6-*tert*-butyl-2-methoxynicotinonitrile

The title compound was synthesized according to the procedure described for the synthesis of 6-*tert*-butylnicotinonitrile starting from 2-methoxynicotinonitrile (8.02 g, 5.98 mmol), pivalic acid (3.05 g, 39.9 mmol), AgNO₃ (0.13 g, 0.78 mmol), (NH₄)₂S₂O₈ (1.78 g, 7.78


mmol) and 6 ml 10 % H₂SO₄. Purified by normal phase chromatography using 95/5 to 90/10 heptane/ethyl acetate. (Yield: 80 mg, 7 %). ¹H NMR (400 MHz, CDCl₃) δ ppm 1.33 (s, 9 H), 4.04 (s, 3 H), 6.97 (d, *J*=7.81 Hz, 2 H), 7.78 (d, *J*=7.81 Hz, 2 H).

Intermediate 23 was also prepared by microwaving intermediate 22 (100 mg, 0.5 mmol) in the presence of K₂CO₃ (140 mg, 1.02 mmol) in 1.5 ml of MeOH at 160 °C for 30 min. (Yield: 68 mg, 72 %)

24) 6-*tert*-butyl-4-methylnicotinonitrile

The title compound was synthesized according to the procedure described for the synthesis of 6-*tert*-butylnicotinonitrile starting from 4-methylnicotinonitrile (0.5 g, 4.23 mmol), pivalic acid (2.2 g, 21.1 mmol), AgNO₃ (0.09 g, 0.55 mmol), (NH₄)₂S₂O₈ (1.25 g, 5.5 mmol) and 7.5 ml 10 % H₂SO₄. Purified by normal phase chromatography using 95/5 to 90/10 heptane/ethyl acetate. (Yield: 578 mg, 78 %). ¹H NMR (400 MHz, CDCl₃) δ ppm 1.36 (s, 9 H), 2.53 (s, 3 H), 7.28 (s, 1 H), 8.72 (s, 1 H).

Syntheses of the intermediates: amines, 25) – 28)



Intermediate 25: R=H, R'=H, R''=CH₃

Intermediate 26: R=H, R'=Cl, R''=CH₃

Intermediate 27: R=H, R'=OCH₃, R''=CH₃

Intermediate 28: R=CH₃, R'=H, R''=CH₃

b) 1. 4 M MeMgBr 75/25 toluene/THF, NaBH₄

25) [1-(6-*tert*-butylpyridin-3-yl)ethyl]amine

A solution of MeMgBr 1.4 M 75/25 toluene/THF (8.9 ml, 12.48 mmol) is added dropwise over 5 min to an ice cooled solution of 6-*tert*-butylnicotinonitrile (intermediate 21) (1 g, 6.24 mmol) in 15 mL of THF. The reaction is stirred for 6 hr and cooled with a dry ice bath. MeOH is then added dropwise followed by the incremental addition of NaBH₄ (0.59 g, 15.9 mmol). The reaction is stirred over night, water and CH₂Cl₂ are then added and the resulting paste is filtered through celite and rinsed with CH₂Cl₂. The reaction is concen-

trated to remove the organics and extracted 3 times with ethyl acetate. The combined organic layers are extracted with 1 H HCl. The aqueous layer is basified with 28 % NH₄OH and extracted 3 times with ethyl acetate. The combined organic layers are washed with brine, dried over Na₂SO₄, filtered and concentrated. (Yield: 488 mg, 49 %). ¹H NMR (400 MHz, CDCl₃) δ ppm 1.36 (s, 9 H) 1.40 (d, *J*=6.60 Hz, 3 H) 4.15 (q, *J*=6.60 Hz, 1 H) 7.31 (d, *J*=8.20 Hz, 1 H) 7.63 (dd, *J*=8.20, 2.34 Hz, 1 H) 8.52 (d, *J*=2.34 Hz, 1 H).

26) [1-(6-*tert*-butyl-2-chloropyridin-3-yl)ethyl]amine


The title compound was synthesized according to the procedure described for the synthesis of [1-(6-*tert*-butylpyridin-3-yl)ethyl]amine starting from 6-*tert*-butyl-2-chloronicotinonitrile (intermediate 22) (2.0 g, 10.3 mmol), MeMgBr (18 ml, 25.7 mmol) and NaBH₄ (970 mg, 25.7 mmol). The resulting material was used crude in the following coupling step. (Yield: 1.76 g, 79 %) ¹H NMR (400 MHz, CDCl₃) δ ppm 1.34 (s, 9 H) 1.39 (d, *J*=6.64 Hz, 3 H) 4.47 (q, *J*=6.64 Hz, 1 H) 7.26 (d, *J*=8.01 Hz, 1 H) 7.78 (d, *J*=8.01 Hz, 1 H).

27) [1-(6-*tert*-butyl-2-methoxypyridin-3-yl)ethyl]amine

The title compound was synthesized according to the procedure described for the synthesis of [1-(6-*tert*-butylpyridin-3-yl)ethyl]amine starting from 6-*tert*-butyl-2-methoxynicotinonitrile (intermediate 23) (66 mg, 0.347 mmol), MeMgBr 1.4 M 75/25 toluene/THF (743 μL, 1.04 mmol) and NaBH₄ (32.8 mg, 0.87 mmol). Material isolated from the workup was used without further purification in the preparation.

28) [1-(6-*tert*-butyl-4-methylpyridin-3-yl)ethyl]amine

The title compound was synthesized according to the procedure described for the synthesis of [1-(6-*tert*-butylpyridin-3-yl)ethyl]amines starting from 6-*tert*-butyl-4-methylnicotinonitrile (intermediate 24) (250 mg, 1.43 mmol), MeMgBr 1.4 M 75/25 toluene/THF (2.55 ml, 3.58 mmol) and NaBH₄ (135 mg, 3.58 mmol). Purified by normal phase chromatography with 15 to 20 % MeOH/CH₂Cl₂. (Yield 55 mg, 20 %). ¹H NMR (400 MHz, CDCl₃) δ ppm 1.34 (s, 9 H) 1.42 (d, *J*=6.64 Hz, 3 H) 2.35 (s, 3 H) 4.34 (q, *J*=6.64 Hz, 1 H) 7.07 (s, 1 H) 8.60 (s, 1 H).

Syntheses of the intermediates: amines, 29) – 32)

a) HATU, DIPEA, $\text{NH}_3(\text{g})$, DMF b) cyanuric chloride c) $(\text{CH}_3)_3\text{CO}_3\text{H}$, AgNO_3 , H_2SO_3 $(\text{NH}_4)_2\text{S}_2\text{O}_4$ d) 1. 4 M MeMgBr 75/25 toluene/THF, NaBH_4

5

29) 2-methylnicotinamide

To a solution of 2-methylnicotinic acid (0.537 mg, 3.9 mmol) in 20 mL of DMF at 0 °C was added HATU (1.56 g, 4.1 mmol) followed by the dropwise addition of DIPEA (0.72 ml, 4.1 mmol). $\text{NH}_3(\text{g})$ was then bubbled into the solution for 15 mins. The reaction was allowed to stir overnight. The resulting paste was filtered and rinsed with cold DMF and discarded. The mother liquor was concentrated and purified by normal phase chromatography using $\text{CH}_2\text{Cl}_2/7 \text{ N } \text{NH}_3$ in MeOH: 93/7 as eluent. Yielded a white solid (405 mg, 76 %). ^1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.34 (s, 9 H), 1.36 (d, $J=6.64$ Hz, 3 H), 2.56 (s, 3 H), 4.32 - 4.40 (m, 1 H), 7.15 - 7.19 (m, $J=8.20$ Hz, 1 H), 7.68 (d, $J=8.20$ Hz, 1 H)

15

30) 2-methyl-nicotinonitrile

Cyanuric acid (418 mg, 2.2 mmol) was added in one portion to a suspension of 2-methylnicotinamide (intermediate 29) (613 mg, 4.5 mmol) in 2.5 ml of DMF cooled in ice. The reaction was stirred for 2.5 hours then poured into ice. The reaction was extracted with ethyl acetate until the organic layer no longer contained product. The combined organic layers, were dried over Na_2SO_4 , filtered and concentrated. Purified on normal phase chromatography with ethyl acetate/heptane 0 to 50 gradient then 50/50 EA/heptane. Yield (216 mg, 41 %). ^1H NMR (400 MHz, CHLOROFORM-D) δ ppm 2.78 (s, 3 H), 7.25 (dd, $J=7.71, 4.98$ Hz, 1 H), 7.89 (dd, $J=7.81, 1.56$ Hz, 1 H), 8.68 (s, 1 H)

25

31) 6-tert-butyl-2-methylnicotinonitrile

The title compound was synthesized according to the procedure described for the synthesis of 6-tert-butyl-nicotinonitrile starting from 2-methyl-nicotinonitrile (intermediate 30) (216

mg, 1.7 mmol), pivalic acid (868 mg, 8.5 mmol), AgNO₃ (38.5 mg, 0.23 mmol), (NH₄)₂S₂O₈ (504 mg, 2.2 mmol) and 3.75 ml 10 % H₂SO₄. Purification by normal phase chromatography with 100 % heptane to 90/10 Heptane/EA yielded 240 mg of a mixture of both mono and di-*t*-butylated pyridines. Material used crude in the preparatin of [1-(6-*tert*-butyl-2-methylpyridin-3-yl)ethyl]amine (intermediate 32) below.

32) [1-(6-*tert*-butyl-2-methylpyridin-3-yl)ethyl]amine

The title compound was synthesized according to the procedure described for the synthesis of 6-*tert*-butylnicotinonitrile starting from 6-*tert*-butyl-2-methylnicotinonitrile (intermediate 31) (100 mg, 0.57 mmol), used crude from the above described description; MeMgBr 1.4 M 75/25 toluene/THF (1.4 ml, 1.4 mmol) and NaBH₄ (55 mg, 1.4 mmol). Purified by normal phase chromatography with 20 % MeOH/CH₂Cl₂. (Yield 31.5 mg, 29 %). ¹H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.34 (s, 9 H), 1.36 (d, *J*=6.64 Hz, 3 H), 2.56 (s, 3 H), 4.32 - 4.40 (m, 1 H), 7.15 - 7.19 (m, *J*=8.20 Hz, 1 H), 7.68 (d, *J*=8.20 Hz, 1 H).

Synthesis of the target compounds

General method 1.

To *N*-[(1*S*)-1-(4-hydroxyphenyl)ethyl]-2-(7-nitro-1*H*-benzimidazol-1-yl)acetamide (0.25 g, 0.73 mmol) in THF (10 mL) an appropriate commercially available alcohol (0.88 mmol) and triphenylphosphine (0.21 g, 0.80 mmol) were added followed by addition of diisopropyl azodicarboxylate (160 mL, 0.80 mmol). The reaction mixture was stirred at ambient temperature for 18 hours and the volatiles were removed. The crude product was purified using reversed phase preparative HPLC.

General method 2.

To a solution of a 7-substituted (1*H*-benzimidazol-1-yl)acetic acid, prepared as described above (0.14 mmol), triethylamine (0.04 mL, 0.28 mmol) and an appropriate amine (commercially available or described in the literature or described above, 0.15 mmol) in acetonitrile (1 ml) *O*-(7-azabenzotriazol-1-yl)-*N,N,N',N'*-tetramethyluronium hexafluorophosphate (80 mg, 0.21 mmol) was added. The reaction mixture was stirred at ambient temperature for 0.5 – 3 h. The mixture was quenched with methanol and the volatiles were removed *in vacuo*.

In Examples 7-51, the crude material was purified by preparative HPLC on XTerra C₈ column (19×300 mm) using a gradient of 0.1 M aqueous ammonium acetate in acetonitrile as an eluent.

In Examples 52-76, the crude material was purified by preparative HPLC on a Phenomenex, Synergi 4 μ Polar RP (or Gemini 5 μC18) column using a gradient of 0.05 % aqueous trifluoroacetic acid and acetonitrile as an eluent (or aqueous ammonium bicarbonate 10 mM and acetonitrile depending on the best pH conditions for separation) .

The compounds in Table 1 below were synthesised according to **General method 1**

10

Table 1

Ex. #	Name	MW found [M+H]	¹ H NMR	Starting material
1	N-[(1S)-1-(4-isopropoxyphenyl)ethyl]-2-(7-nitro-1H-benzimidazol-1-yl)acetamide	383.3	(400 MHz, DMSO-d ₆) δ ppm 8.61 (d, J=7.83 Hz, 1 H) 8.40 (s, 1 H) 8.10 (dd, J=7.96, 0.88 Hz, 1 H) 7.98 (d, J=8.08 Hz, 1 H) 7.39 (t, J=7.96 Hz, 1 H) 7.16 - 7.25 (m, 2 H) 6.81 - 6.88 (m, 2 H) 5.20 (s, 2 H) 4.74 - 4.84 (m, 1 H) 4.52 - 4.63 (m, 1 H) 1.34 (d, J=7.07 Hz, 3 H) 1.25 (d, J=6.06 Hz, 6 H)	propan-2-ol

Ex. #	Name	MW found [M+H]	¹ H NMR	Starting material
2	N-((1S)-1-{4-[2-fluoro-1-(fluoromethyl)ethoxy]phenyl}ethyl)-2-(7-nitro-1H-benzimidazol-1-yl)acetamide	419.0	(400 MHz, DMSO-d ₆) δ ppm 8.64 (d, J=7.83 Hz, 1 H) 8.40 (s, 1 H) 8.10 (d, J=7.07 Hz, 1 H) 7.98 (d, J=7.33 Hz, 1 H) 7.39 (t, J=8.08 Hz, 1 H) 7.21 - 7.29 (m, 2 H) 6.95 - 7.02 (m, 2 H) 5.21 (s, 2 H) 4.54 - 4.98 (m, 6 H) 1.35 (d, J=7.07 Hz, 3 H)	1,3-difluoropropan-2-ol
3	N-{(1S)-1-[4-(2-fluoroethoxy)phenyl]ethyl}-2-(7-nitro-1H-benzimidazol-1-yl)acetamide	387	(400 MHz, DMSO-d ₆) δ ppm 8.66 (d, J=8.08 Hz, 1 H) 8.41 (s, 1 H) 8.10 (dd, J=8.08, 1.01 Hz, 1 H) 7.98 (dd, J=8.08, 0.76 Hz, 1 H) 7.39 (t, J=7.96 Hz, 1 H) 7.20 - 7.28 (m, 2 H) 6.87 - 6.95 (m, 2 H) 5.21 (s, 2 H) 4.63 - 4.86 (m, 3 H) 4.14 - 4.28 (m, 2 H) 1.35 (d, J=6.82 Hz, 3 H)	2-fluoroethanol
4	N-((1S)-1-{4-[(1-methylprop-2-yn-1-yl)oxy]phenyl}ethyl)-2-(7-nitro-1H-benzimidazol-1-yl)acetamide	393.0	(400 MHz, DMSO-d ₆) δ ppm 8.63 (d, J=8.08 Hz, 1 H) 8.40 (s, 1 H) 8.10 (dd, J=8.08, 1.01 Hz, 2 H) 7.98 (dd, J=8.08, 0.76 Hz, 1 H) 7.40 (t, J=7.96 Hz, 1 H) 7.19 - 7.28 (m, 2 H) 6.90 - 6.98 (m, 2 H) 5.21 (s, 2 H) 5.02 - 5.11 (m, 1 H) 4.75 - 4.87 (m, 1 H) 3.47 - 3.52 (m, 1 H) 1.54 (d, J=6.57 Hz, 3 H) 1.35 (d, J=6.82 Hz, 3 H)	but-3-yn-2-ol

Ex. #	Name	MW found [M+H]	¹ H NMR	Starting material
5	N-[(1S)-1-[4-(2-methoxy-1-methylethoxy)phenyl]ethyl]-2-(7-nitro-1H-benzimidazol-1-yl)acetamide	413	(400 MHz, CD ₃ OD) δ ppm 8.29 (s, 1 H) 8.05 (d, J=8.08 Hz, 2 H) 7.42 (t, J=8.08 Hz, 1 H) 7.21 - 7.28 (m, 2 H) 6.86 - 6.93 (m, 2 H) 5.24 - 5.35 (m, 2 H) 4.90 (q, J=6.99 Hz, 1 H) 4.51 - 4.61 (m, 1 H) 3.45 - 3.59 (m, 2 H) 3.38 (s, 3 H) 1.46 (d, J=6.82 Hz, 3 H) 1.26 (d, J=6.06 Hz, 3 H)	1-methoxypropan-2-ol
6	N-[(1S)-1-(4-ethoxyphenyl)ethyl]-2-(7-nitro-1H-benzimidazol-1-yl)acetamide	369.0	(400 MHz, DMSO-d ₆) δ ppm 8.61 (d, J=8.08 Hz, 1 H) 8.40 (s, 1 H) 8.10 (dd, J=7.96, 0.88 Hz, 1 H) 7.95 - 8.01 (m, 1 H) 7.39 (t, J=7.96 Hz, 1 H) 7.18 - 7.25 (m, 2 H) 6.82 - 6.90 (m, 2 H) 5.20 (s, 2 H) 4.74 - 4.85 (m, 1 H) 4.00 (q, J=6.91 Hz, 2 H) 1.25 - 1.39 (m, 6 H)	ethanol

The compounds in Table 2 below were synthesised according to **General method 2**

Table 2

Ex. #	Name	MW found [M+H]	¹ H NMR	Starting ma- terial
7	2-(7-nitro-1H-benzimidazol-1-yl)-N-{1-[6-(2,2,2-trifluoroethoxy)pyridin-3-yl]ethyl}acetamide	424.0	(400 MHz, DMSO-d ₆) δ ppm 8.77 (d, J=7.58 Hz, 1 H) 8.40 (s, 1 H) 8.07 - 8.16 (m, 2 H) 7.97 (dd, J=8.08, 0.76 Hz, 1 H) 7.75 (dd, J=8.46, 2.40 Hz, 1 H) 7.39 (t, J=7.96 Hz, 1 H) 6.96 (d, J=8.34 Hz, 1 H) 5.21 (s, 2 H) 4.97 (q, J=9.26 Hz, 2 H) 4.82 - 4.92 (m, 1 H) 1.39 (d, J=7.07 Hz, 3 H)	1-[6-(2,2,2-trifluoroethoxy)pyridin-3-yl]ethanamine
8	2-(7-chloro-1H-benzimidazol-1-yl)-N-{1-[6-(2,2,2-trifluoroethoxy)pyridin-3-yl]ethyl}acetamide	413.0	(400 MHz, DMSO-d ₆) δ ppm 8.80 (d, J=7.83 Hz, 1 H) 8.20 (s, 1 H) 8.14 (d, J=2.27 Hz, 1 H) 7.77 (dd, J=8.59, 2.53 Hz, 1 H) 7.62 (dd, J=7.71, 1.14 Hz, 1 H) 7.14 - 7.25 (m, 2 H) 6.97 (d, J=8.59 Hz, 1 H) 5.13 - 5.26 (m, 2 H) 4.89 - 5.03 (m, 3 H) 1.40 (d, J=6.82 Hz, 3 H)	1-[6-(2,2,2-trifluoroethoxy)pyridin-3-yl]ethanamine

Ex. #	Name	MW found [M+H]	¹ H NMR	Starting ma- terial
9	N-{1-[6-(2,2-di- fluoroethoxy)pyri- din-3-yl]ethyl}-2-(7- nitro-1H-benzimida- zol-1-yl)acetamide	406.0	(400 MHz, DMSO-d ₆) δ ppm 8.75 (d, J=7.58 Hz, 1 H) 8.40 (s, 1 H) 8.07 - 8.16 (m, 2 H) 7.97 (dd, J=8.08, 0.76 Hz, 1 H) 7.71 (dd, J=8.59, 2.27 Hz, 1 H) 7.39 (t, J=8.08 Hz, 1 H) 6.89 (d, J=8.59 Hz, 1 H) 6.21 - 6.55 (m, 1 H) 5.21 (s, 2 H) 4.80 - 4.91 (m, 1 H) 4.45 - 4.61 (m, 2 H) 1.38 (d, J=7.07 Hz, 3 H)	1-[6-(2,2-di- fluoroethoxy)p yridin-3- yl]ethanamine
10	2-(7-nitro-1H-ben- zimidazol-1-yl)-N- {1-[6-(2,2,3,3-tetra- fluoropropoxy)pyri- din-3- yl]ethyl}acetamide	456.0	(400 MHz, DMSO-d ₆) δ ppm 8.76 (d, J=7.58 Hz, 1 H) 8.40 (s, 1 H) 8.06 - 8.17 (m, 2 H) 7.97 (dd, J=8.08, 0.76 Hz, 1 H) 7.74 (dd, J=8.59, 2.53 Hz, 1 H) 7.39 (t, J=7.96 Hz, 1 H) 6.92 (d, J=8.59 Hz, 1 H) 6.51 - 6.83 (m, 1 H) 5.21 (s, 2 H) 4.77 - 4.94 (m, 3 H) 1.38 (d, J=7.07 Hz, 3 H)	1-[6-(2,2,3,3- tetrafluoropro- poxy)pyridin- 3- yl]ethanamine

Ex. #	Name	MW found [M+H]	¹ H NMR	Starting ma- terial
11	2-(7-chloro-1H-benzimidazol-1-yl)-N-{1-[6-(2,2,3,3-tetrafluoropropoxy)pyridin-3-yl]ethyl}acetamide	445.0	(400 MHz, DMSO-d ₆) δ ppm 8.80 (d, J=7.83 Hz, 1 H) 8.20 (s, 1 H) 8.14 (d, J=2.27 Hz, 1 H) 7.77 (dd, J=8.59, 2.27 Hz, 1 H) 7.62 (dd, J=7.71, 1.14 Hz, 1 H) 7.13 - 7.26 (m, 2 H) 6.94 (d, J=8.34 Hz, 1 H) 6.50 - 6.84 (m, 1 H) 5.13 - 5.26 (m, 2 H) 4.89 - 5.01 (m, 1 H) 4.83 (t, J=14.27 Hz, 2 H) 1.40 (d, J=7.07 Hz, 3 H)	1-[6-(2,2,3,3-tetrafluoropropoxy)pyridin-3-yl]ethanamine
12	N-{1-[6-(cyclopentyloxy)pyridine-3-yl]ethyl}-2-(7-nitro-1H-benzimidazol-1-yl)acetamide	410.0	(400 MHz, DMSO-d ₆) δ ppm 8.71 (d, J=7.58 Hz, 1 H) 8.40 (s, 1 H) 8.04 - 8.14 (m, 2 H) 7.97 (dd, J=8.08, 0.76 Hz, 1 H) 7.61 (dd, J=8.59, 2.53 Hz, 1 H) 7.39 (t, J=7.96 Hz, 1 H) 6.71 (d, J=8.59 Hz, 1 H) 5.28 - 5.36 (m, 1 H) 5.20 (s, 2 H) 4.77 - 4.88 (m, 1 H) 1.85 - 1.98 (m, 2 H) 1.50 - 1.75 (m, 6 H) 1.37 (d, J=6.82 Hz, 3 H)	1-[6-(cyclopentyloxy)pyridin-3-yl]ethanamine

Ex. #	Name	MW found [M+H]	¹ H NMR	Starting ma- terial
13	N-[1-(4-{[(2S)-2-methoxypropyl]oxy}phenyl)ethyl]-2-(7-nitro-1H-benzimidazol-1-yl)acetamide	413.0	(400 MHz, DMSO-d ₆) δ ppm 8.62 (d, J=7.83 Hz, 1 H) 8.40 (s, 1 H) 8.10 (d, J=7.83 Hz, 1 H) 7.98 (d, J=7.33 Hz, 1 H) 7.39 (t, J=8.08 Hz, 1 H) 7.18 - 7.26 (m, J=8.59 Hz, 2 H) 6.85 - 6.93 (m, 2 H) 5.21 (s, 2 H) 4.75 - 4.87 (m, 1 H) 3.86 - 3.95 (m, 2 H) 3.60 - 3.70 (m, 1 H) 3.31 (s, 3 H) 1.34 (d, J=7.07 Hz, 3 H) 1.16 (d, J=6.32 Hz, 3 H)	1-(4-{[(2S)-2-methoxypropyl]oxy}phenyl)ethanamine
14	2-(7-nitro-1H-benzimidazol-1-yl)-N-{1-[4-(2,2,2-trifluoroethoxy)phenyl]ethyl}acetamide	423.0	(400 MHz, DMSO-d ₆) δ ppm 8.68 (d, J=8.08 Hz, 1 H) 8.41 (s, 1 H) 8.10 (dd, J=7.96, 0.88 Hz, 1 H) 7.98 (dd, J=7.96, 0.63 Hz, 1 H) 7.39 (t, J=8.08 Hz, 1 H) 7.24 - 7.31 (m, 2 H) 6.97 - 7.04 (m, 2 H) 5.21 (s, 2 H) 4.77 - 4.88 (m, 1 H) 4.73 (q, J=8.84 Hz, 2 H) 1.35 (d, J=7.07 Hz, 3 H)	1-[4-(2,2,2-trifluoroethoxy)phenyl]ethanamine

Ex. #	Name	MW found [M+H]	¹ H NMR	Starting material
15	N-[(1S)-1-(4-[(1S)-1-methylpropyl]oxy}phenyl)ethyl]-2-(7-nitro-1H-benzimidazol-1-yl)acetamide	397.1	(400 MHz, DMSO-d ₆) δ ppm 0.90 (t, J=7.4 Hz, 3 H) 1.20 (d, J=6.0 Hz, 3 H) 1.34 (d, J=7.0 Hz, 3 H) 1.49 - 1.66 (m, 2 H) 4.28 - 4.38 (m, 1 H) 4.72 - 4.83 (m, 1 H) 5.19 (s, 2 H) 6.82 - 6.86 (m, 2 H) 7.14 - 7.23 (m, J=8.8 Hz, 2 H) 7.39 (t, J=8.0 Hz, 1 H) 7.97 (d, J=7.8 Hz, 1 H) 8.09 (d, J=8.0 Hz, 1 H) 8.39 (s, 1 H) 8.60 (d, J=8.0 Hz, 1 H)	(1S)-1-(4-[(1S)-1-methylpropyl]oxy}phenyl)ethanamine
16	N-(1-{4-[chloro(difluoro)methyl]phenyl}ethyl)-2-(7-nitro-1H-benzimidazol-1-yl)acetamide	409.1	(400 MHz, DMSO-d ₆) δ ppm 1.40 (d, J=7.0 Hz, 3 H) 4.90 (t, J=7.3 Hz, 1 H) 5.25 (s, 2 H) 7.39 (t, J=8.0 Hz, 1 H) 7.51 (d, J=8.5 Hz, 2 H) 7.66 (d, J=8.5 Hz, 2 H) 7.98 (d, J=8.0 Hz, 1 H) 8.10 (dd, J=7.9, 0.9 Hz, 1 H) 8.40 (s, 1 H) 8.83 (d, J=7.8 Hz, 1 H)	1-{4-[chloro(difluoro)methyl]phenyl}ethanamine
17	2-(7-chloro-1H-benzimidazol-1-yl)-N-(1-{4-[chloro(difluoro)methyl]phenyl}ethyl)acetamide	398.1	(400 MHz, DMSO-d ₆) δ ppm 1.41 (d, J=7.0 Hz, 3 H) 4.94 - 5.04 (m, 1 H) 5.22 (s, 2 H) 7.17 (t, J=7.8 Hz, 1 H) 7.21 - 7.25 (m, 1 H) 7.54 (d, J=8.3 Hz, 2 H) 7.61 (dd, J=7.8, 1.0 Hz, 1 H) 7.67 (d, J=8.3 Hz, 2 H) 8.19 (s, 1 H) 8.86 (d, J=7.8 Hz, 1 H)	1-{4-[chloro(difluoro)methyl]phenyl}ethanamine

Ex. #	Name	MW found [M+H]	¹ H NMR	Starting material
18	2-(7-chloro-1H-benzimidazol-1-yl)-N-{1-[4-(2,2-difluoroethoxy)phenyl]ethyl}acetamide	394.2	(400 MHz, DMSO-d ₆) δ ppm 1.37 (d, J=7.0 Hz, 3 H) 4.29 (td, J=14.7, 3.5 Hz, 2 H) 4.85 - 4.95 (m, 1 H) 5.19 (s, 2 H) 6.37 (tt, J=54.5, 3.6 Hz, 1 H) 6.96 (d, J=8.8 Hz, 2 H) 7.17 (t, J=7.8 Hz, 1 H) 7.21 - 7.25 (m, 1 H) 7.26 - 7.31 (m, 2 H) 7.62 (dd, J=7.8, 1.00 Hz, 1 H) 8.19 (s, 1 H) 8.69 (d, J=8.0 Hz, 1 H)	1-[4-(2,2-difluoroethoxy)phenyl]ethanamine
19	N-{1-[4-(2,2-difluoroethoxy)phenyl]ethyl}-2-(7-nitro-1H-benzimidazol-1-yl)acetamide	405.2	(400 MHz, DMSO-d ₆) δ ppm 1.35 (d, J=6.8 Hz, 3 H) 4.29 (td, J=14.7, 3.6 Hz, 2 H) 4.76 - 4.87 (m, 1 H) 5.21 (s, 2 H) 6.37 (tt, J=54.6, 3.5 Hz, 1 H) 6.92 - 6.99 (m, 2 H) 7.23 - 7.28 (m, 2 H) 7.39 (t, J=8.0 Hz, 1 H) 7.98 (d, J=8.0 Hz, 1 H) 8.10 (dd, J=8.0, 1.0 Hz, 1 H) 8.40 (s, 1 H) 8.64 (d, J=8.0 Hz, 1 H)	1-[4-(2,2-difluoroethoxy)phenyl]ethanamine

Ex. #	Name	MW found [M+H]	¹ H NMR	Starting ma- terial
20	2-(7-chloro-1H-benzimidazol-1-yl)-N-(1-{4-[2-fluoro-1-(fluoromethyl)ethoxy]phenyl}ethyl)acetamide	408.2	(400 MHz, DMSO-d ₆) δ ppm 1.37 (d, J=6.8 Hz, 3 H) 4.55 - 4.80 (m, 4 H) 4.80 - 4.96 (m, 2 H) 5.19 (s, 2 H) 6.97 - 7.02 (m, 1 H) 7.17 (t, J=7.8 Hz, 1 H) 7.20 - 7.24 (m, 1 H) 7.24 - 7.29 (m, J=8.5 Hz, 2 H) 7.62 (dd, J=7.7, 1.13 Hz, 1 H) 8.19 (s, 1 H) 8.68 (d, J=7.8 Hz, 1H)	1-{4-[2-fluoro-1-(fluoromethyl)ethoxy]phenyl}ethanamine
21	2-(7-acetyl-1H-benzimidazol-1-yl)-N-(1-{4-[2-fluoro-1-(fluoromethyl)ethoxy]phenyl}ethyl)acetamide	416.2	(400 MHz, DMSO-d ₆) δ ppm 1.34 (d, J=7.0 Hz, 3 H) 2.44 (s, 3 H) 4.54 - 4.78 (m, 4 H) 4.78 - 4.96 (m, 2 H) 5.13 (s, 2 H) 6.96 - 7.01 (m, 2 H) 7.21 - 7.30 (m, 3 H) 7.72 (d, J=7.5 Hz, 1 H) 7.87 (dd, J=8.0, 0.8 Hz, 1 H) 8.22 (s, 1 H) 8.54 (d, J=7.8 Hz, 1 H)	1-{4-[2-fluoro-1-(fluoromethyl)ethoxy]phenyl}ethanamine
22	2-(7-nitro-1H-benzimidazol-1-yl)-N-{1-[4-(1,1,2,2-tetrafluoroethoxy)phenyl]ethyl}acetamide	441.2	(400 MHz, DMSO-d ₆) δ ppm 1.38 (d, J=6.8 Hz, 3 H) 4.82 - 4.92 (m, 1 H) 5.24 (s, 2 H) 6.79 (tt, J=52.0, 3.0 Hz, 1 H) 7.19 - 7.25 (m, 2 H) 7.36 - 7.44 (m, 3 H) 7.98 (d, J=8.0 Hz, 1 H) 8.10 (dd, J=8.0, 1.00 Hz, 1 H) 8.40 (s, 1 H) 8.75 (d, J=7.8 Hz, 1 H)	1-[4-(1,1,2,2-tetrafluoroethoxy)phenyl]ethanamine

Ex. #	Name	MW found [M+H]	¹ H NMR	Starting material
23	2-(7-chloro-1H-benzimidazol-1-yl)-N-{1-[4-(1,1,2,2-tetrafluoroethoxy)phenyl]ethyl}acetamide	430.2	(400 MHz, DMSO-d ₆) δ ppm 1.40 (d, J=7.0 Hz, 3 H) 4.91 - 5.01 (m, 1 H) 5.21 (s, 2 H) 6.79 (tt, J=51.9, 2.9 Hz, 1 H) 7.17 (t, J=7.8 Hz, 1 H) 7.20 - 7.26 (m, 3 H) 7.41 - 7.46 (m, 2 H) 7.62 (dd, J=7.8, 1.25 Hz, 1 H) 8.20 (s, 1 H) 8.79 (d, J=7.8 Hz, 1 H)	1-[4-(1,1,2,2-tetrafluoroethoxy)phenyl]ethanamine
24	2-(7-cyano-1H-benzimidazol-1-yl)-N-(1-{4-[2-fluoro-1-(fluoromethyl)ethoxy]phenyl}ethyl)acetamide	399.2	(400 MHz, DMSO-d ₆) δ ppm 1.38 (d, J=7.0 Hz, 3 H) 4.55 - 4.79 (m, 4 H) 4.80 - 4.96 (m, 2 H) 5.16 - 5.28 (m, 2 H) 6.95 - 7.00 (m, 2 H) 7.26 - 7.32 (m, 2 H) 7.35 (t, J=7.9 Hz, 1 H) 7.71 (d, J=7.5 Hz, 1 H) 8.02 (dd, J=8.0, 0.8 Hz, 1 H) 8.35 (s, 1 H) 8.75 (d, J=7.8 Hz, 1 H)	1-{4-[2-fluoro-1-(fluoromethyl)ethoxy]phenyl}ethanamine
25	2-(7-cyano-1H-benzimidazol-1-yl)-N-{1-[4-(2,2,2-trifluoroethoxy)phenyl]ethyl}acetamide	403.0	(400 MHz, CD ₃ OD) δ ppm 1.49 (d, J= 7.07 Hz, 3H), 4.40 (q, J=8.34 Hz, 2H), 5.00 (q, J=6.95 Hz, 1H), 5.25 (s, 2H), 6.91 (d, J=8.59 Hz, 2H), 7.31 (d, J=8.59 Hz, 2H), 7.37 (t, J=7.83 Hz, 1H), 7.64 (d, J=7.33 Hz, 1H), 7.96 (d, J=7.83 Hz, 1H), 8.16 (s, 1H)	1-[4-(2,2,2-trifluoroethoxy)phenyl]ethanamine

Ex. #	Name	MW found [M+H]	¹ H NMR	Starting material
26	N-(1-{5-chloro-6-[2-fluoro-1-(fluoromethyl)ethoxy]pyridin-3-yl}ethyl)-2-(7-nitro-1H-benzimidazol-1-yl)acetamide	454.0	(400 MHz, CD ₃ OD) δ ppm 1.49 (d, J=7.07 Hz, 3H), 4.66-4.69 (m, 2H), 4.77-4.81 (m, 2H), 4.88-4.95 (m, 1H), 5.30 (s, 2H), 5.61 (tt, J=19.96, 4.55 Hz, 1H), 7.40 (t, J=8.08 Hz, 1H), 7.79 (d, J=2.02 Hz, 1H), 8.0-8.05 (m, 3H), 8.29 (s, 1H)	1-{5-chloro-6-[2-fluoro-1-(fluoromethyl)ethoxy]pyridin-3-yl}ethanamine
27	2-(7-cyano-1H-benzimidazol-1-yl)-N-{1-[4-[2-fluoro-1-(fluoromethyl)ethoxy]-2-(trifluoromethyl)phenyl]ethyl}acetamide	467.0	(400 MHz, CD ₃ OD) δ ppm 1.48 (d, J=6.82 Hz, 3H), 4.56-4.94 (m, 5H), 5.28-5.35 (m, 1H), 5.33 (s, 2H), 7.24 (d, J=2.53 Hz, 1H), 7.30 (dd, J=8.59, 2.78 Hz, 1H), 7.37-7.41 (t, J=7.83 Hz, 1H), 7.65-7.71 (m, 2H), 7.97 (dd, J=8.08, 0.9 Hz, 1H), 8.25 (s, 1H)	1-[4-[2-fluoro-1-(fluoromethyl)ethoxy]-2-(trifluoromethyl)phenyl]ethanamine
28	N-(1-{2-chloro-4-[2-fluoro-1-(fluoromethyl)ethoxy]phenyl}ethyl)-2-(7-cyano-1H-benzimidazol-1-yl)acetamide	433.0	(400 MHz, CD ₃ OD) δ ppm 1.46 (d, J=7.07 Hz, 3H), 4.51-4.79 (m, 5H), 5.27-5.34 (m, 1H), 5.31 (s, 2H), 6.94 (dd, J=8.59, 2.53 Hz, 1H), 7.00 (d, J=2.78 Hz, 1H), 7.36 (t, J=8.07 Hz, 1H), 7.42 (d, J=8.59 Hz, 1H), 7.63 (br.d, J=7.58 Hz, 1H), 7.95 (br.d, J=8.08 Hz, 1H), 8.20 (s, 1H)	1-{2-chloro-4-[2-fluoro-1-(fluoromethyl)ethoxy]phenyl}ethanamine

Ex. #	Name	MW found [M+H]	¹ H NMR	Starting material
29	2-(7-nitro-1H-benzimidazol-1-yl)-N-{1-[5-(trifluoromethyl)pyridin-2-yl]propyl}acetamide	408.0	(400 MHz, CD ₃ OD) δ ppm 0.99 (t, J=7.33 Hz, 3H), 1.79-2.04 (m, 2H), 4.84 - 4.90 (m, 1H), 5.40 (dd, J=17.18, 8.59 Hz, 2H), 7.40 (t, J=8.08 Hz, 1H), 7.57 (br.d, J=8.34Hz, 1H), 7.99-8.08 (m, 3H), 8.30 (s, 1H), 8.80 (br.s, 1H)	1-[5-(trifluoromethyl)pyridin-2-yl]propan-1-amine
30	2-(7-nitro-1H-benzimidazol-1-yl)-N-{1-[5-(trifluoromethyl)pyridin-2-yl]ethyl}acetamide	394	(400 MHz, CD ₃ OD) δ ppm 1.53 (d, J=7.07 Hz, 1H), 5.04 (q, J=7.07 Hz, 1H), 5.38 (s, 2H), 7.39 (t, J=8.08 Hz, 1H), 7.60 (d, J=8.08 Hz, 1H), 8.00-8.08 (m, 3H), 8.30 (s, 1H), 8.79 (br.s, 1H)	1-[5-(trifluoromethyl)pyridin-2-yl]ethanamine
31	2-(7-chloro-1H-benzimidazol-1-yl)-N-{1-[3-chloro-5-(trifluoromethyl)pyridin-2-yl]ethyl}acetamide	416.9	(400 MHz, CD ₃ OD) δ ppm 1.51 (d, J=6.82 Hz, 3H), 5.34 (dd, J=17.4, 10.1 Hz, 2H), 5.61 (q, J=6.82 Hz, 1H), 7.19-7.26 (m, 2H), 7.61 (dd, J=7.07, 1.8 Hz, 1H), 8.15 (s, 1H), 8.20 (d, J=2.02 Hz, 1H), 8.80 (br.s, 1H)	1-[3-chloro-5-(trifluoromethyl)pyridin-2-yl]ethanamine
32	N-{1-[3-chloro-5-(trifluoromethyl)pyridin-2-yl]ethyl}-2-(7-nitro-1H-benzimidazol-1-yl)acetamide	427.9	(400 MHz, CD ₃ OD) δ ppm 1.49 (d, J=6.82 Hz, 3H), 5.37 (dd, J=17.2, 10.6 Hz, 2H), 5.51 (q, J=6.82 Hz, 1H), 7.42 (t, J=8.08 Hz, 1H), 8.01-8.06 (m, 2H), 8.18 (d, J=2.02 Hz, 1H), 8.31 (s, 1H), 8.82 (br.s, 1H)	1-[3-chloro-5-(trifluoromethyl)pyridin-2-yl]ethanamine

Ex. #	Name	MW found [M+H]	¹ H NMR	Starting material
33	N-{1-[5-chloro-6-(2-fluoroethoxy)pyridin-3-yl]ethyl}-2-(7-nitro-1H-benzimidazol-1-yl)acetamide	422.0	(400 MHz, CD ₃ OD) δ ppm 1.48 (d, J=7.07 Hz, 3H), 4.53-4.56 (m, 1H), 4.60-4.63 (m, 1H), 4.66-4.69 (m, 1H), 4.78-4.81 (m, 1H), 4.87-4.95 (m, 1H), 5.25 (s, 2H), 7.38 (t, J=7.9 Hz, 1H), 7.71 (d, J=2.02 Hz, 1H), 7.97 (d, J=2.3 Hz, 1H), 8.00-8.04 (m, 2H), 8.20 (s, 1H)	1-[5-chloro-6-(2-fluoroethoxy)pyridin-3-yl]ethanamine
34	2-(7-chloro-1H-benzimidazol-1-yl)-N-{1-[4-(trifluoromethyl)phenyl]ethyl}acetamide	382.0	(400 MHz, CD ₃ OD) δ ppm 1.51 (d, J=6.82 Hz, 3H), 5.10 (q, J=6.82 Hz, 1H), 5.29 (dd, J=17.2, 3.8 Hz, 2H), 7.18-7.26 (m, 2H), 7.53 (d, J=8.08 Hz, 2H), 7.58-7.64 (m, 3H), 8.14 (s, 1H)	1-[4-(trifluoromethyl)phenyl]ethanamine
35	2-(7-chloro-1H-benzimidazol-1-yl)-N-[1-(6-isopropoxy)pyridin-3-yl]ethyl]acetamide	373.1	(400 MHz, CD ₃ OD) δ ppm 1.31 (d, J=6.06 Hz, 6H), 1.50 (d, J=6.82 Hz, 3H), 5.02 (q, J=6.92 Hz, 1H), 5.15-5.23 (m, 1H), 5.27 (dd, J=17.2, 5.3 Hz, 2H), 6.70 (d, J=8.59 Hz, 1H), 7.20-7.27 (m, 2H), 7.61 (dd, J=7.33, 1.8 Hz, 1H), 7.65 (d, J=8.59, 2.5 Hz, 1H), 8.08 (d, J=2.5 Hz, 1H), 8.15 (s, 1H)	1-(6-isopropoxy)pyridin-3-yl]ethanamine

Ex. #	Name	MW found [M+H]	¹ H NMR	Starting material
36	2-(7-nitro-1H-benzimidazol-1-yl)-N-{1-[4-(trifluoromethoxy)phenyl]ethyl}acetamide	408.9	(400 MHz, CD ₃ OD) δ ppm 1.49 (d, J=7.07 Hz, 3H), 4.97 (q, J=7.07 Hz, 1H), 5.34 (s, 2H), 7.22 (d, J=8.08 Hz, 2H), 7.40-7.45 (m, 3H), 8.05 (d, J=8.08, 2H), 8.30 (s, 1H)	1-[4-(trifluoromethoxy)phenyl]ethanamine
37	2-(7-nitro-1H-benzimidazol-1-yl)-N-{1-[4-(trifluoromethyl)phenyl]ethyl}acetamide	392.9	(400 MHz, CD ₃ OD) δ ppm 1.51 (d, J=6.82 Hz, 3H), 5.01 (q, J=6.82 Hz, 1H), 5.36 (s, 2H), 7.42 (t, J=8.08 Hz, 1H), 7.52 (d, J=8.34 Hz, 2H), 7.62 (d, J=8.34 Hz, 2H), 8.05 (d, J=8.08 Hz, 2H), 8.30 (s, 1H)	1-[4-(trifluoromethyl)phenyl]ethanamine.
38	N-[1-(6-isopropoxy)pyridin-3-yl]ethyl]-2-(7-nitro-1H-benzimidazol-1-yl)acetamide	384.0	(400 MHz, CD ₃ OD) δ ppm 1.31 (d, J=6.06 Hz, 6H), 1.49 (d, J=7.07 Hz, 3H), 4.93 (q, J=7.07 Hz, 1H), 5.14-5.22 (m, 1H), 5.30 (s, 2H), 6.70 (d, J=8.59 Hz, 1H), 7.43 (t, J=8.08 Hz, 1H), 7.65 (dd, J=8.59, 2.5 Hz, 1H), 8.03-8.07 (m, 3H), 8.30 (s, 1H)	1-(6-isopropoxy)pyridin-3-yl)ethanamine

Ex. #	Name	MW found [M+H]	¹ H NMR	Starting material
39	N-{1-[4-(cyclopentyloxy)-3-fluorophenyl]ethyl}-2-(7-nitro-1H-benzimidazol-1-yl)acetamide	426.9	(400 MHz, CD ₃ OD) δ ppm 1.45 (d, J=6.82 Hz, 3H), 1.59-1.70 (m, 2H), 1.75-1.95 (m, 6H), 4.80-4.85 (m, 1H), 4.89 (q, J=6.82 Hz, 1H), 5.31 (s, 2H), 6.96-7.10 (m, 3H), 7.43 (t, J=8.08 Hz, 1H), 8.05 (d, J=8.08 Hz, 2H), 8.30 (s, 1H)	1-[4-(cyclopentyloxy)-3-fluorophenyl]ethanamine
40	N-[1-(4-cyclopropylphenyl)ethyl]-2-(7-nitro-1H-benzimidazol-1-yl)acetamide	365.0	(400 MHz, CHLOROFORM-d) δ ppm 0.60 - 0.70 (m, 2 H) 0.88 - 0.98 (m, 2 H) 1.48 (d, J=7.07 Hz, 3 H) 1.77 - 1.91 (m, 1 H) 4.93 - 5.09 (t, J=6.57 Hz, 1 H) 5.21 (s, 2 H) 6.34 (s, 1H) 7.01 (d, J=6.06 Hz, 2 H) 7.18 (d, J=8.08 Hz, 2 H) 7.43 (t, J=8.21 Hz, 1 H) 8.10 (d, J=8.08 Hz, 1 H) 8.14 (d, J=8.08 Hz, 1 H) 8.49 (s, 1H)	1-(4-cyclopropylphenyl)ethanamine
41	N-[1-(4-ethynylphenyl)ethyl]-2-(7-nitro-1H-benzimidazol-1-yl)acetamide	349.1	(400 MHz, CD ₃ OD) δ ppm 1.37 (d, J=7.07 Hz, 3 H) 3.35 (s, 1 H) 4.85 (q, J=14.15, 7.07 Hz, 1 H) 5.23 (s, 2 H) 7.21 (d, J=8.34 Hz, 2 H) 7.32 (d, J=8.34 Hz, 2 H) 7.95 (d, J=7.83 Hz, 2 H) 8.26 (s, 1 H) 8.68 (d, J=7.58 Hz, 1 H)	1-(4-ethynylphenyl)ethanamine

Ex. #	Name	MW found [M+H]	¹ H NMR	Starting material
42	2-(7-chloro-1H-benzimidazol-1-yl)-N-[1-(4-ethynyl-phenyl)ethyl]acetamide	338.0	¹ H NMR (400 MHz, CD ₃ OD) δ ppm 1.39 (d, J=7.07 Hz, 3 H) 3.36 (s, 1 H) 4.93 (q, J=14.15, 7.07 Hz, 1 H) 5.20 (d, J=4.55 Hz, 2 H) 7.10 - 7.19 (m, 2 H) 7.23 (d, J=8.34 Hz, 2 H) 7.32 (d, J=8.08 Hz, 2 H) 7.52 (dd, J=7.71, 1.39 Hz, 1 H) 8.05 (s, 1 H)	1-(4-ethynyl-phenyl)ethanamine
43	N-{1-[5-(cyclopropylmethoxy)pyridin-2-yl]ethyl}-2-(7-nitro-1H-benzimidazol-1-yl)acetamide	396.0	(400 MHz, CD ₃ OD) δ ppm 0.22 - 0.32 (m, 2 H) 0.46 - 0.57 (m, 2 H) 1.08 - 1.23 (m, 1 H) 1.37 (d, J=6.82 Hz, 3 H) 3.78 (d, J=7.07 Hz, 2 H) 4.84 (q, J=6.99 Hz, 1 H) 5.25 (s, 2 H) 7.23 (d, J=2.02 Hz, 2 H) 7.32 (t, J=8.08 Hz, 1 H) 7.95 (dd, J=8.21, 1.39 Hz, 2 H) 8.03 (t, J=1.77 Hz, 1 H) 8.21 (s, 1 H)	1-[5-(cyclopropylmethoxy)pyridin-2-yl]ethanamine
44	N-[1-(5-isopropoxy)pyridin-2-yl]ethyl)-2-(7-nitro-1H-benzimidazol-1-yl)acetamide	384.1	(400 MHz, CD ₃ OD) δ ppm 1.22 (d, J=5.81 Hz, 6 H) 1.37 (d, J=7.07 Hz, 3 H) 4.45 - 4.61 (m, 1 H) 4.84 (q, J=13.89, 6.82 Hz, 1 H) 5.25 (s, 2H) 7.23 (d, J=1.77 Hz, 2 H) 7.31 (t, J=8.08 Hz, 1 H) 7.94 (dd, J=8.08, 2.02 Hz, 2 H) 8.00 (t, J=1.64 Hz, 1 H) 8.21 (s, 1 H);	1-(5-isopropoxy)pyridin-2-yl)ethanamine

Ex. #	Name	MW found [M+H]	¹ H NMR	Starting ma- terial
45	2-(7-acetyl-1H-benzimidazol-1-yl)-N-[(1S)-1-(4-tert-butylphenyl)ethyl]acetamide	378.3	¹ H NMR (400 MHz, METHANOL-D4) δ ppm 1.29 (s, 9 H) 1.44 (d, J=7.03 Hz, 3 H) 2.41 (s, 3 H) 4.88 (q, J=7.03 Hz, 1 H) 5.25 (s, 2 H) 7.24 (d, J=8.20 Hz, 2 H) 7.29 - 7.42 (m, 3 H) 7.75 (d, J=6.64 Hz, 1 H) 7.87 (d, J=8.98 Hz, 1 H) 8.14 (s, 1 H)	(1S)-1-(4-tert-butylphenyl)ethanamine
46	N-{1-[4-[(1-Methylpiperidin-4-yl)oxy]-3-(trifluoromethyl)phenyl]ethyl}-2-(7-nitro-1H-benzimidazol-1-yl)acetamide	506.0	(400 MHz, DMSO-D6) δ ppm 1.36 (d, J = 7.0 Hz, 3 H), 1.63-1.71 (m, 2 H), 1.85-1.93 (m, 2 H), 2.16 (s, 3 H), 2.22-2.27 (m, 2 H), 2.46-2.48 (m, 2 H), 4.56-4.62 (m, 1 H), 4.81-4.87 (m, 1 H), 5.21 (s, 2 H), 7.22 (d, J = 8.5 Hz, 1 H), 7.39 (t, J = 8.0 Hz, 1 H), 7.48-7.51 (m, 1 H), 7.53-7.54 (m, 1 H), 7.96 (d, J = 8.0 Hz, 1 H), 8.09 (d, J = 8.0 Hz, 1 H), 8.39 (s, 1 H), 8.74 (d, J = 7.8 Hz, 1 H).	1-[4-[(1-methylpiperidin-4-yl)oxy]-3-(trifluoromethyl)phenyl]ethanamine

Ex. #	Name	MW found [M+H]	¹ H NMR	Starting material
47	N-{1-[4-{{[(2S)-2-Methoxypropyl]oxy}-3-(trifluoromethyl)phenyl}ethyl]-2-(7-nitro-1H-benzimidazol-1-yl)acetamide	481.0	(400 MHz, DMSO-D6) δ ppm 1.18 (d, J = 6.5 Hz, 3 H), 1.37 (d, J = 7.0 Hz, 3 H), 3.32 (s, 3 H), 3.63-3.69 (m, 1 H), 3.99-4.10 (m, 2 H), 4.83-4.90 (m, 1 H), 5.22 (s, 2 H), 7.20 (d, J = 8.5 Hz, 1 H), 7.39 (t, J = 8.0 Hz, 1 H), 7.51-7.55 (m, 2 H), 7.97 (d, J = 8.0 Hz, 1 H), 8.09 (d, J = 8.0 Hz, 1 H), 8.40 (s, 1 H), 8.73 (d, J = 7.8 Hz, 1 H).	{1-[4-{{[(2S)-2-methoxypropyl]oxy}-3-(trifluoromethyl)phenyl}ethyl}amine
48	N-{1-methyl-2-[3-(trifluoromethyl)phenoxy]ethyl}-2-(7-nitro-1H-benzimidazol-1-yl)acetamide	423.0	(400 MHz, DMSO-d6) δ ppm 8.39 - 8.47 (m, 2 H) 8.11 (dd, J=8.08, 1.01 Hz, 1 H) 7.98 (dd, J=7.96, 0.88 Hz, 1 H) 7.53 (t, J=7.83 Hz, 1 H) 7.40 (t, J=8.08 Hz, 1 H) 7.23 - 7.33 (m, 3 H) 5.19 (s, 2 H) 3.89 - 4.12 (m, 3 H) 1.19 (d, J=6.57 Hz, 3 H)	1-[3-(trifluoromethyl)phenoxy]propan-2-amine
49	N-[2-(4-chlorophenyl)-1-methylethyl]-2-(7-nitro-1H-benzimidazol-1-yl)acetamide	373.0	(400 MHz, DMSO-d6) δ ppm 8.39 (s, 1 H) 8.23 (d, J=7.83 Hz, 1 H) 8.10 (d, J=8.08 Hz, 1 H) 7.98 (d, J=7.33 Hz, 1 H) 7.37 - 7.43 (m, 1 H) 7.29 - 7.35 (m, 2 H) 7.21 (d, J=8.34 Hz, 2 H) 5.06 - 5.18 (m, 2 H) 3.80 - 3.93 (m, 1 H) 2.58 - 2.77 (m, 2 H) 1.03 (d, J=6.57 Hz, 3 H)	1-(4-chlorophenyl)propan-2-amine

Ex. #	Name	MW found [M+H]	¹ H NMR	Starting ma- terial
50	N-[(3R)-5-Methoxy-3,4-dihydro-2H-chromen-3-yl]-2-(7-nitro-1H-benzimidazol-1-yl)acetamide	383.0	(400 MHz, DMSO-D6) δ ppm 2.50-2.55 (m, 1 H), 2.81-2.87 (m, 1 H), 3.78 (s, 3 H), 3.80-3.84 (m, 1 H), 4.00-4.10 (m, 2 H), 5.15-5.24 (m, 2 H), 6.45 (d, J = 8.3 Hz, 1 H), 6.55 (d, J = 8.0 Hz, 1 H), 7.08 (t, J = 8.3 Hz, 1 H), 7.41 (t, J = 8.0 Hz, 1 H), 7.99 (d, J = 7.8 Hz, 1 H), 8.11 (d, J = 8.0 Hz, 1 H), 8.41 (s, 1 H), 8.49 (d, J = 7.0 Hz, 1 H).	(3R)-5-methoxychroman-3-amine
51	N-[(3R)-8-Fluoro-5-methoxy-3,4-dihydro-2H-chromen-3-yl]-2-(7-nitro-1H-benzimidazol-1-yl)acetamide	401.0	(400 MHz, DMSO-D6) δ ppm 2.53-2.59 (m, 1 H), 2.83-2.89 (m, 1 H), 3.76 (s, 3 H), 3.93-3.97 (m, 1 H), 4.07-4.16 (m, 2 H), 5.19 (s, 2 H), 6.48 (dd, J = 9.0, 3.5 Hz, 1 H), 7.02 (dd, J = 10.8, 9.0 Hz, 1 H), 7.41 (t, J = 8.0 Hz, 1 H), 8.0 (d, J = 8.0 Hz, 1 H), 8.11 (dd, J = 7.9, 0.9 Hz, 1 H), 8.41 (s, 1 H), 8.55 (d, J = 7.0 Hz, 1 H).	(3R)-8-fluoro-5-methoxychroman-3-amine

Ex. #	Name	MW found [M+H]	¹ H NMR	Starting material
52	N-[(1S)-1-(4-tert-butylphenyl)ethyl]-2-(6,7-difluoro-1H-benzimidazol-1-yl)acetamide	372.3	(400 MHz, DMSO-D6) δ ppm 1.16 - 1.26 (m, 9 H), 1.35 (d, J=7.03 Hz, 3 H), 4.81 - 4.90 (m, 1 H), 5.12 - 5.25 (m, 2 H), 7.21 - 7.26 (m, 2 H), 7.26 - 7.34 (m, 3 H), 7.69 (d, J=7.42 Hz, 1 H), 7.98 (d, J=7.81 Hz, 1 H), 8.33 (s, 1 H), 8.75 (d, J=7.81 Hz, 1 H)	[(1S)-1-(4-tert-butylphenyl)ethyl]amine
53	N-[1-(4-tert-butylphenyl)ethyl]-2-(6,7-difluoro-1H-benzimidazol-1-yl)acetamide	372.0	(400 MHz, DMSO-D6) δ ppm 1.26 (s, 9 H), 1.37 (d, J=6.84 Hz, 3 H), 4.85 - 4.94 (m, 1 H), 5.05 (s, 2 H), 7.17 - 7.26 (m, 3 H), 7.31 - 7.36 (m, 2 H), 7.43 - 7.48 (m, 1 H), 8.19 (s, 1 H), 8.76 (d, J=7.81 Hz, 1 H)	[1-(4-tert-butylphenyl)ethyl]amine
54	N-[1-(4-tert-butylphenyl)ethyl]-2-(7-cyano-1H-benzimidazol-1-yl)acetamide	361.3	¹ H NMR (400 MHz, METHANOL-D4) δ ppm 1.28 (s, 9 H) 1.48 (d, J=7.03 Hz, 3 H) 4.99 (q, J=7.03 Hz, 1 H) 5.30 (s, 2 H) 7.27 (d, 2 H) 7.34 (d, 2 H) 7.39 (dd, J=8.20, 7.62 Hz, 1 H) 7.68 (dd, J=7.62, 0.59 Hz, 1 H) 7.97 (dd, J=8.20, 0.98 Hz, 1 H) 8.25 (s, 1 H).	1-(4-tert-butylphenyl)ethanamine

Ex. #	Name	MW found [M+H]	¹ H NMR	Starting ma- terial
55	2-(7-cyano-1H-benzimidazol-1-yl)-N-[1-(4-isopropylphenyl)ethyl]acetamide	347.0	(400MHz, CD3OD) δ ppm 1.19-1.22 (m, 6H), 1.48 (d, J = 7.0 Hz, 3H), 2.77-2.91 (m, 1H), 5.38 (s, 2H), 7.12-7.20 (m, 2H), 7.23-7.31 (m, 2H), 7.45-7.54 (m, 1H), 7.75-7.83 (m, 1H), 8.03 (dd, J = 1.0, 8.2 Hz, 1H), 8.64 (s, 1H), 8.87 (br d, J = 7.4 Hz, 1H)	[1-(4-isopropylphenyl)ethyl]amine
56	2-(7-cyano-1H-benzimidazol-1-yl)-N-{1-[4-(trifluoromethyl)phenyl]ethyl}acetamide	372.8	(400MHz, CD3OD) δ ppm 1.52 (d, J = 7.0 Hz, 3H), 5.08 (q, J = 7.0 Hz, 1H), 5.35 (s, 2H), 7.34-7.42 (m, 1H), 7.51-7.63 (m, 4H), 7.63-7.70 (m, 1H), 7.97 (dd, J = 0.8, 8.2 Hz, 1H), 8.27 (s, 1H)	{1-[4-(trifluoromethyl)phenyl]ethyl}amine
57	2-(7-fluoro-1H-benzimidazol-1-yl)-N-[1-(4-isopropylphenyl)ethyl]acetamide	340.0	(400MHz, CD3OD) δ ppm 1.21 (d, J = 6.2 Hz, 6H), 1.48 (d, J = 6.8 Hz, 3H), 2.80-2.92 (m, 1H), 4.94-5.06 (m, 1H), 5.20-5.35 (m, 2H), 7.14-7.21 (m, 2H), 7.21-7.33 (m, 3H), 7.41-7.53 (m, 1H), 7.60 (d, J = 8.0 Hz, 1H), 8.88-8.96 (m, 1H), 9.01 (br s, 1H)	[1-(4-isopropylphenyl)ethyl]amine

Ex. #	Name	MW found [M+H]	¹ H NMR	Starting material
58	2-(7-cyano-1H-benzimidazol-1-yl)-N-{{(1S)-1-[4-(trifluoromethyl)phenyl]ethyl}acetamide	372.8	(400MHz, CD3OD) δ ppm 1.52 (d, J = 7.0 Hz, 3H), 4.98-5.15 (m, 1H), 5.35 (s, 2H), 7.32-7.45 (m, 1H), 7.51-7.63 (m, 4H), 7.68 (dd, J = 0.9, 8.2 Hz, 1H), 7.97 (dd, J = 1.0, 8.2 Hz, 1H), 8.26 (s, 1H)	{{(1S)-1-[4-(trifluoromethyl)phenyl]ethyl}amine
59	2-(6,7-difluoro-1H-benzimidazol-1-yl)-N-{1-[4-(trifluoromethyl)phenyl]ethyl}acetamide	383.8	(400MHz, CD3OD) δ ppm 1.52 (d, J = 7.0 Hz, 3H), 5.05-5.12 (m, 1H), 5.18-5.27 (m, 2H), 7.24-7.36 (m, 1H), 7.46-7.56 (m, 3H), 7.58-7.66 (m, 2H), 8.59 (br s, 1H), 9.02 (br d, J = 7.4 Hz, 1H)	{1-[4-(trifluoromethyl)phenyl]ethyl}amine
61	2-(7-cyano-1H-benzimidazol-1-yl)-N-{1-[4-(trifluoromethoxy)phenyl]ethyl}acetamide	388.8	(400MHz, CD3OD) δ ppm 1.51 (d, J = 7.0 Hz, 3H), 4.96-5.12 (m, 1H), 5.40 (s, 2H), 7.15-7.26 (m, 2H), 7.39-7.55 (m, 3H), 7.78 (dd, J = 0.8, 7.6 Hz, 1H), 8.02 (dd, J = 1.0, 8.4 Hz, 1H), 8.60 (s, 1H), 8.90-8.99 (m, 1H)	{1-[4-(trifluoromethoxy)phenyl]ethyl}amine
62	methyl (4-tert-butylphenyl){[(6,7-difluoro-1H-benzimidazol-1-yl)acetyl]amino}acetate	415.8	(400 MHz, DMSO-D6) δ ppm 1.25 (s, 9 H), 3.59 (s, 3 H), 5.05 - 5.17 (m, 2 H), 5.36 (d, J=6.84 Hz, 1 H), 7.15 - 7.25 (m, 1 H), 7.27 - 7.33 (m, 2 H), 7.39 - 7.46 (m, 3 H), 8.18 (s, 1 H), 9.23 (d, J=7.03 Hz, 1 H)	methyl amino(4-tert-butylphenyl)acetate

Ex. #	Name	MW found [M+H]	¹ H NMR	Starting ma- terial
63	2-(7-fluoro-1H-benzimidazol-1-yl)-N-{1-[4-(trifluoromethyl)phenyl]ethyl}acetamide	365.8	(400MHz, CD ₃ OD) δ ppm 1.50 (d, J = 7.0 Hz, 3H), 5.05-5.19 (m, 3H), 7.00 (dd, J = 8.1, 11.4 Hz, 1H), 7.14-7.23 (m, 1H), 7.46 (d, J = 8.2 Hz, 1H), 7.48-7.54 (m, 2H), 7.55-7.63 (m, 2H), 8.11 (s, 1H)	{1-[4-(trifluoromethyl)phenyl]ethyl}amine
64	N-[1-(5-tert-butylpyridin-2-yl)ethyl]-2-(7-cyano-1H-benzimidazol-1-yl)acetamide	362.0	(400 MHz, CHLOROFORM-D) δ ppm 1.34 (s, 9 H), 1.50 (d, J=6.84 Hz, 3 H), 5.08 - 5.16 (m, 1 H), 5.12 - 5.26 (m, 2 H), 7.15 (d, J=7.81 Hz, 1 H), 7.35 (dd, J=8.11, 7.71 Hz, 1 H), 7.45 (d, J=6.44 Hz, 1 H), 7.61 (dd, J=7.62, 0.98 Hz, 1 H), 7.66 (dd, J=8.20, 2.54 Hz, 1 H), 8.05 (s, 1 H), 8.07 (dd, J=8.20, 0.98 Hz, 1 H), 8.49 (dd, J=2.54, 0.59 Hz, 1 H)	[1-(5-tert-butylpyridin-2-yl)ethyl]amine
68	2-(7-cyano-1H-benzimidazol-1-yl)-N-{1-[3-fluoro-4-(trifluoromethyl)phenyl]ethyl}acetamide	390.8	(400MHz, CD ₃ OD) δ ppm 1.52 (d, J = 7.0 Hz, 3H), 5.01-5.12 (m, 1H), 5.35-5.49 (m, 2H), 7.30-7.38 (m, 2H), 7.45-7.53 (m, 1H), 7.61 (t, J = 7.7 Hz, 1H), 7.78 (dd, J = 1.0, 7.6 Hz, 1H), 8.03 (dd J = 1, 8.2 Hz, 1H), 8.61 (s, 1H), 9.03-9.12 (m, 1H)	{1-[3-fluoro-4-(trifluoromethyl)phenyl]ethyl}amine

Ex. #	Name	MW found [M+H]	¹ H NMR	Starting material
69	N-[1-(5-tert-butyl-2-thienyl)ethyl]-2-(6,7-difluoro-1H-benzimidazol-1-yl)acetamide	377.8	(400 MHz, DMSO-D6) δ ppm 1.27 (s, 9 H), 1.42 (d, J=7.03 Hz, 3 H), 4.97 - 5.07 (m, 2 H), 5.04 - 5.14 (m, 1 H), 6.66 (d, J=3.52 Hz, 1 H), 6.72 (dd, J=3.61, 1.07 Hz, 1 H), 7.17 - 7.26 (m, 1 H), 7.42 - 7.46 (m, 1 H), 8.21 (s, 1 H), 8.81 (d, J=8.40 Hz, 1H).	[1-(5- <i>tert</i> -butyl-2-thienyl)ethyl]amine
70	N-[1-(5-tert-butyl-2-thienyl)ethyl]-2-(7-fluoro-1H-benzimidazol-1-yl)acetamide	360.0	(400 MHz, DMSO-D6) δ ppm 1.27 (s, 9 H), 1.42 (d, J=6.84 Hz, 3 H), 4.99 - 5.13 (m, 3 H), 6.67 (d, J=3.52 Hz, 1 H), 6.72 (dd, J=3.61, 1.07 Hz, 1 H), 7.02 - 7.11 (m, 1 H), 7.14 - 7.25 (m, 1 H), 7.49 (d, J=8.01 Hz, 1 H), 8.38 (s, 1 H), 8.81 (d, J=8.20 Hz, 1H).	[1-(5- <i>tert</i> -butyl-2-thienyl)ethyl]amine
71	N-[1-(5-tert-butyl-2-thienyl)ethyl]-2-(7-cyano-1H-benzimidazol-1-yl)acetamide	367.0	(400 MHz, METHANOL-D4) δ ppm 1.32 (s, 9 H), 1.56 (d, J=6.84 Hz, 3 H), 5.18 - 5.27 (m, 1 H), 5.26 - 5.37 (m, 2 H), 6.65 (d, J=3.52 Hz, 1 H), 6.79 (d, J=3.52 Hz, 1 H), 7.44 (t, J=7.03 Hz, 1 H), 7.72 (d, J=7.42 Hz, 1 H), 8.03 (s, 1 H), 8.49 (s, 1 H), 8.86 (d, J=7.62 Hz, 1 H).	[1-(5- <i>tert</i> -butyl-2-thienyl)ethyl]amine

Example 72: N-[1-(6-*tert*-butyl-2-methoxypyridin-3-yl)ethyl]-2-(7-cyano-1H-benzimidazol-1-yl)acetamide.

The title compound was synthesized according to the procedure described for the synthesis of 2-methylnicotinamide, starting from [1-(6-*tert*-butyl-2-methoxypyridin-3-yl)ethyl]amine (intermediate 27) (85 mg, 0.48 mmol), 7-cyanobenzimidazole-1-acetic acid (96 mg 0.48 mmol) HATU (173 mg, 0.5 mmol) and DIPEA (209 μ l, 1.20 mmol). The product was recovered by filtration following precipitation induced by the addition of water. (Yield 27 mg, 46 %). ^1H NMR (400 MHz, DMSO- D_6) δ ppm 1.27 (s, 9 H), 1.32 (d, $J=6.84$ Hz, 3 H), 3.86 (s, 3 H), 5.02 (t, $J=7.03$ Hz, 1 H), 5.25 (d, $J=4.69$ Hz, 2 H), 6.91 (d, $J=7.62$ Hz, 1 H), 7.31 - 7.37 (m, 1 H), 7.62 (dd, $J=7.62$, 0.39 Hz, 1 H), 7.71 (dd, $J=7.71$, 1.07 Hz, 1 H), 8.01 (dd, $J=8.20$, 0.98 Hz, 1 H), 8.34 (s, 1 H), 8.78 - 8.83 (m, $J=7.81$ Hz, 1 H). MS $[\text{MH}^+]$ calc. 392.2086 found 392.3.

Example 73: N-[1-(6-*tert*-butyl-2-methylpyridin-3-yl)ethyl]-2-(6,7-difluoro-1H-benzimidazol-1-yl)acetamide.

The title compound was synthesized according to the procedure described for the synthesis of 2-methylnicotinamide, starting from [1-(6-*tert*-butyl-2-methylpyridin-3-yl)ethyl]amine (intermediate 32) (31.5 mg, 0.16 mmol), 6,7-difluorobenzimidazole-1-acetic acid (35 mg 0.16 mmol) HATU (38 mg, 0.18 mmol) and DIPEA (71 μ l, 0.41 mmol). Water was added and the reaction concentrated. The mixture was partitioned between ethyl acetate and water, and extracted 3 more times with ethyl acetate. The product was then purified by silica gel flash chromatography with acetone/hexanes (Yield 25 mg, 40 %). ^1H NMR (400 MHz, $\text{CD}_3\text{OD}-\text{D}_4$) δ ppm 1.32 (s, 9 H), 1.47 (d, $J=7.03$ Hz, 3 H), 2.53 - 2.57 (m, 3 H), 5.04 - 5.15 (m, 2 H), 5.15 - 5.22 (m, 1 H), 7.16 (ddd, $J=11.43$, 8.79, 7.52 Hz, 1 H), 7.28 (d, $J=8.20$ Hz, 1 H), 7.41 (dd, $J=8.89$, 3.61 Hz, 1 H), 7.68 (d, $J=8.20$ Hz, 1 H), 8.11 (s, 1 H) MS $[\text{MH}^+]$ calc. 387.1996 found 387.3.

Example 74: N-[1-(6-*tert*-butyl-4-methylpyridin-3-yl)ethyl]-2-(7-cyano-1H-benzimidazol-1-yl)acetamide.

The title compound was synthesized according to the procedure described for the synthesis of 2-methylnicotinamide, starting from [1-(6-*tert*-butyl-4-methylpyridin-3-yl)ethyl]amine (intermediate 28) (52 mg, 0.27 mmol), 7-cyanobenzimidazole-1-acetic acid (54.4 mg, 0.27

mmol), HATU (108 mg, 0.28 mmol) and DIPEA (117 μ L, 2.5 mmol). Water is added and the reaction is concentrated then purified by reverse phase chromatography. (Yield 31.3 mg, 31 %). ^1H NMR (400 MHz, DMSO- D_6) δ ppm 1.27 (s, 9 H), 1.42 (d, $J=7.03$ Hz, 3 H), 2.29 (s, 3 H), 5.03 - 5.12 (m, 1 H), 5.13 - 5.27 (m, 2 H), 7.17 (s, 1 H), 7.34 (dd, $J=8.11$, 7.71 Hz, 1 H), 7.71 (dd, $J=7.62$, 0.78 Hz, 1 H), 8.01 (dd, $J=8.01$, 0.98 Hz, 1 H), 8.34 (s, 1 H), 8.47 (s, 1 H), 8.88 (d, $J=7.81$ Hz, 1 H). MS $[\text{MH}^+]$ calc. 376.2137 found 376.3.

Example 75: N-[1-(6-*tert*-butyl-2-chloropyridin-3-yl)ethyl]-2-(7-cyano-1H-benzimidazol-1-yl)acetamide.

The title compound was synthesized according to the procedure described for the synthesis of 2-methylnicotinamide, starting from [1-(6-*tert*-butyl-2-chloropyridin-3-yl)ethyl]amine (intermediate 26) (100 mg, 0.47 mmol), 7-cyanobenzimidazole-1-acetic acid (0.42 mmol), HATU (191 mg, 0.5 mmol) and DIPEA (182 μ L, 1.41 mmol). The product was recovered by filtration following precipitation induced by the addition of water. Yield 111 mg, 67 %.

^1H NMR (400 MHz, DMSO- D_6) δ ppm 1.27 (s, 9 H), 1.38 (d, $J=7.03$ Hz, 3 H), 5.05 - 5.13 (m, 1 H), 5.21 - 5.32 (m, 2 H), 7.34 (dd, $J=8.01$, 7.62 Hz, 1 H), 7.43 (d, $J=8.01$ Hz, 1 H), 7.71 (dd, $J=7.62$, 0.98 Hz, 1 H), 7.86 (d, $J=8.01$ Hz, 1 H), 8.01 (dd, $J=8.01$, 0.98 Hz, 1 H), 8.34 (s, 1 H), 9.06 (d, $J=7.23$ Hz, 1 H). MS $[\text{MH}^+]$ calc. 396.1591 found 396.3.

Example 76: N-[1-(6-*tert*-butylpyridin-3-yl)ethyl]-2-(7-cyano-1H-benzimidazol-1-yl)acetamide.

The title compound was synthesized according to the procedure described for the synthesis of 2-methylnicotinamide, starting from [1-(6-*tert*-butylpyridin-3-yl)ethyl]amine (intermediate 25) (93 mg, 0.52 mmol), 7-cyanobenzimidazole-1-acetic acid (100 mg, 0.5 mmol), HATU (198 mg, 0.52 mmol) and DIPEA (226 μ L, 1.3 mmol). Water is added and the reaction is concentrated then purified by reverse phase chromatography. ^1H NMR (400 MHz, DMSO- D_6) δ ppm 1.26 (s, 9 H), 1.39 (d, $J=7.03$ Hz, 3 H), 4.87 - 4.97 (m, 1 H), 5.12 - 5.27 (m, 2 H), 7.32 (dd, $J=8.01$, 7.62 Hz, 1 H), 7.35 (d, $J=8.20$ Hz, 1 H), 7.66 (dd, $J=8.30$, 2.25 Hz, 1 H), 7.69 (dd, $J=7.52$, 0.88 Hz, 1 H), 7.99 (dd, $J=8.20$, 0.98 Hz, 1 H), 8.32 (s, 1 H), 8.45 (d, $J=2.54$ Hz, 1 H), 8.85 (d, $J=7.42$ Hz, 1 H). MS $[\text{MH}^+]$ calc. 362.1981 found 362.3.

Pharmacology

1. hVR1 FLIPR (Fluorometric Image Plate Reader) screening assay

Transfected CHO cells, stably expressing hVR1 (15,000 cells/well) are seeded in 50 μ l media in a black clear bottom 384 plate (Greiner) and grown in a humidified incubator (37°C, 2% CO₂), 24-30 hours prior to experiment.

Subsequently, the media is removed from the cell plate by inversion and 2 μ M Fluo-4 is added using a multidrop (Labsystems). Following the 40 minutes dye incubation in the dark at 37°C and 2% CO₂, the extracellular dye present is washed away using an EMBLA (Scatron), leaving the cells in 40 μ l of assay buffer (1 X HBSS, 10 mM D-Glucose, 1 mM CaCl₂, 10 mM HEPES, 10 X 7.5% NaHCO₃ and 2.5 mM Probenecid).

FLIPR assay - IC₅₀ determination protocol

For IC₅₀ determinations the fluorescence is read using FLIPR filter 1 (em 520-545 nm). A cellular baseline recording is taken for 30 seconds, followed by a 20 μ l addition of 10, titrated half-log concentrations of the test compound, yielding cellular concentration ranging from 3 μ M to 0.1 nM. Data is collected every 2 seconds for a further 5 minutes prior to the addition of a VR1 agonist solution: 20-50 nM solution of capsaicin by the FLIPR pipettor. The FLIPR continues to collect data for a further 4 minutes. Compounds having antagonistic properties against the hVR1 will inhibit the increase in intracellular calcium in response to the capsaicin addition. This consequently leading to a reduction in fluorescence signal and providing a reduced fluorescence reading, compared with no compound, buffer controls. Data is exported by the FLIPR program as a sum of fluorescence calculated under the curve upon the addition of capsaicin. Maximum inhibition, Hill slope and IC₅₀ data for each compound are generated.

2. hVR1 FLIPR (Fluorometric Image Plate Reader) screening assay with HEK T-REX hVR1.

HEK T-REX hVR1 inducible cells are grown in supplemented DMEM medium (10% FBS, 2 mM Glutamine, 5 μ g/ml Blasticidine & 350 μ g/ml Zeocin). HEK cells are plated in 384-black polylysine coated plate (Costar) at 10000 cells/well/50 μ l for 24 hours or 5,500 cells /well 48 hours in a humidified incubator (5% CO₂ and 37°C) in DMEM medium

without selection agent. HEK T-Rex hVR1 cells are induced with 0.1 µg/ml Tetracycline 16 hours prior the experiment.

Subsequently, the media is removed from the cell plate by inversion and 2 µM Fluo-4 is added using a multidrop (Labsystems). Following the 30 to 40 minutes dye incubation in the dark at 37°C and 2% CO₂, the extracellular dye present is washed away using an MicroplateWasher Skatron Embla 384, leaving the cells in 25 µl of assay buffer (1X HBSS without Ca⁺⁺/Mg⁺⁺/sodium bicarbonate, 1mM CaCl₂ & 5 mM D-Glucose).

FLIPR assay - IC₅₀ determination protocol

For IC₅₀ determinations the fluorescence is read using FLIPR filter 1 (em 520-545 nM). A cellular baseline recording is taken for 10 seconds, followed by 12,5 µl addition of test compounds, 10 points dilution 3 fold concentration, yielding cellular concentration ranging from 22.5 µM to 0.1 nM. Data are collected every 2 seconds for a further 5 minutes prior to the addition of a VR1 agonist solution: 20 nM (or 50 nM) capsaicin solution is added by the FLIPR pipettor. The FLIPR continues to collect data for a further 4 minutes.

Compounds having antagonistic properties against the hVR1 will inhibit the increase in intracellular calcium in response to the capsaicin addition. This consequently leading to a reduction in fluorescence signal and providing a reduced fluorescence reading, compared with no compound, buffer controls. Data is exported by the FLIPR program as a sum of fluorescence calculated under the curve upon the addition of capsaicin. Maximum inhibition, Hill slope and IC₅₀ data for each compound are generated.

3. DRGs were dissected out from adult Sprague Dawley rats (100-300 gr), and placed on ice in L15 Leibovitz medium. The ganglia were enzyme treated with Collagenase 80U/ml+ Dispase 34 U/ml dissolved in DMEM +5% serum, overnight at 37 °C. The next day, cells were triturated with fire polished pasteur pipettes, and seeded in the center of 58 mm diameter Nunc cell dishes coated with Poly-D Lysine (1 mg/ml). The DRGs were cultured in a defined medium without foetal bovine serum, containing Dulbecco's MEM / NUT MIX F-12 (1:1) without L-glutamine but with pyridoxine, 6 mg/mL D(+)-Glucose, 100 µg/mL apo-transferrin, 1 mg/mL BSA, 20 µg/mL insulin, 2 mM L-glutamine, 50 IU/ mL Penicillin, 50 µg / mL Streptomycin and 0.01 µg/mL NGF-7S.

When the cells had grown for 2 days up to 4 weeks, the experiments were done. Cells were chosen based on size and presence of neurites. Small cells with long processes were used for recording (most likely to be C neurons, with native VR1 receptors).

The cells were recorded with conventional whole cell voltage clamp patch clamp, using the following solutions (calcium ion free):

The extracellular solution comprised (in mM): NaCl 137, KCl 5, MgCl₂ * H₂O 1.2, HEPES 10, Glucose 10, EGTA 5, Sucrose 50, pH to 7.4 with NaOH.

The intracellular solution comprised K-gluconate 140, NaCl 3, MgCl₂ * H₂O 1.2, HEPES 10, EGTA 1, pH to 7.2 with KOH. When the cells were penetrated with suction, a puff of capsaicin (500 nM) was used to determine if the cell expressed VR1 receptor. If not, a new cell was chosen. If yes, then the compounds were added in increasing doses before the capsaicin pulse (500 nM), to determine an IC₅₀ value.

List of abbreviations

VR1	vanilloid receptor 1
IBS	irritable bowel syndrome
IBD	inflammatory bowel disease
GERD	gastro-esophageal reflux disease
DRG	Dorsal Root Ganglion
BSA	Bovine Serum Albumin
HEPES	4-(2-Hydroxyethyl)piperazine-1-ethanesulfonic acid
EGTA	Ethylene glycol-bis(2-aminoethylether)- <i>N,N,N',N'</i> -tetraacetic acid
DMEM	Dulbeccos Modified Eagle's Medium

Results

Typical IC₅₀ values as measured in the assays described above are 150 nM or less. In one aspect of the invention the IC₅₀ is below 10 nM

Table 3. Specimen results from the hVR1 FLIPR

Example No.	Name	IC ₅₀
1	N-[(1S)-1-(4-isopropoxyphenyl)ethyl]-2-(7-nitro-1H-benzimidazol-1-yl)acetamide	1 nM
4	N-((1S)-1-{4-[(1-methylprop-2-yn-1-yl)oxy]phenyl}ethyl)-2-(7-nitro-1H-benzimidazol-1-yl)acetamide	3 nM
12	N-{1-[6-(cyclopentyloxy)pyridine-3-yl]ethyl}-2-(7-nitro-1H-benzimidazol-1-yl)acetamide	5 nM
15	N-[(1S)-1-(4-{[(1S)-1-methylpropyl]oxy}phenyl)ethyl]-2-(7-nitro-1H-benzimidazol-1-yl)acetamide	1 nM
16	N-(1-{4-[chloro(difluoro)methyl]phenyl}ethyl)-2-(7-nitro-1H-benzimidazol-1-yl)acetamide	10 nM
22	2-(7-nitro-1H-benzimidazol-1-yl)-N-{1-[4-(1,1,2,2-tetrafluoroethoxy)phenyl]ethyl}acetamide	5 nM
36	2-(7-nitro-1H-benzimidazol-1-yl)-N-{1-[4-(trifluoromethoxy)phenyl]ethyl}acetamide	9 nM
37	2-(7-nitro-1H-benzimidazol-1-yl)-N-{1-[4-(trifluoromethyl)phenyl]ethyl}acetamide	6 nM
39	N-{1-[4-(cyclopentyloxy)-3-fluorophenyl]ethyl}-2-(7-nitro-1H-benzimidazol-1-yl)acetamide	1 nM
40	N-[1-(4-cyclopropylphenyl)ethyl]-2-(7-nitro-1H-benzimidazol-1-yl)acetamide	3 nM
47	N-{1-[4-{[(2S)-2-Methoxypropyl]oxy}-3-(trifluoromethyl)phenyl]ethyl}-2-(7-nitro-1H-benzimidazol-1-yl)acetamide	8 nM
48	N-{1-methyl-2-[3-(trifluoromethyl)phenoxy]ethyl}-2-(7-nitro-1H-benzimidazol-1-yl)acetamide	7 nM

Table 4. Specimen results from the aqueous solubility test

Example No.	Name	Aqueous solubility at pH 7.4
3	N-((1S)-1-[4-(2-fluoroethoxy)phenyl]ethyl)-2-(7-nitro-1H-benzimidazol-1-yl)acetamide	90 μ M
5	N-((1S)-1-[4-(2-methoxy-1-methyl)ethoxy]phenyl]ethyl)-2-(7-nitro-1H-benzimidazol-1-yl)acetamide	97 μ M
6	N-[(1S)-1-(4-ethoxyphenyl)ethyl]-2-(7-nitro-1H-benzimidazol-1-yl)acetamide	72 μ M
9	N-{1-[6-(2,2-difluoroethoxy)pyridin-3-yl]ethyl}-2-(7-nitro-1H-benzimidazol-1-yl)acetamide	98 μ M
14	2-(7-nitro-1H-benzimidazol-1-yl)-N-{1-[4-(2,2,2-trifluoroethoxy)phenyl]ethyl}acetamide	63 μ M
19	N-{1-[4-(2,2-difluoroethoxy)phenyl]ethyl}-2-(7-nitro-1H-benzimidazol-1-yl)acetamide	75 μ M
24	2-(7-cyano-1H-benzimidazol-1-yl)-N-(1-{4-[2-fluoro-1-(fluoromethyl)ethoxy]phenyl}ethyl)acetamide	94 μ M
29	2-(7-nitro-1H-benzimidazol-1-yl)-N-{1-[5-(trifluoromethyl)pyridin-2-yl]propyl}acetamide	92 μ M
30	2-(7-nitro-1H-benzimidazol-1-yl)-N-{1-[5-(trifluoromethyl)pyridin-2-yl]ethyl}acetamide	97 μ M
31	2-(7-chloro-1H-benzimidazol-1-yl)-N-{1-[3-chloro-5-(trifluoromethyl)pyridin-2-yl]ethyl}acetamide	87 μ M
32	N-{1-[3-chloro-5-(trifluoromethyl)pyridin-2-yl]ethyl}-2-(7-nitro-1H-benzimidazol-1-yl)acetamide	87 μ M
35	2-(7-chloro-1H-benzimidazol-1-yl)-N-[1-(6-isopropoxy)pyridin-3-yl]ethyl]acetamide	100 μ M
38	N-[1-(6-isopropoxy)pyridin-3-yl]ethyl]-2-(7-nitro-1H-benzimidazol-1-yl)acetamide	86 μ M

Example No.	Name	Aqueous solubility at pH 7.4
41	N-[1-(4-ethynylphenyl)ethyl]-2-(7-nitro-1H-benzimidazol-1-yl)acetamide	82 μ M
42	2-(7-chloro-1H-benzimidazol-1-yl)-N-[1-(4-ethynylphenyl)ethyl]acetamide	77 μ M
46	N-{1-[4-[(1-Methylpiperidin-4-yl)oxy]-3-(trifluoromethyl)phenyl]ethyl}-2-(7-nitro-1H-benzimidazol-1-yl)acetamide	100 μ M

Biological tests

In vivo experiments

The *in vivo* pharmacological properties of some of the compounds according to the present invention have been determined using two classical NSAID-sensitive inflammatory models, the Carrageenan model and the Freund's Complete Adjuvant (FCA) model.

In the former, Carrageenan-lambda (algae-derived polysaccharide, type IV, 100 μ l, from Sigma-Aldrich), dissolved in sterile saline 0.9% at a concentration of 1%, and in the latter FCA (25 μ l, from Sigma-Aldrich, (1ml of FCA contains 1mg mycobacterium tuberculosis heat killed and dried, 0.85 ml mineral oil and 0.15ml mannide monooleate, cf. Nagakura et al. in *Journal of Pharmacology and Experimental Therapeutics*, 2003; 306(2):490-497)) is injected into the subcutaneous space under the plantar surface (intra-plantar; i.pl.) of the rat left hind paw. This creates an inflammatory response, with accompanying edema, redness, and hyperalgesia. Heat (and mechanical) hyperalgesia is fully developed by 3 hours for carrageenan, and remains stable for 6 hours, while FCA is fully developed by 24h and remains stable for weeks. In order to assess the degree of hyperalgesia, the heat plantar test was chosen, as it is a robust, consistent, and reproducible endpoint (based on the Hargreaves method of assessing nociception, cf. *Pain*, 1988; 32(1):77-88). Rats are placed in individual plexiglass boxes on a glass surface, which is maintained at 30°C, and a heat-source (rate of heat increase: \sim 1.1 °C/s) is focused onto the plantar surface of the affected paw. The time from the initiation of the heat until the animal withdraws the paw is re-

corded. A decrease in Paw Withdrawal Latency (PWL) relative to naïve animals indicates a hyperalgesic state.

The degree of reversal of hyperalgesia is measured by the ability of the compounds to return PWL to normal levels.

N-[(1S)-1-(4-tert-butylphenyl)ethyl]-2-(6,7-difluoro-1H-benzimidazol-1-yl)acetamide from Example 52, the more active enantiomer of 2-(7-Nitro-benzoimidazol-1-yl)-N-{1-[6-(2,2,3,3-tetrafluoro-propoxy)-pyridin-3-yl]-ethyl}-acetamide from Example 10, and N-
10 {(S)-1-[4-(2-Fluoro-1-fluoromethyl-ethoxy)-phenyl]-ethyl}-2-(7-nitro-benzoimidazol-1-yl)-acetamide from Example 2 were orally administered (the more active enantiomer of 2-(7-Nitro-benzoimidazol-1-yl)-N-{1-[6-(2,2,2-trifluoro-ethoxy)-pyridin-3-yl]-ethyl}-aceta-
mide from Example 7 was given by subcutaneous injection) during the established phase of inflammation and tested at their respective T_{max}. Said more active enantiomers were
15 obtained by preparing the compounds from intermediates that had been resolved enzymatically and coupled to the acids to produce target compounds having ~90% enantiopurity. The latter were additionally purified by means of chiral chromatography. The PWL of each animal is measured twice, and the average of the two is taken as the response. The responses of all animals within a given group are then averaged, and Standard Deviation and
20 Standard Error of the Mean (SEM) are calculated for each group. The data is expressed as mean ± SEM. Statistical significance is assessed with a T-test for comparison between naïve and treated groups, and One Way ANOVA followed by Holm-Sidak multiple comparisons versus control (vehicle) group test for drug effectiveness. The level of statistical significance is set at $p < 0.05$. GraphPad Prism® version 4 is used for non-linear regression
25 analysis (using the variable slope sigmoidal equation model) of raw data to calculate the ED₅₀, EC₅₀, EC₈₀, and E_{max}.

Prior to any manipulation, rats (150-175g, Charles River, St. Constant, Canada) were housed in groups of 7-9 in a temperature controlled room (22±1.5°C, 30-80% humidity,
30 12h light/dark cycle) and were acclimatized in the animal facility for at least one day prior to use. All experimental protocols are approved by the AstraZeneca Animal Care Com-

mittee. Experiments are performed during the light phase of the cycle, rooms are illuminated at 300 lux intensity. Animals have food and water ad libitum.


In vivo efficacy and potency of the tested compounds in nociceptive pain are summarized in Table 5 below. The tested compounds are potent and effective in reversing both carrageenan- and FCA-induced heat hyperalgesia.

Table 5. Efficacy and Potency of tested compounds in the carrageenan and FCA models in vivo

	Carrageenan model				FCA model
Compound from Example #	52	10 active enantiomer	2	7 active enantiomer	52
ED50 ($\mu\text{mol/kg}$)	37.4	3.2	1.3	6.0	119.7
EC50 (μM)	0.5	0.39	0.105	0.75	1.6
E _{max} observed (%)	74	81	79	94	78
Extrapolated E _{max} (%)	>100	>100	79	>100	>100
EC80 (μM)	1.4	2.1	0.17	2.0	4.6

CLAIMS

1. A compound having the formula:



5 wherein:

R^1 is selected from nitro, cyano, halo, and acetyl;

R^2 is selected from phenyl, heteroaryl, phenylmethyl, and phenyloxymethyl;

where R^2 is optionally substituted with one or more substituents Q selected from C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} haloalkyl, halo, C_{1-6} haloalkoxy, C_{3-7} cycloalkoxy, C_{3-7} cycloalkyl, C_{1-6} alkynyl, C_{3-7} cycloalkylalkoxy, C_{3-7} heterocycloalkyloxy, and C_{1-3} alkoxy C_{1-6} alkoxy, said
 10 substituent(s) Q being attached to the aromatic and/or heteroaromatic ring(s) of R^2 ;

R^3 is H or F;

R^4 is methyl, methoxycarbonyl or ethyl; or R^2 and R^4 may together form a monocyclic or bicyclic ring system;

15 and salts, solvates or solvated salts thereof.

2. The compound according to claim 1, wherein R^1 is selected from nitro, cyano, fluoro, chloro, and acetyl.

20 3. The compound according to claim 1, wherein R^1 is nitro.

4. The compound according to claim 1, wherein R^1 is cyano or halo.

5. The compound according to claim 1, wherein R^1 is cyano, chloro, or fluoro.

25

6. The compound according to claim 1, wherein R^2 is selected from phenyl, pyridinyl, thienyl, phenylmethyl, and phenyloxymethyl.

7. The compound according to claim 1, wherein R^2 is phenyl substituted with one or more substituent(s) Q with one substituent Q in para-position relative to the point of attachment.

8. The compound according to claim 1, wherein R^2 is pyridin-3-yl substituted with one or more substituent(s) Q, wherein one substituent Q is a substituent at position 6 of the pyridine ring.

9. The compound according to claim 1, wherein R^2 is pyridin-2-yl substituted with one or more substituent(s) Q, wherein one substituent Q is a substituent at position 5 of the pyridine ring.

10. The compound according to claim 1, wherein R^2 is thien-2-yl substituted with one or more substituent(s) Q, wherein one substituent Q is a substituent at position 5 of the thiophene ring.

11. The compound according to claim 1, wherein R^2 is phenylmethyl.

12. The compound according to claim 1, wherein R^2 is phenoxyethyl.

13. The compound according to claim 1, wherein Q is selected from (1-methylprop-2-yn-1-yl)oxy, 1-methylpropyloxy, 2,2,2-trifluoro-ethoxy, 2,2,3,3-tetrafluoro-propoxy, 2,2-difluoro-ethoxy, 2-fluoro-1-fluoromethyl-ethoxy, 2-fluoroethoxy, 2-methoxy-1-methyl-ethoxy, 2-methoxy-propoxy, chloro, chloro(difluoro)methyl, cyclopentyloxy, cyclopropyl, cyclopropylmethoxy, ethoxy, ethynylphenyl, fluoro, isopropoxy, isopropyl, methoxy, methylpiperazinyl, methylpiperidinyl, propoxy, tert-butyl, trifluoromethoxy, and trifluoromethyl.

14. The compound according to claim 1, where R^2 is substituted with two substituents Q, one of which is selected from 2-fluoro-1-fluoromethyl-ethoxy, 2-fluoroethoxy, cyclopentyloxy, methoxy, 2-fluoro-1-fluoromethyl-ethoxy, 2-methoxypropyloxy, methylpiperazinyl, and methylpiperidinyl; and the other one of which is selected from chloro, fluoro, and trifluoromethyl.

15. The compound according to claim 1, wherein R⁴ is methyl.

16. The compound according to claim 1, wherein R² and R⁴ together form a monocyclic or
5 bicyclic ring system.

17. The compound according to claim 1, wherein R² and R⁴ together form a bicyclic ring system.

10 18. The compound according to claim 1, wherein R² and R⁴ together form a chromanyl group.

19. The compound according to claim 1, wherein

R¹ is selected from nitro, cyano, chloro, fluoro, and acetyl; and

15 R² is phenyl substituted with one or more substituent(s) Q selected from (1-methylprop-2-yn-1-yl)oxy, 1-methylpropyloxy, 2,2,2-trifluoro-ethoxy, 2,2,3,3-tetrafluoro-propoxy, 2,2-difluoroethoxy, 2-fluoro-1-fluoromethyl-ethoxy, 2-fluoroethoxy, 2-methoxy-1-methyl-ethoxy, 2-methoxy-propoxy, chloro, chloro(difluoro)methyl, cyclopentyloxy, cyclopropyl, ethoxy, ethynylphenyl, fluoro, isopropyl, methylpiperazinyl, methylpiperidinyloxy, pro-
20 poxy, tert-butyl, trifluoromethoxy, and trifluoromethyl, with one substituent Q in para-position relative to the point of attachment.

20. The compound according to claim 19, wherein

R¹ is selected from nitro, cyano, and fluoro; and

25 R² is phenyl substituted with one or more substituent(s) Q selected from (1-methylprop-2-yn-1-yl)oxy, 1-methylpropyloxy, 2,2,2-trifluoro-ethoxy, 2,2,3,3-tetrafluoro-propoxy, 2-fluoroethoxy, 2-methoxy-1-methyl-ethoxy, chloro, cyclopentyloxy, cyclopropyl, ethoxy, ethynylphenyl, fluoro, isopropyl, methylpiperazinyl, methylpiperidinyloxy, propoxy, tert-butyl, trifluoromethoxy, and trifluoromethyl, with one substituent Q in para-position rela-
30 tive to the point of attachment.

21. The compound according to claim 1, wherein

R¹ is selected from nitro, cyano, chloro, and fluoro; and

R² is pyridinyl or thienyl substituted with one or more substituent(s) Q selected from 2,2,2-trifluoro-ethoxy, 2,2,3,3-tetrafluoro-propoxy, 2,2-difluoro-ethoxy, 2-fluoro-1-fluoro-methyl-ethoxy, 2-fluoroethoxy, 2-isopropoxy, chloro, cyclopentyloxy, cyclopropylmethoxy, isopropoxy, tert-butyl, and trifluoromethyl.

22. The compound according to claim 21, wherein

R² is pyridinyl or thienyl substituted with one or more substituent(s) Q selected from 2,2,2-trifluoro-ethoxy, 2,2,3,3-tetrafluoro-propoxy, 2,2-difluoro-ethoxy, 2-isopropoxy, chloro, cyclopentyloxy, cyclopropylmethoxy, isopropoxy, tert-butyl, and trifluoromethyl.

23. The compounds according to claim 1 selected from the group consisting of

2-(6,7-difluoro-1H-benzimidazol-1-yl)-N-{1-[4-(trifluoromethyl)phenyl]ethyl}acetamide, 2-(7-acetyl-1H-benzimidazol-1-yl)-N-(1-{4-[2-fluoro-1-(fluoro-methyl)ethoxy]phenyl}ethyl)acetamide,

2-(7-chloro-1H-benzimidazol-1-yl)-N-(1-{4-[2-fluoro-1-(fluoro-methyl)ethoxy]phenyl}ethyl)acetamide,

2-(7-chloro-1H-benzimidazol-1-yl)-N-(1-{4-[chloro(difluoro)methyl]phenyl}ethyl)acetamide,

2-(7-chloro-1H-benzimidazol-1-yl)-N-[1-(4-ethynylphenyl)ethyl]acetamide,

2-(7-chloro-1H-benzimidazol-1-yl)-N-{1-[3-chloro-5-(trifluoromethyl)pyridin-2-yl]ethyl}acetamide,

2-(7-chloro-1H-benzimidazol-1-yl)-N-{1-[4-(1,1,2,2-tetrafluoroethoxy)phenyl]ethyl}acetamide,

2-(7-chloro-1H-benzimidazol-1-yl)-N-{1-[4-(2,2-difluoroethoxy)phenyl]ethyl}acetamide,

2-(7-chloro-1H-benzimidazol-1-yl)-N-{1-[4-(trifluoromethyl)phenyl]ethyl}acetamide,

2-(7-chloro-1H-benzimidazol-1-yl)-N-{1-[6-(2,2,2-trifluoroethoxy)pyridin-3-yl]ethyl}acetamide,

2-(7-chloro-1H-benzimidazol-1-yl)-N-{1-[6-(2,2,3,3-tetrafluoropropoxy)pyridin-3-yl]ethyl}acetamide,

2-(7-Chloro-benzimidazol-1-yl)-N-[1-(6-isopropoxy-pyridin-3-yl)-ethyl]-acetamide,

- 2-(7-cyano-1H-benzimidazol-1-yl)-N-(1-{4-[2-fluoro-1-(fluoromethyl)ethoxy]phenyl}ethyl)acetamide,
2-(7-cyano-1H-benzimidazol-1-yl)-N-[1-(4-isopropylphenyl)ethyl]acetamide,
2-(7-cyano-1H-benzimidazol-1-yl)-N-{1-[3-fluoro-4-(trifluoromethyl)phenyl]ethyl}acetamide,
5 2-(7-cyano-1H-benzimidazol-1-yl)-N-{1-[4-(2,2,2-trifluoroethoxy)phenyl]ethyl}acetamide,
2-(7-cyano-1H-benzimidazol-1-yl)-N-{1-[4-(trifluoromethoxy)phenyl]ethyl}acetamide,
2-(7-cyano-1H-benzimidazol-1-yl)-N-{1-[4-(trifluoromethyl)phenyl]ethyl}acetamide,
10 2-(7-cyano-1H-benzimidazol-1-yl)-N-((1S)-1-[4-(trifluoromethyl)phenyl]ethyl)acetamide,
2-(7-cyano-1H-benzimidazol-1-yl)-N-{1-[4-[2-fluoro-1-(fluoromethyl)ethoxy]-2-(trifluoromethyl)phenyl]ethyl}acetamide,
2-(7-fluoro-1H-benzimidazol-1-yl)-N-[1-(4-isopropylphenyl)ethyl]acetamide,
2-(7-fluoro-1H-benzimidazol-1-yl)-N-{1-[4-(trifluoromethyl)phenyl]ethyl}acetamide,
15 2-(7-nitro-1H-benzimidazol-1-yl)-N-{1-[4-(1,1,2,2-tetrafluoroethoxy)phenyl]ethyl}acetamide,
2-(7-nitro-1H-benzimidazol-1-yl)-N-{1-[4-(2,2,2-trifluoroethoxy)phenyl]ethyl}acetamide,
2-(7-nitro-1H-benzimidazol-1-yl)-N-{1-[4-(trifluoromethoxy)phenyl]ethyl}acetamide,
2-(7-nitro-1H-benzimidazol-1-yl)-N-{1-[4-(trifluoromethyl)phenyl]ethyl}acetamide,
20 2-(7-nitro-1H-benzimidazol-1-yl)-N-{1-[5-(trifluoromethyl)pyridin-2-yl]propyl}acetamide,
2-(7-nitro-1H-benzimidazol-1-yl)-N-{1-[5-(trifluoromethyl)pyridin-2-yl]ethyl}acetamide,
2-(7-nitro-1H-benzimidazol-1-yl)-N-{1-[6-(2,2,2-trifluoroethoxy)pyridin-3-yl]ethyl}acetamide,
25 2-(7-nitro-1H-benzimidazol-1-yl)-N-{1-[6-(2,2,3,3-tetrafluoropropoxy)pyridin-3-yl]ethyl}acetamide,
methyl (4-tert-butylphenyl){[(6,7-difluoro-1H-benzimidazol-1-yl)acetyl]amino}acetate,
N-((1S)-1-{4-[(1-methylprop-2-yn-1-yl)oxy]phenyl}ethyl)-2-(7-nitro-1H-benzimidazol-1-yl)acetamide,
30 N-((1S)-1-{4-[2-fluoro-1-(fluoromethyl)ethoxy]phenyl}ethyl)-2-(7-nitro-1H-benzimidazol-1-yl)acetamide,

N-(1-{2-chloro-4-[2-fluoro-1-(fluoromethyl)ethoxy]phenyl}ethyl)-2-(7-cyano-1H-benzimidazol-1-yl)acetamide,

N-(1-{4-[chloro(difluoro)methyl]phenyl}ethyl)-2-(7-nitro-1H-benzimidazol-1-yl)acetamide,

5 N-(1-{5-chloro-6-[2-fluoro-1-(fluoromethyl)ethoxy]pyridin-3-yl}ethyl)-2-(7-nitro-1H-benzimidazol-1-yl)acetamide,

N-(1-{6-[2-fluoro-1-(fluoromethyl)ethoxy]pyridin-3-yl}ethyl)-2-(7-nitro-1H-benzimidazol-1-yl)acetamide,

10 N-[(1S)-1-(4-{[(1S)-1-methylpropyl]oxy}phenyl)ethyl]-2-(7-nitro-1H-benzimidazol-1-yl)acetamide,

N-[(1S)-1-(4-ethoxyphenyl)ethyl]-2-(7-nitro-1H-benzimidazol-1-yl)acetamide,

N-[(1S)-1-(4-isopropoxyphenyl)ethyl]-2-(7-nitro-1H-benzimidazol-1-yl)acetamide,

N-[(3R)-5-Methoxy-3,4-dihydro-2H-chromen-3-yl]-2-(7-nitro-1H-benzimidazol-1-yl)acetamide,

15 N-[(3R)-8-Fluoro-5-methoxy-3,4-dihydro-2H-chromen-3-yl]-2-(7-nitro-1H-benzimidazol-1-yl)acetamide,

N-[1-(4-{[(2S)-2-methoxypropyl]oxy}phenyl)ethyl]-2-(7-nitro-1H-benzimidazol-1-yl)acetamide,

N-[1-(4-cyclopropylphenyl)ethyl]-2-(7-nitro-1H-benzimidazol-1-yl)acetamide,

20 N-[1-(4-ethynylphenyl)ethyl]-2-(7-nitro-1H-benzimidazol-1-yl)acetamide,

N-[1-(4-tert-butylphenyl)ethyl]-2-(6,7-difluoro-1H-benzimidazol-1-yl)acetamide,

N-[(1S)-1-(4-tert-butylphenyl)ethyl]-2-(6,7-difluoro-1H-benzimidazol-1-yl)acetamide,

N-[1-(4-tert-butylphenyl)ethyl]-2-(7-cyano-1H-benzimidazol-1-yl)acetamide,

N-[1-(5-isopropoxypyridin-2-yl)ethyl]-2-(7-nitro-1H-benzimidazol-1-yl)acetamide,

25 N-[1-(5-tert-butyl-2-thienyl)ethyl]-2-(6,7-difluoro-1H-benzimidazol-1-yl)acetamide,

N-[1-(5-tert-butyl-2-thienyl)ethyl]-2-(7-cyano-1H-benzimidazol-1-yl)acetamide,

N-[1-(5-tert-butyl-2-thienyl)ethyl]-2-(7-fluoro-1H-benzimidazol-1-yl)acetamide,

N-[1-(5-tert-butylpyridin-2-yl)ethyl]-2-(7-fluoro-1H-benzimidazol-1-yl)acetamide,

N-[1-(6-isopropoxypyridin-3-yl)ethyl]-2-(7-nitro-1H-benzimidazol-1-yl)acetamide,

30 N-[2-(4-chlorophenyl)-1-methylethyl]-2-(7-nitro-1H-benzimidazol-1-yl)acetamide,

N-{(1S)-1-[4-(2-fluoroethoxy)phenyl]ethyl}-2-(7-nitro-1H-benzimidazol-1-yl)acetamide,

- N-{(1S)-1-[4-(2-methoxy-1-methylethoxy)phenyl]ethyl}-2-(7-nitro-1H-benzimidazol-1-yl)acetamide,
N-{1-[3-chloro-5-(trifluoromethyl)pyridin-2-yl]ethyl}-2-(7-nitro-1H-benzimidazol-1-yl)acetamide,
5 N-{1-[4-(2,2-difluoroethoxy)phenyl]ethyl}-2-(7-nitro-1H-benzimidazol-1-yl)acetamide,
N-{1-[4-(cyclopentyloxy)-3-fluorophenyl]ethyl}-2-(7-nitro-1H-benzimidazol-1-yl)acetamide,
N-{1-[4-[(1-Methylpiperidin-4-yl)oxy]-3-(trifluoromethyl)phenyl]ethyl}-2-(7-nitro-1H-benzimidazol-1-yl)acetamide,
10 N-{1-[4-[(2S)-2-Methoxypropyl]oxy]-3-(trifluoromethyl)phenyl]ethyl}-2-(7-nitro-1H-benzimidazol-1-yl)acetamide,
N-{1-[5-(cyclopropylmethoxy)pyridin-2-yl]ethyl}-2-(7-nitro-1H-benzimidazol-1-yl)acetamide,
N-{1-[5-chloro-6-(2-fluoroethoxy)pyridin-3-yl]ethyl}-2-(7-nitro-1H-benzimidazol-1-yl)acetamide,
15 N-{1-[6-(2,2-difluoroethoxy)pyridin-3-yl]ethyl}-2-(7-nitro-1H-benzimidazol-1-yl)acetamide,
N-{1-[6-(2-fluoroethoxy)pyridin-3-yl]ethyl}-2-(7-nitro-1H-benzimidazol-1-yl)acetamide,
N-{1-[6-(cyclopentyloxy)pyridine-3-yl]ethyl}-2-(7-nitro-1H-benzimidazol-1-yl)acetamide,
20 N-{1-methyl-2-[3-(trifluoromethyl)phenoxy]ethyl}-2-(7-nitro-1H-benzimidazol-1-yl)acetamide,
N-[1-(6-tert-butyl-2-methoxypyridin-3-yl)ethyl]-2-(7-cyano-1H-benzimidazol-1-yl)acetamide,
N-[1-(6-tert-butyl-2-methylpyridin-3-yl)ethyl]-2-(6,7-difluoro-1H-benzimidazol-1-yl)acetamide,
25 N-[1-(6-tert-butyl-4-methylpyridin-3-yl)ethyl]-2-(7-cyano-1H-benzimidazol-1-yl)acetamide,
N-[1-(6-tert-butyl-2-chloropyridin-3-yl)ethyl]-2-(7-cyano-1H-benzimidazol-1-yl)acetamide, and
30 N-[1-(6-tert-butylpyridin-3-yl)ethyl]-2-(7-cyano-1H-benzimidazol-1-yl)acetamide.

24. The compounds according to claim 1 selected from the group consisting of
N-((1S)-1-{4-[2-fluoro-1-(fluoromethyl)ethoxy]phenyl}ethyl)-2-(7-nitro-1H-benzimidazol-1-yl)acetamide,

2-(7-nitro-1H-benzimidazol-1-yl)-N-{1-[6-(2,2,3,3-tetrafluoropropoxy)pyridin-3-yl]ethyl}acetamide,
5 N-[1-(4-tert-butylphenyl)ethyl]-2-(6,7-difluoro-1H-benzimidazol-1-yl)acetamide, and
N-[(1S)-1-(4-tert-butylphenyl)ethyl]-2-(6,7-difluoro-1H-benzimidazol-1-yl)acetamide

25. The compounds according to claim 1 selected from the group consisting of

10 2-(6,7-difluoro-1H-benzimidazol-1-yl)-N-{1-[4-(trifluoromethyl)phenyl]ethyl}acetamide,
2-(7-acetyl-1H-benzimidazol-1-yl)-N-(1-{4-[2-fluoro-1-(fluoromethyl)ethoxy]phenyl}ethyl)acetamide,

2-(7-chloro-1H-benzimidazol-1-yl)-N-(1-{4-[2-fluoro-1-(fluoromethyl)ethoxy]phenyl}ethyl)acetamide,

15 2-(7-chloro-1H-benzimidazol-1-yl)-N-(1-{4-[chloro(difluoro)methyl]phenyl}ethyl)acetamide,

2-(7-chloro-1H-benzimidazol-1-yl)-N-[1-(4-ethynylphenyl)ethyl]acetamide,

2-(7-chloro-1H-benzimidazol-1-yl)-N-{1-[4-(1,1,2,2-tetrafluoroethoxy)phenyl]ethyl}acetamide,

20 2-(7-chloro-1H-benzimidazol-1-yl)-N-{1-[4-(2,2-difluoroethoxy)phenyl]ethyl}acetamide,

2-(7-chloro-1H-benzimidazol-1-yl)-N-{1-[4-(trifluoromethyl)phenyl]ethyl}acetamide,

2-(7-cyano-1H-benzimidazol-1-yl)-N-(1-{4-[2-fluoro-1-(fluoromethyl)ethoxy]phenyl}ethyl)acetamide,

2-(7-cyano-1H-benzimidazol-1-yl)-N-[1-(4-isopropylphenyl)ethyl]acetamide,

25 2-(7-cyano-1H-benzimidazol-1-yl)-N-{1-[3-fluoro-4-(trifluoromethyl)phenyl]ethyl}acetamide,

2-(7-cyano-1H-benzimidazol-1-yl)-N-{1-[4-(2,2,2-trifluoroethoxy)phenyl]ethyl}acetamide,

2-(7-cyano-1H-benzimidazol-1-yl)-N-{1-[4-(trifluoromethoxy)phenyl]ethyl}acetamide,

30 2-(7-cyano-1H-benzimidazol-1-yl)-N-{1-[4-(trifluoromethyl)phenyl]ethyl}acetamide,

2-(7-cyano-1H-benzimidazol-1-yl)-N-((1S)-1-[4-(trifluoromethyl)phenyl]ethyl)acetamide,

- 2-(7-cyano-1H-benzimidazol-1-yl)-N-{1-[4-[2-fluoro-1-(fluoromethyl)ethoxy]-2-(trifluoromethyl)phenyl]ethyl}acetamide,
2-(7-fluoro-1H-benzimidazol-1-yl)-N-[1-(4-isopropylphenyl)ethyl]acetamide,
2-(7-fluoro-1H-benzimidazol-1-yl)-N-{1-[4-(trifluoromethyl)phenyl]ethyl}acetamide,
5 2-(7-nitro-1H-benzimidazol-1-yl)-N-{1-[4-(1,1,2,2-tetrafluoroethoxy)phenyl]ethyl}acetamide,
2-(7-nitro-1H-benzimidazol-1-yl)-N-{1-[4-(2,2,2-trifluoroethoxy)phenyl]ethyl}acetamide,
2-(7-nitro-1H-benzimidazol-1-yl)-N-{1-[4-(trifluoromethoxy)phenyl]ethyl}acetamide,
2-(7-nitro-1H-benzimidazol-1-yl)-N-{1-[4-(trifluoromethyl)phenyl]ethyl}acetamide,
10 methyl (4-tert-butylphenyl){[(6,7-difluoro-1H-benzimidazol-1-yl)acetyl]amino}acetate,
N-((1S)-1-{4-[(1-methylprop-2-yn-1-yl)oxy]phenyl}ethyl)-2-(7-nitro-1H-benzimidazol-1-yl)acetamide,
N-((1S)-1-{4-[2-fluoro-1-(fluoromethyl)ethoxy]phenyl}ethyl)-2-(7-nitro-1H-benzimidazol-1-yl)acetamide,
15 N-(1-{2-chloro-4-[2-fluoro-1-(fluoromethyl)ethoxy]phenyl}ethyl)-2-(7-cyano-1H-benzimidazol-1-yl)acetamide,
N-(1-{4-[chloro(difluoro)methyl]phenyl}ethyl)-2-(7-nitro-1H-benzimidazol-1-yl)acetamide,
N-[(1S)-1-(4-{[(1S)-1-methylpropyl]oxy}phenyl)ethyl]-2-(7-nitro-1H-benzimidazol-1-yl)acetamide,
20 N-[(1S)-1-(4-ethoxyphenyl)ethyl]-2-(7-nitro-1H-benzimidazol-1-yl)acetamide,
N-[(1S)-1-(4-isopropoxyphenyl)ethyl]-2-(7-nitro-1H-benzimidazol-1-yl)acetamide,
N-[1-(4-{[(2S)-2-methoxypropyl]oxy}phenyl)ethyl]-2-(7-nitro-1H-benzimidazol-1-yl)acetamide,
25 N-[1-(4-cyclopropylphenyl)ethyl]-2-(7-nitro-1H-benzimidazol-1-yl)acetamide,
N-[1-(4-ethynylphenyl)ethyl]-2-(7-nitro-1H-benzimidazol-1-yl)acetamide,
N-[1-(4-tert-butylphenyl)ethyl]-2-(6,7-difluoro-1H-benzimidazol-1-yl)acetamide,
N-[(1S)-1-(4-tert-butylphenyl)ethyl]-2-(6,7-difluoro-1H-benzimidazol-1-yl)acetamide,
N-[1-(4-tert-butylphenyl)ethyl]-2-(7-cyano-1H-benzimidazol-1-yl)acetamide,
30 N-{(1S)-1-[4-(2-fluoroethoxy)phenyl]ethyl}-2-(7-nitro-1H-benzimidazol-1-yl)acetamide,
N-{(1S)-1-[4-(2-methoxy-1-methylethoxy)phenyl]ethyl}-2-(7-nitro-1H-benzimidazol-1-yl)acetamide,

N-{1-[4-(2,2-difluoroethoxy)phenyl]ethyl}-2-(7-nitro-1H-benzimidazol-1-yl)acetamide,
N-{1-[4-(cyclopentyloxy)-3-fluorophenyl]ethyl}-2-(7-nitro-1H-benzimidazol-1-yl)acetamide,
N-{1-[4-[(1-Methylpiperidin-4-yl)oxy]-3-(trifluoromethyl)phenyl]ethyl}-2-(7-nitro-1H-benzimidazol-1-yl)acetamide, and
N-{1-[4-[(2S)-2-Methoxypropyl]oxy]-3-(trifluoromethyl)phenyl]ethyl}-2-(7-nitro-1H-benzimidazol-1-yl)acetamide.

26. The compounds according to claim 1 selected from the group consisting of

N-{1-[6-(2-fluoroethoxy)pyridin-3-yl]ethyl}-2-(7-nitro-1H-benzimidazol-1-yl)acetamide,
N-(1-{6-[2-fluoro-1-(fluoromethyl)ethoxy]pyridin-3-yl}ethyl)-2-(7-nitro-1H-benzimidazol-1-yl)acetamide,

N-{1-[6-(cyclopentyloxy)pyridine-3-yl]ethyl}-2-(7-nitro-1H-benzimidazol-1-yl)acetamide,
N-(1-{5-chloro-6-[2-fluoro-1-(fluoromethyl)ethoxy]pyridin-3-yl}ethyl)-2-(7-nitro-1H-benzimidazol-1-yl)acetamide,

2-(7-nitro-1H-benzimidazol-1-yl)-N-{1-[5-(trifluoromethyl)pyridin-2-yl]propyl}acetamide,

2-(7-nitro-1H-benzimidazol-1-yl)-N-{1-[5-(trifluoromethyl)pyridin-2-yl]ethyl}acetamide,

2-(7-chloro-1H-benzimidazol-1-yl)-N-{1-[3-chloro-5-(trifluoromethyl)pyridin-2-yl]ethyl}acetamide,

N-{1-[3-chloro-5-(trifluoromethyl)pyridin-2-yl]ethyl}-2-(7-nitro-1H-benzimidazol-1-yl)acetamide,

N-{1-[5-chloro-6-(2-fluoroethoxy)pyridin-3-yl]ethyl}-2-(7-nitro-1H-benzimidazol-1-yl)acetamide,

2-(7-Chloro-benzoimidazol-1-yl)-N-[1-(6-isopropoxy-pyridin-3-yl)-ethyl]-acetamide,

N-[1-(6-isopropoxypyridin-3-yl)ethyl]-2-(7-nitro-1H-benzimidazol-1-yl)acetamide,

N-{1-[5-(cyclopropylmethoxy)pyridin-2-yl]ethyl}-2-(7-nitro-1H-benzimidazol-1-yl)acetamide,

N-[1-(5-isopropoxypyridin-2-yl)ethyl]-2-(7-nitro-1H-benzimidazol-1-yl)acetamide,

N-[1-(5-tert-butylpyridin-2-yl)ethyl]-2-(7-fluoro-1H-benzimidazol-1-yl)acetamide,

N-[1-(5-tert-butyl-2-thienyl)ethyl]-2-(7-fluoro-1H-benzimidazol-1-yl)acetamide,

N-[1-(5-tert-butyl-2-thienyl)ethyl]-2-(7-cyano-1H-benzimidazol-1-yl)acetamide,

2-(7-nitro-1H-benzimidazol-1-yl)-N-{1-[6-(2,2,2-trifluoroethoxy)pyridin-3-yl]ethyl}acetamide,

2-(7-chloro-1H-benzimidazol-1-yl)-N-{1-[6-(2,2,2-trifluoroethoxy)pyridin-3-yl]ethyl}acetamide,

5 2-(7-nitro-1H-benzimidazol-1-yl)-N-{1-[6-(2,2,3,3-tetrafluoropropoxy)pyridin-3-yl]ethyl}acetamide,

2-(7-chloro-1H-benzimidazol-1-yl)-N-{1-[6-(2,2,3,3-tetrafluoropropoxy)pyridin-3-yl]ethyl}acetamide,

10 N-{1-[6-(2,2-difluoroethoxy)pyridin-3-yl]ethyl}-2-(7-nitro-1H-benzimidazol-1-yl)acetamide, and

N-[1-(5-tert-butyl-2-thienyl)ethyl]-2-(6,7-difluoro-1H-benzimidazol-1-yl)acetamide.

27. The compounds according to claim 1 selected from the group consisting of N-[1-(6-tert-butyl-2-methoxypyridin-3-yl)ethyl]-2-(7-cyano-1H-benzimidazol-1-

15 yl)acetamide,

N-[1-(6-tert-butyl-2-methylpyridin-3-yl)ethyl]-2-(6,7-difluoro-1H-benzimidazol-1-yl)acetamide,

N-[1-(6-tert-butyl-4-methylpyridin-3-yl)ethyl]-2-(7-cyano-1H-benzimidazol-1-yl)acetamide,

20 N-[1-(6-tert-butyl-2-chloropyridin-3-yl)ethyl]-2-(7-cyano-1H-benzimidazol-1-yl)acetamide,

N-[1-(6-tert-butylpyridin-3-yl)ethyl]-2-(7-cyano-1H-benzimidazol-1-yl)acetamide,

N-[1-(4-tert-butylphenyl)ethyl]-2-(7-cyano-1H-benzimidazol-1-yl)acetamide, and

25 2-(7-acetyl-1H-benzimidazol-1-yl)-N-[(1S)-1-(4-tert-butylphenyl)ethyl]acetamide.

28. A pharmaceutical composition comprising as active ingredient a therapeutically effective amount of the compound according to any one of claims 1 to 27, in association with one or more pharmaceutically acceptable diluents, excipients and/or inert carriers.

30 29. The pharmaceutical composition according to claim 28, for use in the treatment of VR1 mediated disorders and for treatment of acute and chronic pain disorders such as acute or

chronic neuropathic pain and acute or chronic inflammatory pain; and/or respiratory diseases.

30. The compound according to any one of claims 1 to 27, for use in therapy.

31. Use of the compounds of formula I according to any one of claims 1 to 27, in the manufacture of a medicament.

32. Use of the compounds of formula I according to any one of claims 1 to 27, in the manufacture of a medicament for treatment of VR1 mediated disorders and/or for treatment of acute and/or chronic pain disorders such as acute or chronic neuropathic pain, and acute or chronic inflammatory pain; and/or respiratory diseases.

33. Use of the compounds of formula I according to any one of claims 1 to 27, in the manufacture of a medicament for treatment acute and chronic nociceptive pain.

34. Use of the compounds of formula I according to any one of claims 1 to 27, in the manufacture of a medicament for treatment of arthritis; osteoarthritis; rheumatoid arthritis; fibromyalgia; low back pain; post-operative pain; visceral pains like chronic pelvic pain; cystitis; irritable bowel syndrome (IBS); pancreatitis; ischeamic, sciatica, diabetic neuropathy, multiple sclerosis, interstitial cystitis and/or pain related to interstitial cystitis; HIV neuropathy; asthma; cough; chronic obstructive lung disease, specifically chronic obstructive pulmonary disease (COPD) and emphysema; lung fibrosis and interstitial lung disease; and/or inflammatory bowel disease (IBD); gastro-esophageal reflux disease (GERD); pain and other signs and symptoms associated with psoriasis; pain and other signs and symptoms associated with cancer; emesis; urinary incontinence; and/or hyperactive bladder, including signs and/or symptoms related to said diseases.

35. Use of the compounds of formula I according to any one of claims 1 to 27, in the manufacture of a medicament for treatment of obesity and/or migraine.

36. Use of the compounds of formula I according to any one of claims 1 to 27, in the manufacture of a medicament for treatment of burn induced pain and/or inflammatory pain resulting from burn injuries.

5 37. A method of treatment of VR1 mediated disorders and for treatment of acute and chronic pain disorders such as acute or chronic neuropathic pain and acute or chronic inflammatory pain; and/or respiratory diseases, comprising administering to a mammal, including man in need of such treatment, a therapeutically effective amount of the compounds of formula I, according to any one of claims 1 to 27.

10

38. Compounds selected from the group consisting of

N-[(1S)-1-(4-hydroxyphenyl)ethyl]-2-(7-nitro-1H-benzimidazol-1-yl)acetamide,

1-[6-(2-fluoroethoxy)pyridin-3-yl]ethanamine,

1-[6-(2,2,2-trifluoroethoxy)pyridin-3-yl]ethanamine,

15 1-[6-(2,2-difluoroethoxy)pyridin-3-yl]ethanamine,

1-[6-(2,2,3,3-tetrafluoropropoxy)pyridin-3-yl]ethanamine,

1-[6-(cyclopentyloxy)pyridin-3-yl]ethanamine,

1-(4-{[(2S)-2-methoxypropyl]oxy}phenyl)ethanamine,

1-[4-(2,2,2-trifluoroethoxy)phenyl]ethanamine,

20 1-[4-[(1-Methylpiperidin-4-yl)oxy]-3-(trifluoromethyl)phenyl]ethanamine,

1-[4-{[(2S)-2-Methoxypropyl]oxy}-3-(trifluoromethyl)phenyl]ethanamine,

6-*tert*-butyl-4-methylnicotinonitrile,

[1-(6-*tert*-butylpyridin-3-yl)ethyl]amine,

[1-(6-*tert*-butyl-2-chloropyridin-3-yl)ethyl]amine,

25 [1-(6-*tert*-butyl-2-methoxypyridin-3-yl)ethyl]amine,


[1-(6-*tert*-butyl-4-methylpyridin-3-yl)ethyl]amine,

6-*tert*-butyl-2-methylnicotinonitrile, and

[1-(6-*tert*-butyl-2-methylpyridin-3-yl)ethyl]amine.

30 39. Use of compounds according to claim 38 as intermediates in the preparation of the compound of formula I.

40. A process for preparing a compound of formula I, wherein R^1 , R^2 , R^3 , and R^4 are defined as in formula I:




wherein

- 5 a compound of formula II, or a deprotonated form thereof, is treated in a suitable solvent with an activator selected from oxalyl chloride, *O*-(7-azabenzotriazol-1-yl)-*N,N,N',N'*-tetramethyluronium hexafluorophosphate, 1,3-dicyclohexylcarbodiimide, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride or 1,1'-carbonyldiimidazole, and thereafter treated with $NH_2CHR^2R^4$.

10

41. A process for preparing a compound of formula Ia, wherein R^1 and R^3 are defined as in formula I:



wherein

- 15 a compound of formula III is converted into the compound of formula Ia in a Mitsunobu reaction with an alcohol R^5OH , where R^5 is selected from from C_{1-6} alkyl, C_{1-6} haloalkyl, C_{3-7} cycloalkyl, C_{3-7} cycloalkylalkyl, C_{3-7} heterocycloalkyl, C_{1-3} alkoxy C_{1-6} alkyl, and C_{1-3} alkyl C_{1-6} alkoxy.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
28 June 2007 (28.06.2007)

PCT

(10) International Publication Number
WO 2007/073303 A3

(51) International Patent Classification:

C07D 235/08 (2006.01) **A61P 19/02** (2006.01)
A61K 31/4184 (2006.01) **A61P 29/00** (2006.01)
A61K 31/4439 (2006.01) **A61P 35/00** (2006.01)
A61P 1/04 (2006.01) **C07D 401/12** (2006.01)
A61P 11/06 (2006.01) **C07D 405/12** (2006.01)
A61P 17/06 (2006.01) **C07D 409/12** (2006.01)

AstraZeneca R & D Södertälje, S-151 85 Södertälje (SE).
NYLÖF, Martin [SE/SE]; AstraZeneca R & D Södertälje,
S-151 85 Södertälje (SE). **SKOGHOLM, Karin** [SE/SE];
AstraZeneca R & D Södertälje, S-151 85 Södertälje (SE).

(74) Agent: **ASTRAZENECA AB**; Global Intellectual Prop-
erty, S-151 85 Södertälje (SE).

(21) International Application Number:

PCT/SE2006/001467

(22) International Filing Date:

21 December 2006 (21.12.2006)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/753,604 23 December 2005 (23.12.2005) US

(71) Applicant (for all designated States except US): **AS-
TRAZENECA AB** [SE/SE]; S-151 85 Södertälje (SE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BESIDSKI, Yev-
geni** [SE/SE]; AstraZeneca R & D Södertälje, S-151
85 Södertälje (SE). **GRIFFIN, Andrew** [GB/CA]; As-
traZeneca R & D Montreal, 7171 Frederick-banting,
Ville St. Laurent, Montreal, Québec H4S 1Z9 (CA).
LABRECQUE, Denis [CA/CA]; AstraZeneca R & D
Montreal, 7171 Frederick-banting, Ville St. Laurent,
Montreal, Québec H4S 1Z9 (CA). **JOHNSTONE, Shawn**
[CA/CA]; AstraZeneca R & D Montreal, 7171 Freder-
ick-banting, Ville St. Laurent, Montreal, Québec H4S
1Z9 (CA). **JONES, Paul** [CA/CA]; AstraZeneca R &
D Montreal, 7171 Frederick-banting, Ville St. Laurent,
Montreal, Québec H4S 1Z9 (CA). **KERS, Inger** [SE/SE];

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS,
JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS,
LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY,
MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS,
RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT,
RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA,
GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:


— with international search report

(88) Date of publication of the international search report:

30 August 2007

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: NOVEL BENZIMIDAZOLE DERIVATIVES AS VANILLOID RECEPTOR 1 (VRL) INHIBITORS



(I)

(57) Abstract: The present invention relates to new compounds
(I) or salts, solvates or solvated salts thereof, processes for their
preparation and to new intermediates used in the preparation
thereof, pharmaceutical compositions containing said compounds
and to the use of said compounds in therapy.

WO 2007/073303 A3

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE2006/001467

A. CLASSIFICATION OF SUBJECT MATTER

IPC: see extra sheet

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC: C07D, A61K, A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-INTERNAL, WPI DATA, PAJ

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	WO 2006033620 A1 (ASTRAZENECA AB), 30 March 2006 (30.03.2006) --	1-3,16-17, 28-34,36,40
X	WO 2004100865 A2 (ASTRAZENECA AB), 25 November 2004 (25.11.2004) --	1-7,13, 15-17,19-20, 23-25,27-34, 36,38-41
A	WO 2005095327 A1 (AJINOMOTO CO., INC.), 13 October 2005 (13.10.2005) --	1-41
A	WO 2005021539 A1 (PFIZER INC.), 10 March 2005 (10.03.2005) --	1-41

☒ Further documents are listed in the continuation of Box C.☒ See patent family annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier application or patent but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

7 March 2007

Date of mailing of the international search report

28 -05- 2007

Name and mailing address of the ISA/
Swedish Patent Office
Box 5055, S-102 42 STOCKHOLM
Facsimile No. +46 8 666 02 86

Authorized officer

Eva Johansson/EÖ
Telephone No. +46 8 782 25 00

INTERNATIONAL SEARCH REPORT

International application No.
PCT/SE2006/001467

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 2004108712 A1 (ASTRAZENECA AB), 16 December 2004 (16.12.2004) -- -----	1-41

INTERNATIONAL SEARCH REPORT

International application No.
PCT/SE2006/001467

International patent classification (IPC)

C07D 235/08 (2006.01)
A61K 31/4184 (2006.01)
A61K 31/4439 (2006.01)
A61P 1/04 (2006.01)
A61P 11/06 (2006.01)
A61P 17/06 (2006.01)
A61P 19/02 (2006.01)
A61P 29/00 (2006.01)
A61P 35/00 (2006.01)
C07D 401/12 (2006.01)
C07D 405/12 (2006.01)
C07D 409/12 (2006.01)

Download your patent documents at www.prv.se

The cited patent documents can be downloaded at www.prv.se by following the links:

- In English/Searches and advisory services/Cited documents (service in English) or
- e-tjänster/anförda dokument(service in Swedish).

Use the application number as username.

The password is **NWUPQUJKA**.

Paper copies can be ordered at a cost of 50 SEK per copy from PRV InterPat (telephone number 08-782 28 85).

Cited literature, if any, will be enclosed in paper form.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/SE2006/001467

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 37
because they relate to subject matter not required to be searched by this Authority, namely:
Claim 37 relates to a method of treatment of the human or animal body by surgery or by therapy, as well as diagnostic
.../...
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

In order to fulfil the requirements of unity of invention, the intermediate compounds must be closely interconnected with the end products. Such close interconnection requires that the essential structural part of the end product is incorporated by the intermediate compound. However, the present application

.../...

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- ☐ The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/SE2006/001467

Box II.1

methods /Rule 39.1(iv). Nevertheless, a search has been executed for this claim. The search has been based on the alleged effects of the compounds.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/SE2006/001467

Box III

lacks a single general inventive concept based on the above principle. This leads to the presence of the subjects listed below, each falling under its own restricted inventive concept.

1: Claims 1-37, 38-39 (partly), 40-41 directed to compounds of formula I, to compositions containing them, to the use of these compounds in the treatment of VR1-mediated disorders, to a benzimidazole derivative (compound 1 of claim 38) and to the use of this compound as an intermediate in the preparation of compounds of formula I.

2: Claims 38-39 (partly) directed to ten 1-(pyridin-3-yl)ethanamine derivatives (compounds 2-6, 12-15, 17 of claim 38) and to the use of these compounds as intermediates in the preparation of compounds of formula I.

3: Claims 38-39 (partly) directed to four 1-phenyl-ethanamine derivatives (compounds 7-10 of claim 38) and to the use of these compounds as intermediates in the preparation of compounds of formula I.

4: Claims 38-39 (partly) directed to two nicotinonitrile derivatives (compounds 11 and 16 of claim 38) and to the use of these compounds as intermediates in the preparation of compounds of formula I.

Consequently, the four groups of inventions are not so linked as to form a single general inventive concept as required by Rule 13.1 PCT.

INTERNATIONAL SEARCH REPORT
Information on patent family members

31/03/2007

International application No.
PCT/SE2006/001467

WO	2006033620	A1	30/03/2006	AU SE	2005285656 A 0402284 D	30/03/2006 00/00/0000
WO	2004100865	A2	25/11/2004	AU AU BR CA CA CN EP EP JP KR MX NO RU SE US US SE	2003261053 A 2004238177 A PI0410316 A 2498151 A 2525628 A 1784387 A 1543094 A 1626964 A 2006528971 T 20060009936 A PA05012247 A 20055977 A 2005136529 A 0301446 D 20060059768 A 20060287377 A 0400043 D	00/00/0000 25/11/2004 23/05/2006 01/04/2004 25/11/2004 07/06/2006 22/06/2005 22/02/2006 28/12/2006 01/02/2006 10/02/2006 16/02/2006 10/06/2006 00/00/0000 23/03/2006 21/12/2006 00/00/0000
WO	2005095327	A1	13/10/2005	EP US	1736465 A 20070066586 A	27/12/2006 22/03/2007
WO	2005021539	A1	10/03/2005	AU BR CA CN EP IS KR MX NL NO US	2004268840 A PI0414105 A 2537127 A 1845922 A 1664036 A 8289 A 20060087540 A PA06002550 A 1026959 A,C 20061519 A 20050148573 A	10/03/2005 21/11/2006 10/03/2005 11/10/2006 07/06/2006 09/02/2006 02/08/2006 20/06/2006 07/03/2005 01/06/2006 07/07/2005
WO	2004108712	A1	16/12/2004	AU AU BR CA CN EP EP JP KR NO RU SE US	2003280905 A 2004245298 A PI0411246 A 2528925 A 1805956 A 1579119 A 1636214 A 2006527249 T 20060018258 A 20060147 A 2005138366 A 0301701 D 20060205802 A	00/00/0000 16/12/2004 18/07/2006 16/12/2004 19/07/2006 28/09/2005 22/03/2006 30/11/2006 28/02/2006 07/03/2006 27/07/2006 00/00/0000 14/09/2006